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Abstract
Glucocorticoids have diverse physiological functions: they affect central nervous
system function, intermediary metabolism and restore homeostasis after stress.
Secretion of glucocorticoids is regulated by the hypothalamic-pituitary-adrenal
(HPA) axis; negative feedback at the hypothalamus and pituitary suppresses
glucocorticoid secretion while the hippocampus exerts additional control over HPA
axis activity.
Glucocorticoids exert most of their actions, including negative feedback, via the
glucocorticoid receptor (GR). The glucocorticoid sensitivity of a given cell/tissue is
dependent on the level ofGR expression. The regulation of the GR gene is complex;
GR levels in adult animals are subject to glucocorticoid regulation and can be
permanently "programmed" by early life events, with hippocampal GR permanently
increased by neonatal handling (via alterations in serotonin turnover) and decreased
by prenatal dexamethasone exposure. Evidence suggests that these effects may be
mediated through differential regulation of variant exon-1 containing GR mRNAs; in
rats the GR gene contains 8 protein-coding exons (exons 2-9) and at least 11
alternate untranslated exons 1 (exons li-ln) which may reflect transcription
regulated by alternate promoters. The aim of this thesis was to further investigate the
distribution of these variant GR transcripts and examine whether glucocorticoids
themselves differentially regulate GR mRNA and its alternate exons 1 in a tissue and
region-specific manner.
Tissue and region-specific differences in the expression of variant GR mRNA
transcripts were found in rat and mouse. Most GR mRNA variants were ubiquitously
expressed, but those containing exon 11 were restricted to rat thymus, liver and
hippocampus and mouse spleen, while those containing exon 14 were absent from rat
cerebral cortex and mouse lung, heart and abdominal fat. In situ mRNA hybridisation
on rat brain showed that all the exons 1 studied showed differences in their regional
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expression when compared to distribution of the total population ofGR mRNAs. In
contrast, in rat liver and thymus GR mRNA variants showed the same regional
distribution as total GR mRNA with highest expression in periportal region of the
liver and the thymic cortex.
To investigate whether glucocorticoids differentially regulate variant GR mRNAs, in
situ mRNA hybridisation was used to investigate the expression variant exons 1 in
the hippocampus of adult rats subjected to 72h (ST) or 3-week (LT) adrenalectomy
with glucocorticoid replacement. Variant GR mRNAs containing exons 15, 17, 110
and 111 were not affected by adrenalectomy or supraphysiological glucocorticoid
replacement in ST or LT animals. However, both adrenalectomy and
supraphysiological glucocorticoid replacement significantly upregulated total GR
mRNA in the hippocampus of ST animals while adrenalectomy significantly
upregulated total GR mRNA in the hippocampus of LT animals.
In situ mRNA hybridisation and RNase protection analysis were used to investigate
expression of variant GR mRNAs in the liver. Glucocorticoid manipulations did not
significantly affect expression of variant GR mRNAs containing exons 15, 1$, Lo or
In. However, in ST adrenalectomised animals glucocorticoid replacement
significantly downregulated GR mRNA levels compared to adrenalectomised
animals given vehicle alone. Adrenalectomy had no effect on total GR mRNA
expression in the LT animals, although in these animals the periportal :perivenous
ratio of GR expression was significantly increased by adrenalectomy compared to
sham. Preliminary data from DNase I hypersensitive site mapping in control animals
showed an area of DNase I sensitive chromatin around the position of exon 110,
present in the majority ofGR mRNA in the liver.
In the thymus, although adrenalectomy with either high and low dose glucocorticoid
replacement in ST animals caused a significant downregulation ofGR mRNA in the
cortex and medulla compared to sham, the expression of exons 11, U and 110 of the
GR gene was not significantly affected by glucocorticoid manipulations. There was
no effect of glucocorticoid manipulation on GR or its variants in the LT animals.
27
These results demonstrate tissue-specific differences in the distribution ofGR
mRNA variants, suggesting that variations in promoter usage may have a role in
determining the "set-point" ofGR expression in different tissues. The observed
tissue-specific effects of glucocorticoids on GR mRNA expression could not be
accounted for by changes in expression of any of the variant GR mRNA transcripts
studied. This suggests that either the expression of another variant mRNA (known or
novel) is regulated by glucocorticoids or that expression of all or a subset of the
variant GR mRNAs changed with a magnitude too small to be detected in this study.
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1 Introduction
Glucocorticoids are steroid hormones which exert effects on virtually all tissues in
the body. Their effects are mediated by an intracellular receptor, the glucocorticoid
receptor (GR), the regulation of which is the subject of this thesis. The principal
determinants of glucocorticoid action are the intracellular level of receptor and the
circulating levels of hormone, although other factors also modulate their actions in
various tissues. In this introduction I shall first describe the synthesis of
glucocorticoids and briefly discuss some of the factors determining access of
glucocorticoids to their receptor. I shall also discuss the structure and function of the
GR protein and gene, with particular reference to the regulation ofGR levels in
various tissues and the role ofGR in transcriptional regulation. The remainder of the
chapter will deal with the diverse physiological effects of glucocorticoids and the
various transgenic models of GR function.
1.1 Glucocorticoid structure and synthesis
1.1.1 Glucocorticoid structure
Glucocorticoids are steroid hormones derived from cholesterol, which contains 27
carbon atoms in a cyclopentanoperhydrophenanthrene nucleus of 4 rings (A-D) with
a A5 double bond (Figure 1.1). All steroid hormones have an a-oriented hydrogen
atom at carbon 5, giving the A and B rings a trans conformation and a nearly planar
structure (Ganong, 1989).
The several groups of steroid hormone molecules have different numbers of carbon
atoms. The C21 steroids (progestagens, glucocorticoids and mineralocorticoids) have
a 2-carbon side-chain at carbon 17 of the D ring. The C19 steroids (testosterone,
dihydroepiandrosterone and androstenedione - the androgens) have a keto or
hydroxyl group at carbon 17 of the D ring and are mainly synthesised in the testis.
TheC is steroids (the oestrogens) are derived from the androgens and are mainly
synthesised in the ovary (Ganong, 1989).
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Figure 1.1: structure of cholesterol showing nomenclature of rings and numbering of carbon
atoms in rings and side-chains.
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1.1.2 Glucocorticoid synthesis
Glucocorticoids are synthesised in the zona fasciculata and zona reticularis of the
adrenal cortex along with the mineralocorticoid aldosterone and trace amounts of
oestradiol (Ganong, 1989). The synthetic pathway of glucocorticoids from
cholesterol is shown in Figure 1.2. Cholesterol (supplied from circulating low-
density lipoprotein or synthesised de novo from acetate) is esterified and stored in
lipid droplets in the cytoplasm. These esters are hydrolysed to produce free
cholesterol for steroid synthesis, which occurs in the mitochondria and smooth
endoplasmic reticulum (Ganong, 1989). The initial step in steroid synthesis is under
the control of adrenocorticotrophic hormone (section 1.9.2.2). Synthesised
glucocorticoids are not stored in the adrenal but are immediately released into the
circulation (Ganong, 1989). In the zona glomerulosa of the adrenal cortex,
corticosterone is converted into aldosterone by aldosterone synthase (Ganong, 1989).
Rodents lack the enzyme 17a-hydroxylase, thus corticosterone is the major
glucocorticoid in rodents while Cortisol is the major glucocorticoid in humans and
other mammals (Orth, 1998).
In addition to their synthesis in the adrenal, some evidence suggests that
glucocorticoids can be synthesised locally in thymic epithelium (section 1.9.5.2).
Also, the expression ofmRNA for all of the enzymes required for the synthesis of
adrenal steroids has now been identified in human or rat brain or cultured CNS cells
(Brown et al., 2000; Gomez et al., 1996; LeGoascogne et al., 1987; Mellon and
Deschepper, 1993; Yu et ah, 2002; Zhou et al., 1997)), although the physiological
significance ofCNS glucocorticoid secretion is unknown.
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1.2 Transport of glucocorticoids
Approximately 96% of circulating glucocorticoids are bound to the protein
corticosteroid binding globulin (CBG), with much of the remainder bound to
albumin (Dunn et al., 1981). In rats, hepatic synthesis ofCBG occurs in the foetus
(especially around the end of the second trimester of pregnancy), is very low at birth
then increases to adult levels by 3 weeks of age (Smith and Hammond, 1991).
Several factors modulate CBG levels. Adult rats show strain differences in CBG
expression (Dhabhar et al., 1993) and tissue-associated CBG levels are higher in
females than in males (Turner, 1992). CBG synthesis is stimulated by oestrogen, and
CBG levels fall in certain disease states e.g. hepatic cirrhosis, nephrosis and multiple
myeloma (Ganong, 1989). Glucocorticoids may also be important in maintaining
normal CBG levels, since mice lacking a functional GR show increased circulating
CBG (Cole et al., 1999).
Cortisol has a higher affinity for CBG than corticosterone, which increases its plasma
half-life (60-90min compared to about 50min for corticosterone (Ganong, 1989)).
Generally, if total plasma glucocorticoids exceed 20pg/dl CBG is saturated, so
additional glucocorticoids circulate unbound (Ganong, 1989). Although it is
generally accepted that CBG acts as a "sink", there is evidence to suggest that CBG
may specifically deliver glucocorticoids to tissues (reviewed in (Pardridge, 1987)).
Proteolytic cleavage results in dissociation of glucocorticoids from CBG and the
release of glucocorticoids in close proximity to the target cell (Hammond et al.,
1990; Pemberton et al., 1988). After delivery to target tissues, the lipid-soluble
glucocorticoids enter cells mainly by diffusion across the plasma-membrane,
although some active transport may occur (Orth, 1998).
Since CBG modulates delivery of glucocorticoids to tissues, the availability of
glucocorticoids is determined at least partially by CBG levels. Interestingly,
intracellular CBG may limit the access of glucocorticoids to their receptors e.g. in the
pituitary, which has high levels of CBG (McEwen et al., 1986).
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1.3 Metabolism and excretion of glucocorticoids
An important metabolism of glucocorticoids is carried out by the enzyme 11 (3-
hydroxysteroid dehydrogenase (11P-HSD) (reviewed in (Krozowski et al., 1999;
Seckl and Chapman, 1997)). 2 isozymes have been described, both members of a
member of the short chain alcohol dehydrogenase/reductase family: the type II
enzyme (11P-HSD2) is NAD-dependent and acts unidirectionally to convert Cortisol
(in humans) and corticosterone (in rats) into their inactive 11-keto metabolites,
cortisone and 11-dehydrocorticosterone. The type I enzyme (1 lp-HSDl) is a
bidirectional enzyme in vitro but in intact cells acts predominantly as a NADPH-
dependent reductase, regenerating active glucocorticoids from cortisone or 11-
dehydrocorticosterone (reviewed in (Krozowski et ah, 1999; Seckl and Chapman,
1997)).
The highest 11P-HSD1 activity is found in the liver, where it may promote the
effects of glucocorticoids by increasing the level of active hormone in the tissues
(reviewed in (Krozowski et ah, 1999; Seckl and Chapman, 1997)). Indeed, transgenic
mice lacking lip-HSDl show reduced activation ofhepatic gluconeogenic enzymes
(attributed to intrahepatic glucocorticoid deficiency) and resist hyperglycaemia in
stress or obesity (Kotelevtsev et ah, 1997).
I lp-HSDl is widely expressed in the rat brain, with high levels in hippocampus
(where glucocorticoids increase 1 lp-HSDl expression (Low et ah, 1994), cerebral
cortex and pituitary and lower levels in hypothalamus (reviewed in (Seckl, 1997)).
II p-HSDl may modulate glucocorticoid actions in the brain, where it has been
shown to reactivate 11 -dehydrocorticosterone in cultured hippocampal cells,
potentiating glucocorticoid-mediated neurotoxicity (Rajan et ah, 1996). Furthermore,
aged 1 lpHSDl knockout mice show significantly lower hippocampal tissue
corticosterone levels than wild-type controls and resistance to age-related learning
deficits despite elevated plasma corticosterone levels throughout life (Yau et ah,
2001b).
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11P-HSD1 is also found in omental fat (where it may increase local glucocorticoid
activation and promote obesity (Livingstone et al., 2000), ovary and vasculature
(reviewed in (Krozowski et al., 1999)).
11 p-HSD2 plays a pivotal role in protecting the mineralocorticoid receptor in target
tissues, including the kidney, by preventing access of corticosterone and allowing
aldosterone to bind. Thus, congenital deficiency in humans (Ferrari et al., 1996) or
mice (Kotelevtsev et al., 1999), or inhibition of 1 lp-HSD by liquorice derivatives
causes massively increased MR signalling in these tissues and hence sodium and
water retention, potassium loss and severe hypertension ((Ferrari et al., 1996;
Flolmes et al., 2001; Kotelevtsev et al., 1999), reviewed in (Krozowski et al., 1999)).
In rodents, 11P-HSD2 levels are high in the placenta in mid-gestation then drop
towards birth in parallel with expression levels in foetal tissues (Brown et al., 1996).
Thus in rodents placental 11P-HSD2 may have a similar role to in humans, where it
protects the foetus from high circulating levels ofmaternal glucocorticoids by
inactivating them (reviewed in (Edwards et al., 1993)). Placental 1 lp-HSD2
dysfunction has been suggested as a potential cause of adult hypertension (reviewed
in (Edwards et al., 1993)) and intrauterine growth retardation (reviewed in (Seckl,
1994)) in humans. Bypass of the placental 11P-HSD2 barrier by inhibition with
carbenoxolone in pregnant rats leads to changes in GR expression in the amygdala of
the offspring and altered behaviour (Welberg et al., 2000). In the adult brain,
expression of 11P-FISD2 is confined to regions of the brainstem and the
subcomissural organ, which are potential aldosterone targets. However, the high
levels of 11P-HSD2 expressed in the foetal brain may serve to protect the developing
brain from inappropriate glucocorticoid signalling (reviewed in (Seckl, 1997)). In the
vasculature, loss of 11P-HSD2 leads to endothelial dysfunction (Hadoke et al.,
2001).
Glucocorticoids are catabolised in the liver by a variety of reduction, oxidation and
hydroxylation reactions (Orth, 1998). Most of their metabolites are conjugated and
rapidly excreted in the urine (Figure 1.3). In humans (but not rodents), enterohepatic
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circulation of glucocorticoids results in excretion of about 15% of secreted Cortisol in
the faeces (Ganong, 1989). The metabolism of corticosterone is broadly the same as
that ofCortisol, but 17-keto derivatives are not formed (Ganong, 1989). The balance
of glucocorticoid secretion and clearance from the body determines the level of

























Figure 1.3: outline of the hepatic metabolism of Cortisol. Adapted from (Ganong, 1989)
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1.4 Mode of action of glucocorticoids
Glucocorticoids act via intracellular corticosteroid receptors, either the type I
(mineralocorticoid) receptor (MR) or the type II (glucocorticoid) receptor (GR)
(Orth, 1998). The two receptors show specific patterns of expression, both between
and within tissues ((Herman et al., 1989a; Reul et ah, 1989; Reul and DeKloet, 1985)
and reviewed in (McEwen et ah, 1986)). Briefly, the GR is ubiquitous and mediates
most of the functions of glucocorticoids, although in hippocampus and heart, which
lack expression of the enzyme 11P-HSD2 (section 1.3) both receptors bind
glucocorticoids. MR has a higher affinity for corticosterone than GR (Feldman et ah,
1973). In brain at least, MR has been shown to be an important mediator of
glucocorticoid effects, particularly in HPA axis feedback regulation (section 1.9.2.4).
The ubiquitous requirement for GR to mediate the effects of glucocorticoids has been
demonstrated in transgenic animals such as GRdim/dim and GRAS mice (section 1.8).
Conversely, mineralocorticoid receptor knockout mice show only abnormalities of
mineral balance consistent with hypoaldosteronism (Berger et ah, 1998) and death of
dentate gyrus neurones (Gass et ah, 2000). As it is the subject of this thesis, only the
GR will be discussed in detail here.
1.5 The glucocorticoid receptor
1.5.1 Structure and function of the glucocorticoid receptor
The glucocorticoid receptor is a member of the nuclear hormone receptor
superfamily, which includes all of the classical steroid receptors as well as numerous
other receptors for small ligands (retinoic acid and derivatives, thyroid hormone,
fatty acids etc.) as well as several receptors for which the ligand has not been
identified, the so-called "orphan receptors" (reviewed in (Beato, 1989; Kumar and
Thompson, 1999)). The nuclear receptors all contain 4 distinct domains; a variable
N-terminal domain, a highly conserved DNA binding domain, a moderately
conserved C-terminal or ligand binding domain and a hinge domain (reviewed in
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(Beato, 1989; Kumar and Thompson, 1999)). All of these domains are involved in
receptor function.
The first event in the classical model of steroid hormone action is binding of the
ligand to a cytoplasmic form of the receptor (reviewed in (Beato, 1989; Truss et al.,
1992)) which is thought to form a dynamically dissociating and reassociating
"foldosome" with various proteins including hsp90, hsp56, hsp70 and p23,
maintaining the monomeric GR in a conformation able to bind ligand (reviewed in
(Beato et al., 1996; Bertorelli et al., 1998)). The crystal structure of the GR ligand
binding domain (LBD) has recently been determined using GR with a point mutation
in helix 5 (phenylalanine 602 to serine) bound to dexamethasone and a section of the
TIF2 coactivator peptide (Bledsoe et al., 2002). The GR LBD contains 1 la-helices
and 4 small P-strands that fold into a 3-layer helical domain with helices 1 and 3 on
one side of a helical sandwich and helices 7 and 10 on the other side (Bledsoe et al.,
2002). This structure is similar to that of the oestrogen, retinoic acid and thyroid
hormone receptors (reviewed in (Kumar and Thompson, 1999)). The middle layer of
helices (4,5,8 and 9) are absent in the bottom half of the GR LBD, creating the ligand
binding pocket which is composed of residues from helices 3, 4, 5, 6, 7, 10 and the
AF-2 helix as well as from P-strands 1 and 2 (Bledsoe et al., 2002). Following the
AF-2 helix is an extended strand that forms a conserved P-sheet with a P-strand
between helices 8 and 9 (Bledsoe et al., 2002).
The conformation of the ligand binding pocket varies between the different nuclear
receptors (reviewed in (Kumar and Thompson, 1999)). The structure of the GR
steroid pocket seems to be especially distinctive, since unlike the PR, AR and ER the
GR pocket has an additional branch extending from the centre which may help to
explain the GR selectivity of glucocorticoids (Bledsoe et al., 2002).
The AF2 activation helix of the LBD has been shown to have a ligand-inducible
activation function in the oestrogen, thyroid hormone and retinoic acid receptors
(Green and Chambon, 1988; Nagpal et al., 1993). On ligand binding the GR AF2
helix is thought to undergo a conformational change from a helix extending away
from the core of the LBD to a tight part of the globular LBD (reviewed in (Beato et
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al., 1996)). This hypothesis is supported by the fact that in the liganded GR crystal
structure discussed above the AF-2 helix adopts the so-called agonist-bound
conformation where it packs against helices 3,4 and 10 (Bledsoe et al., 2002). AF-2
also interacts directly with dexamethasone, which may stabilize the AF-2 helix in the
active conformation and may serve as a molecular basis for ligand-dependent
activation of GR (Bledsoe et al., 2002). The conformational change in AF-2 is
thought to lead to dissociation from the GR/hsp complex (reviewed in (Beato et al.,
1996)), conformational derepression of the DNA binding domain (Godowski et al.,
1987), hyperphosphorylation of the GR protein and translocation into the nucleus
(reviewed in (Bertorelli et al., 1998)). In its active conformation AF-2 also
participates in one of the 2 charge clamps that GR uses to interact with coactivators
(Bledsoe et al., 2002). The second charge clamp is conserved in GR, AR, PR and
MR but not in ER or the retinoic acid receptor, so it may account for the differential
binding of coactivator motifs by many nuclear receptors (Bledsoe et al., 2002).
It is possible that steroid receptor antagonists exert their effects by preventing AF2
from entering its active conformation; in the oestrogen receptor, the agonist 1713-
oestradiol is buried inside the receptor when bound whereas the antagonist raloxifene
enters the hydrophobic core in a different orientation, causing an alteration in the
position of the AF2 helix that blocks the LBD binding site for coactivators
(Brzozowski et al., 1997).
The GR LBD contains a dimerisation interface consisting of a core hydrophobic
interface between residues P625 and 1628 in the P-turn of strands 3 and 4 surrounded
by an extensive network of hydrogen bonds mediated by the extended strand
between helices 1 and 3 and the last residue of helix 5 (Bledsoe et al., 2002). The
crystallographically observed GR dimerisation interface is structurally distinct from
those of the PPARy and retinoic acid receptors and allows the GR to form a
homodimer with a C2 symmetric packing arrangement (Bledsoe et al., 2002).
Mutations of 1628 prevent dimerisation and inhibit the ability ofGR to activate the
MMTV promoter but do not affect GR inhibition of activation by NF-kB (section
1.11.2), suggesting that the monomer and dimer forms ofGR may regulate distinct
signaling pathways (Bledsoe et al., 2002).
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After ligand binding GR translocates into the nucleus, where it binds to DNA as a
homodimer (reviewed in (Beato, 1989; Truss et ah, 1992)). Recent studies utilizing
fusions ofGR and green fluorescent protein have elegantly demonstrated that both
agonist and antagonist-bound GR translocate into the nucleus (Htun et ah, 1996).
However, agonist-bound GR appeared to concentrate into a discrete series of nuclear
foci, whereas antagonist-bound GR did not (Htun et al., 1996). A short sequence of
amino acids towards the C-terminal end of the GR DBD appears to be responsible
for nuclear translocation: another similar sequence lies in the carboxy-terminal half
of the DBD that overlaps the LBD (Picard and Yamamoto, 1987). Nuclear
translocation of the GR requires an intact cytoskeleton (Galigniana et al., 1998) and
thus presumably involves microtubule/microfilament systems.
GR binds to DNA via the highly-conserved DNA binding domain (DBD), which is
the most conserved region amongst the nuclear receptors. The DNA sequence
recognized by the DBD is a 15-mer partially palindromic consensus sequence, the
glucocorticoid response element or GRE (5'-GGTACAnnnTGTTCT-3'). The DBD
also contacts an additional turn of the DNA double helix on each side of the GRE
(reviewed in (Beato, 1989)). Both positive and negative (5'-
ATYACNnnnTGATCW-3') GREs exist, with the positive GRE also being also
being able to mediate induction by progesterone receptor (PR), AR and MR binding
((Strahle et al., 1988), reviewed in (Beato, 1989)). The structures of the GR DBD in
solution (Hard et al., 1990) and bound to DNA (Luisi et al., 1991) have been
determined and are very similar. The main feature of the secondary structure of the








Figure 1.4: structure of the glucocorticoid receptor DNA binding domain.
The two Zn ions are represented by filled circles. HI-HIII are the amino acid helices. Adapted
from (Kumar and Thompson, 1999).
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Helices I and II are a-helices (Hard et al., 1990) and lie perpendicular to each other at
the base of a hydrophobic core (Luisi et al., 1991), while helix III is somewhat
distorted (Hard et al., 1990). The DBD of each GR monomer contains 2 "zinc finger"
motifs (consisting of 4 highly conserved cysteine residues coordinating binding of a
Zn atom) and can be considered as two structurally and functionally distinct
subdomains, each nucleated by one of the zinc coordination centres followed by an
amphipathic protein helix ((Luisi et al., 1991), reviewed in (Kumar and Thompson,
1999)). The first subdomain mediates site-specific recognition ofDNA, especially
via 3-4 amino acid residues in helix I termed the P box (Luisi et al., 1991). During
DNA binding helix I lies in the major groove of the DNA (Luisi et al., 1991). The
second subdomain contains a sequence of amino acids termed the D box which is
important for protein-protein interactions in the dimeric DBD:GRE complex (Luisi et
al., 1991). A single lysine residue in the DBD may act as an "allosteric lock",
interpreting GRE signals by serving as a determinant ofGR conformation and
function and thus preventing transcriptional activation by GR at sites other than
positive GREs (Starr et al., 1996). However, the structure of the DBD may be
somewhat flexible and may undergo a degree of rearrangement during DNA binding
(reviewed in (Kumar and Thompson, 1999)).
The N-terminal domain of GR contains a powerful transactivation domain termed
activation function 1 (AFl/taul/enh2) that plays an important role in gene regulation
(Giguere et al., 1986; Hollenberg et al., 1987). This region is largely unstructured in
aqueous solution but forms a-helices in the presence of trifluoroethanol (Dahlman-
Wright et al., 1995). Mutational studies show that the ability of this domain to
activate a reporter gene in vivo correlates with ability to form a-helices in vitro and
that hydrophobic residues in these a-helices are important in transactivation
(Dahlman-Wright et al., 1995; McEwan et al., 1993). However, the mechanism by
which AF1 might adopt a a-helical conformation in vivo is unclear. It also unclear
how AF1 interacts with other proteins to induce transcription. However, AF1 has
been shown to physically interact with the transcriptional machinery, specifically
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with the Ada2 and TATA-binding protein subunits (Ford et ah, 1997; Henriksson et
ah, 1997). It may do so by an induced fit mechanism, leading to the formation of a
stable complexed structure (Tjian and Maniatis, 1994). Interactions with coactivators
are also likely to be important (reviewed in (Kumar and Thompson, 1999)).
Transcriptional activation and repression by GR is discussed in detail in section 1.11.
In addition, distinct membrane-associated GRs may also exist (Harrison et ah, 1979;
Hua and Chen, 1989; Orchinik et ah, 1991; Sadler et ah, 1985), signalling via G
proteins (Iwasaki et ah, 1997) and possibly mediating some of the rapid non-genomic
effects of glucocorticoids that have been observed (Evans et ah, 1998; Iwasaki et ah,
1997). As they are unlikely to be related to the classical GR, they will not be
discussed further here.
1.5.2 GR isoforms in human cells
The isolation of 2 human GR cDNA clones predicted the existence of 2 receptors
with different carboxyl termini (Hollenberg et ah, 1985). The first 727 amino acids
of the 2 isoforms are the same, but exons 9a and 9(3 undergo alternate splicing with
9a (in GRa mRNA) coding for 50 amino acids while 9P (in GRP rnRNA) codes for
15 nonhomologous amino acids (Encio and Detera-Wadleigh, 1991). Exons 9a and
9P may form 1 large exon encoding the 3' end of the LBD and containing
approximately 4kb of 3' untranslated sequence (Oakley et ah, 1996). The structure of
the GR gene is discussed in section 1.6.
GRa is the predominantly expressed isoform, although 2 variant GRa mRNA
transcripts of 7 and 5.5kb have been reported. Both are widely distributed but the 7kb
variant is more abundant and the 5.5kb variant is particularly scarce in brain (Oakley
et ah, 1996). GRP mRNA is widely expressed in human tissues although it is
approximately 200-500 times less abundant than GRa mRNA (Oakley et ah, 1996).
Homologous genomic sequences for exon 9p have been found in the rat GR cDNA
sequence and RT-PCR products from rat liver and a mouse lymphoma cell line
(Encio and Detera-Wadleigh, 1991). However, the presumed mouse exon 9P contains
an open reading frame of 59 amino acids whereas human exon 9p encodes only 15
(Otto et ah, 1997) and RT-PCR failed to detect GRP mRNA in mice (Otto et ah,
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1997). Furthermore, the rat and mouse sequences homologous to exon 9(3 are not
preceded by a splice site (Otto et ah, 1997). Thus it is not yet known if the GRP
mRNA is translated into protein in vivo and, if so, what the relative levels ofGRa
and GRP are in the cell.
Studies with transfected GRP have shown that it cannot bind the GR ligands
dexamethasone or RU38486 (Oakley et ah, 1996). Its natural ligand, if any, is
unknown. In contrast to ligand-free GRa (section 1.6) it resides primarily in the
nucleus (Oakley et ah, 1996) although it can interact with hsp90, albeit with a lower
affinity than GRa (Oakley et ah, 1999). GRP has been reported to bind DNA with a
greater affinity than GRa in the absence of ligand, although in contrast to GRa the
presence of glucocorticoids does not enhance this binding affinity (Oakley et al.,
1999). GRP inhibits activation of the mouse mammary tumour virus (MMTV)
promoter (section 1.6) by an unknown mechanism (Oakley et al., 1996). GRP can
form heterodimers with GRa (Oakley et al., 1999) and thus may interfere with GRa
activity. Alternatively, GRP may compete with GRa for GREs or for cofactor
binding (Oakley et al., 1996) (section 1.6). Whatever the precise mechanism, the
dominant negative activity ofGRP is dependent on the terminal 15 amino acid
residues (Oakley et al., 1999). The effects of GRP on GR-mediated transcriptional
activation are yet to be demonstrated in vivo and the existence of GRI3 has not been
demonstrated in other species than humans, so its physiological significance is
uncertain.
Recent work has demonstrated the presence of an additional, slightly smaller, 91 kDa
GR protein not recognized by antibodies specific for GRP in human cells (Yudt and
Cidlowski, 2001). When a single human GR cDNA is expressed in COS-1 cells or by
in vitro transcription two forms of GR are observed, similar to those seen in cells that
contain endogenous GR (Yudt and Cidlowski, 2001). These data suggest that two
forms of GRa (GR-A and GR-B) are produced by alternative translation of the same
gene. Mutagenesis of an internal ATG codon corresponding to methionine 27 (M27)
to ACG in human, rat, and mouse GR cDNA resulted in production of GR-A, while
mutagenesis of the initial ATG codon to ACG resulted in production ofGR-B (Yudt
and Cidlowski, 2001). A leaky ribosomal scanning mechanism may be responsible
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for generating these two isoforms (Yudt and Cidlowski, 2001). The two isoforms
exhibit similar subcellular localization and nuclear translocation after ligand
activation but functional analyses show the shorter GR-B to be nearly twice as
effective as the longer GR-A in gene transactivation, but not in transrepression (Yudt
and Cidlowski, 2001). The physiological significance of this is as yet unknown.
1.6 The glucocorticoid receptor gene
The GR gene is large and complex (Figure 1.5). Originally cloned in 1985, the
human glucocorticoid receptor cDNA spans approximately lOOkb and contains 9
exons; a non-coding exon (now designated 1C) and 8 protein-coding exons (2-9)
(Hollenberg et al., 1985). The N-terminal end of the protein is encoded by exon 2,
the zinc fingers are encoded by exons 3 and 4, exon 5 encodes residues involved in
transactivation and exons 6-8 encode the ligand-binding domain (Encio and Detera-
Wadleigh, 1991). Recent evidence suggests that at least 2 other alternate exons 1
exist within GR mRNA from human muscle (Reynolds R, personal communication)
and at least 5 variant exons 1 are present in the human MOLT-4 T cell leukaemia cell
line, one ofwhich lies at least 31kb upstream of the translation start (Breslin et al.,
2001). Primer extension, ribonuclease protection (Zong et al., 1990) and SI nuclease
analysis (Encio and Detera-Wadleigh, 1991) of the human GR mRNA reveals at least
4 transcription start sites for exon 1C. The 5' flanking region of this exon (to -860bp,
with ATG designated as +1) contains no obvious TATA or CAAT boxes but
contains multiple GC boxes which are bound by SP1 and related factors (Encio and
Detera-Wadleigh, 1991; Zong et al., 1990). Additionally, transcription start sites in
the human GR gene corresponding to the rat exons le, lio and In have recently been
identified (Suzuki et al., 2002). Transfection experiments have shown differential
activity of promoters IB and 1C in various cell lines (Nunez and Vedeckis, 2002),
while DNase I footprint and gel mobility shift analysis reveals that AP2 may be an
important activator of the gene (Nobukuni et al., 1995). Also, the human GR gene
promoter contains four binding sites for the transcription factor YinYangl (Breslin
and Vedeckis, 1998) and several SP1 binding sites (Breslin and Vedeckis, 1998;
Nunez and Vedeckis, 2002). As well as the 5' alternate exons described above, 3'
alternate exons of the GR gene may also exist in humans (section 1.5.2).
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The mouse GR gene contains at least 5 alternate exons 1 (Chen et al., 1999b; Strahle
et al., 1992), 4 ofwhich lie within a CpG island (IB-IE) while 1 (1 A) lies
approximately 32kb upstream of the translation start site (Strahle et al., 1992). At
least 3 of the alternate exons (1A-1C) show considerable 5' heterogeneity (Strahle et
al., 1992). Two of the alternate exons are ubiquitously expressed (IB and 1C) while
1A may be restricted to T lymphocytes, since it is found in T-lymphoma cell lines
but not in lines derived from a range of other tissues (Strahle et al., 1992). However,
recent evidence suggests that exon 1A may be more widely distributed (Chen et al.,
1999b) and one report suggests it may be involved in targeting GR to the cell
membrane (Gametchu et al., 1999). Exons ID and IE are widely expressed (Chen et
al., 1999b) and DNase hypersensitive sites are found upstream of exons IB and 1C in
liver and fibroblast cells, consistent with ubiquitous activity of their putative
associated promoters (Strahle et al., 1992).
The rat GR gene has at least 12 alternate exons 1 (Gearing et al., 1993; McCormick
et al., 2000): 5 of these correspond to those identified in the mouse GR gene and two
correspond to the human exons IB and 1C (Figure 1.5). 10 of these alternate exons 1
lie in a 3kb CpG island and 3 are likely to lie over 15kb 5' of the translation start as
they are not present in the rat genomic clone X208, which contains exon 2 and
approximately 15kb of its 5' flanking sequence (McCormick et al., 2000). In the rat,
the alternate exons 1 of the GR gene vary in their tissue-specific relative abundance.
In the hippocampus, approximately 60% of GR mRNA contains exon 1 io and
approximately 20% contains exon U; the remainder of the GR mRNA pool contains
3 other exon 1 variants (~ 8% exon 15, ~ 8% exon 17 and ~ 10% exon In)
(McCormick et al., 2000). In liver, 3 exons 1 are present in most GR mRNA; ~ 10%
contains exon 16, ~ 75% contains exon lio and ~ 2% contains exon In (McCormick
et al., 2000). Most of the GR mRNA in thymus contains exon 1 io (~ 55%) with most
of the remainder containing either exon 11 (~ 25%) or exon H (~ 20%) (McCormick
et al., 2000). Interestingly, expression of some variants appears restricted to certain
tissues: exons I5 and 17 were found in hippocampus but not liver and thymus, while
























1.7 Control of GR gene expression
There is much evidence that the level of GR in the cell is a major determinant of the
level of glucocorticoid signaling in tissues and that the correct level of functional GR
in tissues is critical for its correct physiological function. Overexpression ofGR
leads to increased glucocorticoid sensitivity, while reduced amounts of functional
GR in the cell leads to glucocorticoid resistance. For example, in vitro experiments
show that the level of GR expression in a cell correlates with its glucocorticoid
sensitivity (Vanderbilt et al., 1987). Also, a heterozygous missense mutation in the
GR caused glucocorticoid resistance due to inhibited GR-mediated transcriptional
activation and nuclear translocation ofGR, resulting in pituitary Cushing's Disease
(Karl et ah, 1996). Other human GR mutations are associated with malfunctioning
GR in asthma patients and a frameshift mutation in GR is associated with
glucocorticoid resistance in Nelson's Syndrome (reviewed in (Tenbaum and
Baniahmad, 1997)).
Further evidence for the importance of the level ofGR in the cell comes from
transgenic animals, which are further discussed in section 1.8. For example, GRAS
mice have a 50-70% reduction in GR levels compared to wild-type controls and
show impaired sensitivity of their F1PA axis to glucocorticoid negative feedback
(Pepin et ah, 1992b). The lungs, liver and adrenal glands of GRhypo/hypo mice, which
lack normal GR protein, fail to respond normally to glucocorticoids during
development and these mice show decreased sensitivity of their HPA axis to
glucocorticoid negative feedback (Cole et ah, 1995a). Furthermore, reduced GR
levels in the thymocytes of GRhypo/hypo and GRAS(Thy' mice causes them to be resistant
to glucocorticoid-mediated apoptosis (Cole et ah, 1995a; King et ah, 1995). These
data support the hypothesis that reduced intracellular GR leads to glucocorticoid
resistance. Furthermore, an increase in GR sensitizes tissues to the effects of
glucocorticoids. YGR mice (section 1.8.6) variably overexpress GR in their tissues
(e.g. by 170% in the hippocampus) due to the insertion of a YAC transgene,
resulting in increased sensitivity of their HPA axis to glucocorticoid negative
feedback and increased sensitivity of their thymocytes to glucocorticoid-mediated
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apoptosis (Reichardt et al., 2000b). These data support the hypothesis that increased
intracellular GR leads to increased glucocorticoid sensitivity.
1.7.1 Transcriptional regulation of the GR gene
Much data is available on the dynamic regulation and perinatal programming of GR
levels in various tissues (sections 1.7.2 and 1.7.3), in which GR clearly has an
important role. Although the mechanisms by which GR regulates transcription have
been extensively studied (section 1.11), surprisingly little is known about the
molecular mechanisms regulating expression of the GR gene.
Studies ofGR expression in rat liver (Dong et al., 1988) as well as rat pancreatic
tumour (Rosewicz et al., 1988), rat hepatoma (Dong et al., 1988) and human
lymphoma (Rosewicz et al., 1988) cells suggest that the control of GR levels is
probably at the level of transcription. However, the observation that dexamethasone
reduces the half-life ofGR protein in rat hepatoma cells (Dong et al., 1988) and that
acute stress alters the availability of GR mRNA without demonstrably affecting
transcription (Paskitti et al., 2000) suggests that some post-transcriptional regulation
may occur.
The expression of multiple variant GR exons 1 in rat, mouse and human, the report
that one promoter in the human GR gene (promoter 1A3) is activated by
glucocorticoids (Breslin et al., 2001) and the differential activity of promoters IB
and 1C in different cell lines (Nunez and Vedeckis, 2002) suggest that tissue-specific
control of GR levels may involve alternate promoter usage (section 1.10.2). Indeed,
increased activity of the human promoter 1A has been implicated in T cell apoptosis
and T cell maturation (Chen et al., 1999b; Chen et al., 1999a) and glucocorticoid
autoregulation of promoter 1A activity has been reported (Breslin et al., 2001).
In the human GR gene, a region between 250bp and 750bp 5' of the transcription
start of exon 1C (section 1.6) is implicated in autoregulation and is bound by an
unidentified protein (Leclerc et al., 1991). The transcription factors AP2 (Nobukuni
et al., 1995), YinYangl (Breslin and Vedeckis, 1998) and SP1 (Breslin and
Vedeckis, 1998; Encio and Detera-Wadleigh, 1991; Nunez and Vedeckis, 2002;
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Zong et al., 1990) may be important in regulation of human GR expression. Also, a
mechanism for autoregulation of the human GR gene has been proposed in which
ligand-bound monomeric GR interacts with the jun component ofAP1, reducing
induction of GR expression by reducing API binding to the GR promoter (Vig et al.,
1994).
1.7.2 Dynamic regulation of GR expression
1.7.2.1 Glucocorticoid autoregulation of GR
Glucocorticoids are reported to regulate GR expression in most tissues in which
autoregulation has been investigated. The regulation ofGR expression by
glucocorticoids has been studied most extensively in the hippocampus, since it
contains high levels ofGR (section 1.9.2) and is an important site of glucocorticoid
feedback on the HPA axis (section 1.9.2.4). Interpretation of the various studies
requires a degree of care, however, since a wide range of experimental
methodologies are employed.
Adrenalectomy (i.e. a reduction in circulating glucocorticoids) of up to 8 days
duration increased hippocampal GR mRNA in rats (Herman et al., 1989a; Herman
and Spencer, 1998; Holmes et al., 1995b; Reul et al., 1989; Sheppard et al., 1990).
Adrenalectomy also increased hippocampal glucocorticoid binding capacity in rats
(Lowy, 1989; Spencer etal., 1991).
Initially, increased hippocampal total GR mRNA (Kalinyak et al., 1987) and
glucocorticoid binding capacity (Reul et al., 1987a) were reported 2 weeks after
adrenalectomy, suggesting that the effects of adrenalectomy were permanent.
However, this was disputed by later studies. In one, hippocampal GR mRNA levels
6h and 2d after adrenalectomy were elevated, yet those 14d after adrenalectomy were
not different from control animals (Holmes et al., 1995b). Another study
demonstrated a transient rise in hippocampal GR mRNA that was abolished by 3d
post-adrenalectomy (Reul et al., 1989). These data suggest that the level ofGR in the
hippocampus may initially rise after adrenalectomy then return slowly to control
levels.
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The administration of exogenous glucocorticoids reduces hippocampal GR levels in
both adrenalectomised and adrenally-intact animals. Corticosterone replacement
given to adrenalectomised rats orally over 5 days (Sheppard et al., 1990) or by
subcutaneous pellets over 4 (O'Donnell et al., 1995), 6 (Spencer et al., 1991), or 7
days (Reul et al., 1987a) at levels similar to physiological either abolished
(O'Donnell et al., 1995; Sheppard et al., 1990; Spencer et al., 1991) or significantly
reduced (Reul et al., 1987a) the adrenalectomy-induced rise in hippocampal GR.
Similar doses of corticosterone reduced the GR levels in adrenally intact animals
(Sapolsky et al., 1984b; Sapolsky and McEwen, 1985; Spencer et al., 1991).
Corticosterone replacement at higher doses administered orally, by injection or by
subcutaneous pellet either reduced (Peiffer et al., 1991a) or had no effect on
(Sheppard et al., 1990) hippocampal GR mRNA and reduced hippocampal
glucocorticoid binding sites (O'Donnell et al., 1995; Patacchioli et al., 1998;
Sapolsky et al., 1984b; Sapolsky and McEwen, 1985; Tornello et al., 1982). Higher
replacement doses also reduced hippocampal GR protein levels (O'Donnell et al.,
1995). Thus it appears that the effects of corticosterone are dose-dependent. Indeed,
one of the above studies clearly showed a dose-dependent effect of corticosterone
replacement in adrenalectomised animals on hippocampal GR binding sites, with
higher replacement doses resulting in reduced GR binding sites compared to controls
(Spencer et al., 1991). Corticosterone also downregulates GR mRNA in cultured
hippocampal neurones (Erdeljan et al., 2001) and reduces glucocorticoid binding
capacity in cultured rat neocortical and hippocampal cells (Vedder et al., 1993).
Similarly, dexamethasone administration abolishes the adrenalectomy-induced rise in
GR mRNA (Herman et al., 1989a; Holmes et al., 1995b; Peiffer et al., 1991a; Reul et
al., 1989), variably reduces hippocampal GR mRNA in adrenally intact animals
(Sheppard et al., 1990) and downregulates GR mRNA in cultured hippocampal
neurones (Erdeljan et al., 2001). Like corticosterone, the effects of dexamethasone
seem to vary with dose, since the magnitude of the reduction in hippocampal GR
mRNA in adrenalectomised animals increased as the amount of dexamethasone
administered increased (Reul et al., 1987a).
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Although several studies report that adrenalectomy increases GR mRNA in CA1/2
and dentate gyrus with corticosterone replacement abolishing this effect (Chao et al.,
1998a; Herman et al., 1989a; Herman and Spencer, 1998; Holmes et al., 1995b), only
two of these four studies report that glucocorticoid manipulation affects GR mRNA
levels in CA3 (Chao et al., 1998a; Holmes et al., 1995b). Thus there may be a region-
specific difference in the magnitude of the effect of glucocorticoids on hippocampal
GR levels. This may reflect the distribution of GR in the hippocampus, since
glucocorticoid manipulation appears to have less effect in areas where is there is less
GR (section 1.9.2).
Several studies have investigated whether hippocampal GR expression is regulated
by glucocorticoids via MR or GR. Both dexamethasone and corticosterone will bind
to either receptor, although dexamethasone has a higher affinity for GR (Arriza et al.,
1988; Spencer et al., 1990) and corticosterone has a higher affinity for MR (Spencer
et al., 1990). Since the hippocampus lacks 11B-HSD2 (Robson et al., 1998) the MR
there are open to corticosterone binding (section 1.3). Thus the effects of
dexamethasone described above are likely to be occurring via GR, while those of
corticosterone could theoretically be modulated via either receptor. Indeed,
administration of the specific MR ligand aldosterone or the specific GR ligand
RU28362 both attenuate the adrenalectomy-induced increase in hippocampal GR
mRNA levels in CA1, while in CA3 only aldosterone has this effect (Chao et al.,
1998a). Also, administration of the MR antagonist spironolactone to adrenally-intact
animals increased GR mRNA and protein in CA1 and DG to levels similar to those
in adrenalectomised animals, while corticosterone administration to the same animals
had no effect on GR mRNA levels (Herman and Spencer, 1998). Taken together with
the data from adrenalectomy/replacement experiments, these data suggest that in vivo
autoregulation of hippocampal GR by corticosterone is occurring via both GR and
MR. Due to their relative affinities for corticosterone (see above) and different
abundances in the hippocampus (section 1.9.2.4), it is likely that at basal
corticosterone levels MR signalling predominates, while at higher glucocorticoid
levels GR signalling becomes more important (reviewed in (Seckl and Olsson,
1995)).
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Glucocorticoids also regulate GR levels in other tissues. In the liver, adrenalectomy
increased GR mRNA expression in rats (Kalinyak et al., 1987; Reul et ah, 1989) and
caused a 2-2.5 x increase in hepatic glucocorticoid binding capacity in mice (Svec et
ah, 1989). However, the effect of adrenalectomy may be less pronounced than in
brain since in rats hepatic GR was increased by only 15% 2 weeks after
adrenalectomy compared to a 40% increase in brain (Kalinyak et ah, 1987). Hepatic
GR in mice may be more sensitive to glucocorticoid regulation since 24h
adrenalectomy caused a 2-2.5 x increase in hepatic glucocorticoid binding capacity
(Svec et ah, 1989). However, this may have reflected loss of endogenous ligand from
the receptors, making them available for binding. Corticosterone replacement in
adrenalectomised rats reduced hepatic GR binding capacity compared to
adrenalectomised controls (Alexandrova et ah, 1989) and intraperitoneal injection of
lmg of corticosterone in adrenalectomised mice downregulated hepatic GR number
by 25% compared to adrenalectomised controls (Svec, 1988). Dexamethasone
treatment of adrenal-intact rats also reduces hepatic GR mRNA levels by
approximately 40% (Kalinyak et ah, 1987). Furthermore, stress reduces GR levels in
the liver of adrenally intact rats, probably due to increased circulating corticosterone
levels (Alexandrova and Farkas, 1992). Overall, these data suggest that
glucocorticoid regulation ofGR levels in the liver is broadly similar to that in the
hippocampus.
In the immune system, however, there is some controversy as to the precise effects of
glucocorticoids on GR levels. One study reported that 6d adrenalectomy had no
effect on thymic GR levels compared to 24h adrenalectomy (Spencer et ah, 1991)
and another reported that 16h adrenalectomy had no effect on thymic GR levels
compared to intact animals (Miller et ah, 1990). This might be due to paracrine
production of glucocorticoids in the thymus ((Lechner et ah, 2000), section 1.9.5.2)
which could maintain their local concentration. This hypothesis is supported by the
fact that adrenalectomy increased GR mRNA in the spleen compared to adrenal-
intact animals (Miller et ah, 1990). However, another study reported a 50% increase
in thymic GR mRNA after 6d adrenalectomy (Peiffer et ah, 1994). One explanation
for this discrepancy could be that there is some post-transcriptional control of GR
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levels in the thymus, although evidence from other tissues suggests that this is
unlikely (section 1.7.1). Alternatively, as postulated in the hippocampus (see above),
the effects of adrenalectomy may vary in the thymus over time.
The effects of glucocorticoid administration in the thymus are also controversial. In
one study, corticosterone replacement caused a reduction in thymic GR binding
capacity and a dose-dependent reduction of GR binding capacity in the spleen
(Spencer et ah, 1991). However, a stress-induced rise in corticosterone sufficient to
reduce GR levels in the hippocampus by 25% had no effect in the thymus (Miller et
al., 1990). Also, glucocorticoids have been shown to increase total GR mRNA in the
human CEM-C7 T cell line (Antakly et ah, 1989; Ashraf et ah, 1991; Denton et ah,
1993; Eisen et ah, 1988). One explanation for this could be that glucocorticoids
upregulate GR in these cells as they undergo apoptosis ((Ramdas et ah, 1999; Tonko
et ah, 2001), section 1.9.5.2).
1.7.2.2 Regulation of GR by other hormones and neurotransmitters
Perhaps the most important neurotransmitter that dynamically influences GR
expression is 5-HT: it may also have an important role in perinatal programming of
GR expression (section 1.7.3). 5-HT upregulated GR mRNA (Erdeljan et ah, 2001;
Hery et ah, 2000; Mitchell et ah, 1990b; Mitchell et ah, 1992) but not MR mRNA
(Erdeljan et ah, 2001; Mitchell et ah, 1990b) in cultures of foetal rat hippocampal
neurones. There is also evidence that 5-HT regulates GR (Seckl et ah, 1990) and MR
(Yau et ah, 1997b) mRNA in hippocampal neurons in vivo.
The interplay between hippocampal glucocorticoid and 5-HT signalling and receptor
regulation in vivo appears to be extremely complex. Reduced hippocampal 5-HT
levels due to lesions of the serotonergic innervation of the hippocampus
downregulate hippocampal GR but not MR mRNA (Seckl et ah, 1990). However,
treatment with the selective 5-HT neurotoxin 3,4-methylenedioxymetamphetamine
(which causes both corticosterone and 5-HT release) decreases GR and upregulates
MR mRNA (Yau et ah, 1997b). Also, the effects of these manipulations are greater
in the dentate gyrus than other hippocampal subfields (Seckl et ah, 1990; Yau et ah,
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1997b). The effects of 3,4-methylenedioxymetamphetamine on GR expression seem
to require both serotonin and corticosterone release throughout the hippocampus,
while its effects on MR expression seem to require corticosterone release only in
CA1-4 (Yau et al., 1997b). Thus it appears that there is a considerable degree of
crosstalk between the 5-HT and GR receptor systems in the hippocampus.
The mechanism by which 5-HT regulates GR and MR expression is not fully
understood. However, there is evidence that it may act via the 5HT2 and/or 5HTic
receptors to cause an increase in intracellular cyclic AMP levels (Mitchell et al.,
1990b; Mitchell et al., 1992).
Several other neurotransmitters downregulate hippocampal GR, e.g. those acting via
NMDA receptors (such as glutamate, aspartate and glycine), gamma-aminobutyric
acid and adrenaline (Tritos et al., 1999). Given that stress modulates the expression
ofmany receptor proteins in the hippocampus such as growth hormone receptor
(Fujikawa et al., 2000), the gamma-amino butyric acid A receptor (Cullinan and
Wolfe, 2000) and MR (Fujikawa et al., 2000), these neurotransmitters are likely to
mediate (along with the effects of 5-HT described above ) many of the effects of
stress on hippocampal GR expression.
GR expression may be regulated by sex hormones, particularly oestrogen. Although
gonadally-intact male and female rats showed no differences in hippocampal GR and
MR number (Turner, 1992), treatment with oestrogen resulted in a reduction of
hippocampal GR number in ovariectomised and adrenalectomised female rats
(Turner, 1992). However, another study reported no change in hippocampal GR with
oestrogen treatment and a downregulation ofMR in the pituitary (Ferrini et al.,
1990). Nevertheless, these data suggest that the effect of oestrogen on GR in the
normally-cycling female rat is relatively small and the mechanism by which
oestrogen might affect GR mRNA expression is unknown. Conversely, thymic GR
mRNA levels varied significantly during the oestrus cycle of rats, with the highest
levels in oestrus and the lowest in proestms. This suggests that the effects of
oestrogen on GR level are tissue-specific. GR levels may also be regulated by
androgens. In the hippocampus, testosterone administration to castrated rats
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downregulated GR mRNA by approximately 30% in CA1 compared to intact
animals (Kerr et al., 1996). Conversely, in the rest of the hippocampus (which, unlike
CA1, has little or no expression of the androgen receptor) testosterone had no effect
(Kerr et al., 1996).
1.7.2.3 Pharmacological regulation of GR
Tricyclic antidepressants can increase GR mRNA levels in cultured primary
hippocampal (Pepin et al., 1989), mouse fibroblast and mouse neuroblastoma cells
(Barden, 1996). They have similar effects in vivo; in rats imipramine and
desipramine increased hypothalamic GR mRNA levels (Peiffer et al., 1991b) and
amytryptiline and desipramine increased hippocampal MR and GR mRNA (Seckl
and Fink, 1992). Amytryptiline and desipramine also increase hippocampal
glucocorticoid binding sites (Okugawa et al., 1999).
The effects of antidepressants on GR and MR expression may be timecourse-
specific, since amytryptiline and desipramine show no effect on GR mRNA after 2d
treatment but do after 14d (Seckl and Fink, 1992). The effects of antidepressants may
also be drug-specific. Chronic lithium chloride injection increased hippocampal GR
but not MR mRNA (Semba et al., 2000), citalopram did not affect hippocampal GR
mRNA at all (Seckl and Fink, 1992) and 9d treatment with the selective serotonin
reuptake inhibitors fluoxetine and venlafaxine had an oppsite effect to the tricyclic
antidepressants, downregulating MR mRNA throughout the hippocampus and GR
mRNA specifically in CA3 (Yau et al., 2001a). Also, the effects seem to be receptor-
specific since amytryptiline administration affected MR expression more quickly
than GR expression (Seckl and Fink, 1992).
5HT regulates GR in hippocampal neurones (section 1.7.2.2), suggesting that these
drugs may exert their effects by altering hippocampal 5HT levels. However,
amytryptiline and desipramine have acute effects on GR expression which may be
due to a direct effect on the cell (Barden, 1996; Okugawa et al., 1999), as does
citalopram (Hery et al., 2000). In particular, desipramine may facilitate GR
translocation and function (Pariante et al., 1997).
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1.7.3 Perinatal programming of GR expression
Over the last decade the "foetal origins hypothesis" that early life events can
"program" the development of tissues and organs, thus influencing adult physiology
and disease (Barker, 1990) has gained wide acceptance. Based on the observations
that low birth weight in humans correlates with adult hypertension (Barker et al.,
1990), glucose intolerance (Hales et al., 1991), non-insulin dependent diabetes
mellitus (McCance et al., 1994) and ischaemic heart disease (Barker, 1991; Valdez et
al., 1994), this hypothesis was linked to glucocorticoid exposure by the observations
that administration of glucocorticoids to pregnant humans and rats throughout
pregnancy leads to reduced birthweight of offspring (Reinisch et al., 1978) and that
foetal Cortisol levels are elevated in intrauterine growth disorder (Goland et al.,
1993). Dexamethasone administration in the third trimester of pregnancy causes
reduced birthweight (Levitt et al., 1996; Nyirenda et al., 1998) as well as high blood
pressure (Levitt et al., 1996) and fasting and post-glucose hyperglycaemia (Nyirenda
et al., 1998) in adult offspring. The effects of dexamethasone on carbohydrate
metabolism are associated with increased PEPCK and GR mRNA in the periportal
region of the liver, a major site of hepatic gluconeogenesis (Nyirenda et al., 1998).
Taken together, these data suggest that increased glucocorticoid exposure in utero
may be responsible for programming in humans and rats. The precise mechanism by
which the programming of hepatic GR levels by glucocorticoids occurs is unknown.
Recent investigations in our laboratory suggest that changes in alternate promoter
usage may be involved, since prenatal glucocorticoid exposure decreases the
proportion of hepatic GR mRNA containing exon 1 io of the GR gene (section 1.6),
suggesting an increase in usage of a minor exon 1 variant (McCormick et al., 2000).
In contrast to the effect in the liver, foetal overexposure to glucocorticoids due to in
utero dexamethasone exposure in the third trimester of pregnancy permanently
decreased GR and MR mRNA in the hippocampus (Levitt et al., 1996) while
maternal restraint stress reduced hippocampal GR and MR levels in the offspring
(Henry et al., 1994). The programming effect appears to be region and receptor-
specific since the reduction in GR mRNA due to dexamethasone exposure was
confined to CA1 and dentate gyrus while that in MR mRNA was confined to CA1
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and CA2 (Levitt et al., 1996). Interestingly, animals exposed to dexamethasone in
utero throughout pregnancy showed no change in their hippocampal GR and MR
levels (Welberg et al, 2001), suggesting that the programming effect only occurs if
the hormonal environment of the foetus is different during the last trimester to that
earlier in pregnancy. Postnatal exposure to dexamethasone in the first week of life
permanently reduces hippocampal GR (but interestingly not MR) levels with no
effect on basal corticosterone secretion (Felszeghy et al., 1996), providing further
evidence that the effect of the programming stimulus depends on the time of
exposure. Animals exposed to dexamethasone during the third trimester show
hypertension and increased basal plasma corticosterone levels in adulthood (Levitt et
al., 1996). They also show impaired learning and increased anxiety (Welberg et al.,
2001), as do the offspring of stressed dams (Vallee et al., 1997) which also show
impaired post-stress HPA axis feedback (Henry et al., 1994). The observed increase
in anxiety may be a consequence of elevated CRH expression in the amygdala
(Welberg et al., 2001).
"Neonatal handling" of rat pups has profound programming effects. In this paradigm,
rat pups are subjected to 15 minutes daily maternal separation during the first 3
weeks of life (Meaney et al., 1985). In fact, the effects of handling were later found
to be due to altered maternal behaviour, with increased licking and grooming of
handled pups being induced by the brief separation (Liu et al., 1997). Adult handled
animals showed increased hippocampal GR compared to nonhandled controls
(Meaney et al., 1985; Meaney and Aitken, 1985). They also secreted less ACTH and
corticosterone in response to stress and terminated corticosterone secretion more
quickly following stress than did the nonhandled rats (Meaney et al., 1988; Meaney
et al., 1989). The offspring of high licking/grooming dams showed similar changes in
hippocampal GR mRNA expression and HPA axis activity to handled animals (Liu
et al., 1997). Handled animals also showed increased GR mRNA and protein in the
hippocampus and frontal cortex in old age (Meaney et al., 1985; Sarrieau et al.,
1988) and maintained lower basal corticosterone levels, showed reduced
hippocampal cell loss and had improved spatial memory compared to nonhandled
controls (Meaney et al., 1988). Thus the effects of handling or high licking/grooming
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seem to be to reduce the cumulative exposure of these animals to glucocorticoids
over their lifespan and perhaps to prevent the deleterious effects of glucocorticoids
during aging (section 1.9.2.6).
Interestingly, prolonged maternal separation (for 3h daily for the first 3 weeks of life
or 24h once at postnatal days 3-4) seems to have the opposite effect to neonatal
handling. Adult maternally-deprived animals showed reduced GR mRNA in their
frontal cortex, hypothalamic paraventricular nucleus and hippocampal CA1 subfield
(Avishai-Eliner et al., 1999), elevated ACTH levels in response to mild stress
(Plotsky and Meaney, 1993) and may have impaired spatial memory in old age
(Meaney et al., 1996) compared to nonseparated control animals. Unlike handled
animals that show reduced anxiety, separated animals show normal anxiety responses
to novelty (Biagini et al., 1998). These data suggest that maternally separated
animals may be less able to "cope" with stress.
The overall effect of handling is proposed to be that the early postnatal environment
increases glucocorticoid receptor gene expression, leading to increased sensitivity to
the feedback effects of glucocorticoids, thus altering the responsivity of the axis to
subsequent stressors (reviewed in (Meaney et al., 1996)). The mechanisms
underlying the handling effect are not fully understood. The current model proposes
that increased levels of circulating thyroxine and its metabolite triiodothyronine in
handled pups lead to increased hippocampal 5-HT turnover, activation of
hippocampal 5-HT receptors which increase intracellular cAMP leading to changes
in GR expression (Meaney et al., 1987; Meaney et al., 2000; Mitchell et al., 1990a;
Smythe et al., 1994). This hypothesis is supported by studies showing that in vivo
administration of the 5-HT receptor antagonist ketanserin or the 5-HT neurotoxin
5,7-DHT decreased the handling effect on GR expression (Mitchell et al., 1990b).
Also, 5-HT increased cAMP levels and subsequently GR levels in primary
hippocampal cultures (Mitchell et al., 1990b; Mitchell et al., 1992) but not in glial
cells (Mitchell et al., 1990a), while hippocampal cAMP is increased in rat pups
immediately post-handling (Meaney et al., 1996). Finally, treatment of cultured
hippocampal cells with the stable cAMP analogue 8-bromo-cAMP increases GR
levels (Mitchell et al., 1992). However, there is as yet no direct in vivo evidence that
60
the effects of handling on GR expression are via 5-HT receptors activating the cAMP
second messenger cascade. The mechanism by which GR gene expression is altered
by handling is unknown, but recent work from this laboratory suggests that changes
in alternate promoter usage in the GR gene may be involved, since neonatal handling
caused a selective increase in the expression of GR mRNA transcripts containing the
hippocampus-specific exon I7 (McCormick et al., 2000). This change in promoter
usage may be via cyclic AMP-protein kinase A pathways involving the activation of
NGFI-A and AP-2 (Meaney et al., 2000). It has been recently proposed that
increased expression of these factors after handling might protect areas of the GR
gene promoter from methylation during development, thus increasing their
transcriptional activity in later life (Weaver et al., 2001). However, this is highly
speculative.
During development, the expression ofmany receptors is influenced by the first
encounter of receptor and ligand, a phenomenon termed "hormonal imprinting"
(Csaba and Inczefi-Gonda, 1998; Gaal and Csaba, 1998). Also, perinatal exposure to
molecules similar to the specific ligand can cause receptor binding and "false
imprinting". GR is thus by no means unique, since the programming effect of
prenatal dexamethasone on hepatic GR expression may be considered hormonal
imprinting (Nyirenda et al., 1998) and GR is also subject to false imprinting by in
utero exposure to the pollutant benzpyrene and neonatal administration of vitamin A,
which permanently reduce and increase thymic GR levels respectively (Csaba et al.,
1991; Csaba and Inczefi-Gonda, 1992; Gaal and Csaba, 1998). As seen above for
perinatal programming ofGR expression, the mechanism by which hormonal
imprinting affects receptor expression is unknown. Like programming, however,
imprinting is thought to involve postreceptor events (Csaba and Inczefi-Gonda,
2001).
1.8 Transgenic models of altered glucocorticoid action
A number of transgenic mouse models have been generated to help elucidate the
functions of glucocorticoids in various tissues. In this section I shall summarise the
various models and the phenotype associated with each. The relevance of particular
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aspects of the phenotype in different organ systems will be highlighted in subsequent
sections. The structure of the GR gene is described in section 1.6.
Some of the transgenic models alter the endogenous GR gene in all or a subset of
tissues, while others were generated by addition of a transgene.
1.8.1 GRhyp°/hyp° mice
These mice were generated by insertion of a neomycin resistance cassette into exon 2
of the GR gene (Cole et al., 1995b). Mice homozygous for this mutant allele show no
detectable GR mRNA by Northern blotting (Cole et al., 1995b) and a variety of
phenotypic features consistent with abolished GR signalling. The majority of these
mice die within a few hours of birth due to lung atelectasis (Cole et al., 1995b; Cole
et al., 1995a).Also, they exhibit impaired HPA axis feedback regulation, increased
plasma ACTH and corticosterone concentrations, reduced induction of
glucocorticoid-induced enzymes (glucose-6-phosphatase, tyrosine aminotransferase
and phosphoenolpyruvate carboxykinase) in the liver at birth and abnormal adrenal
gland development with a lack ofmedullary chromaffin cells (Cole et al., 1995b;
Cole et al., 1995a).
Despite these abnormalities, up to 20% of these mice survive to adulthood (Finotto et
al., 1999) and, despite a lack of detectable GR mRNA and protein, surfactant levels
in the lungs of these survivors are normal (Cole et al., 1995a). These data suggested
that some GR activity persisted and it was subsequently discovered that the mice
express mRNAs encoding an amino-terminal truncated GR protein containing the
DNA and ligand-binding domains (Tranche et al., 1998). In fact, these mice show
high affinity binding of dexamethasone in protein extracts of liver, kidney, lung and
brain at levels 30-60% of those in wild-type mice (Cole et al., 2001). However,
thymocytes and cultured hepatocytes from these animals remain dexamethasone-
insensitive (Cole et al., 2001).
1.8.2 GRnull/nul1 mice
These mice have a complete lack ofGR activity due to deletion of exon 3 of the GR
gene which encodes the first zinc finger of the DNA binding domain (Finotto et al.,
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1999). The phenotype of these mice is similar to that of the GRhypo/hypomice but with
increased penetrance and severity: 100% ofmice homozygous for this allele die at
birth due to lung atelectasis (Finotto et al., 1999) and show reduced gluconeogenic
enzyme expression in the liver, a lack of glucocorticoid-mediated T cell apoptosis in
vitro, impaired proliferation of erythroid progenitors (Tronche et al., 1998) and
impaired stress erythropoiesis (Bauer et al., 1999).
Subsequently, a modified strategy placing the Cre recombinase under the control of
the neuron-specific nestin promoter allowed the generation ofmice (GRNesCre mice)
with a brain-specific GR knockout (Tronche et al., 1998; Tronche et al., 1999). These
mice have no detectable GR in brain but normal pituitary GR (Tronche et al., 1999).
Phenotypically, the mice show impaired HPA axis feedback, with increased CRH
peptide levels in the hypothalamus, increased ACTH and POMC mRNA in the
anterior pituitary and increased basal plasma ACTH and corticosterone levels
(Tronche et al., 1999). They also show reduced growth rates, an increased incidence
of osteoporosis and reduced anxiety responses (Tronche et al., 1999). Adult GRNesCre
mice also have disturbed energy balance, with reduced fat and protein deposition,
reduced food intake and reduced metabolic efficiency which is possibly accompanied
by disturbed control of circulating leptin levels (Kellendonk et al., 2002).
1.8.3 GRdim/dim mice
A point mutation altering a single amino acid (Ala458 to Thr) in the D loop of the
GR protein disrupts the formation ofGR homodimers (section 1.6). This mutation
was engineered into the endogenous GR gene in mouse embryonic stem cells using a
Cre/LoxP targeting strategy (Reichardt et al., 1998).
Transgenic mice homozygous for this allele have dimerisation-deficient GR but
survive to adulthood and have normal fertility (Reichardt et al., 1998). There is a loss
of transactivation associated with the DNA binding ofGR dimers e.g. of the tyrosine
aminotransferase gene, although the repressing function of GR via direct protein-
protein interactions with other transcription factors (section 1.11.2) is retained
(Reichardt et al., 1998). CRF expression in these animals is normal, but they exhibit
increased pituitary POMC and ACTH expression (though serum ACTH
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concentrations are normal) and increased basal serum corticosterone concentrations
(Reichardt et al., 1998). Development of the adrenal medulla is normal (Reichardt et
al., 1998), but thymocytes from these animals are completely resistant to
dexamethasone (section 1.9.5.2).
These mutant receptors retain some ability to activate a mouse mammary tumour
virus promoter in vitro (Heck et al., 1994; Reichardt et al., 1998). The normal
development of the adrenal glands and lungs (section 1.9) of these mice (Reichardt et
al., 1998) and their survival to adulthood suggests that such activation is also
occurring in vivo, perhaps through cross-talk of the GR with other transcription
factors (Reichardt et al., 1998). However, dimerisation of liganded GR monomers
could occur via protein-protein interactions between their ligand-binding domains, so
some dimerisation activity may still be present in these mice. Thus genes with high-
affinity GREs in these mice may still be activated at low levels due to binding of GR
monomers to GRE half-sites.
1.8.4 GRASmice
These mice express a 1.8kb GR antisense mRNA under the control of the
neurofilament gene promoter (Pepin et al., 1992b). This promoter was originally
intended to target expression of the antisense mRNA to the central nervous system,
but this was unsuccessful: the mice in fact express the transgene in all tissues
examined (Pepin et al., 1992b).
Transgenic mice exhibit a variable reduction in GR mRNA expression in all tissues
studied, with a 50-70% reduction in the hypothalamus and frontal cortex and a 30-
55% reduction in the liver. They also exhibit reduced GR binding sites in frontal
cortex, hypothalamus, pituitary and liver (Pepin et al., 1992b). From this data it can
be seen that this model is by no means a complete GR knockout. Grossly, the mice
are much larger than control animals, with increased fat deposition but, interestingly,
decreased appetite (Pepin et al., 1992b). The mice show HPA axis dysregulation with
increased plasma ACTH and corticosterone levels (Pepin et al., 1992b).
64
1.8.5 GRAS(Thv) mice
These mice show thymus-specific expression of a GR antisense transgene and were
also generated using a GR antisense mRNA construct, but expression of the
transgene was restricted to thymocytes by placing it under the control of the Ick
promoter (King et al., 1995) which is only active in immature thymocytes (Garvin et
al., 1990). Indeed, expression of the transgene was only detected in the thymus and at
very low levels in the spleen (King et ah, 1995). Phenotypically, these mice exhibit
normal HPA axis activity and plasma corticosterone levels, a 50% reduction in GR
mRNA and 43% reduction in GR protein in the thymus, normal GR mRNA levels in
splenocytes, impaired glucocorticoid-mediated gene induction in thymocytes and
altered thymocyte selection (section 1.9.5.2) (King et ah, 1995).
Pazirandeh et al independently generated mice expressing antisense and sense GR
transgenes in the thymus by the same technique (Pazirandeh et ah, 2002). The mice
expressing the antisense transgene show a 25% reduction in thymocyte GR, while
those expressing the sense transgene show a twofold increase in thymocyte GR
(Pazirandeh et ah, 2002). Both transgenics show altered thymocyte selection,
thymocyte numbers and thymus size (Pazirandeh et ah, 2002).
1.8.6 Mice overexpressing GR from a YAC transgene (YGR mice)
These mice were created by microinjection of a 290kb yeast artificial chromosome
(YAC) carrying 2 additional copies of the GR allele into mouse oocytes (Reichardt et
ah, 2000b). The mice showed a variable increase in GR mRNA expression in
different tissues, with the highest overexpression in the pituitary and brain (43% and
60% respectively) and a 20-24% overexpression in spleen, thymus and liver
(Reichardt et ah, 2000b). However, in all tissues expression of the transgene is
exactly equivalent to that of the endogenous GR gene, demonstrating autoregulation
of the transgene by glucocorticoids (Reichardt et ah, 2000b). YGR mice had
approximately 50% more GR in the hippocampus than wild-type controls, indicating
that the increase in GR mRNA expression was followed by an increase in GR protein
levels (Reichardt et ah, 2000b).
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Phenotypically, these mice showed reduced basal corticosterone levels, increased
basal ACTH levels, reduced responses to restraint stress, faster resolution of the
stress response and reduced inflammatory responses compared to wild-type controls
(Reichardt et ah, 2000b).
1.9 The physiological role of glucocorticoids and GR
1.9.1 Glucocorticoids and development
Glucocorticoids influence many aspects of foetal development. Glucocorticoid
synthesis begins early in the development of the foetal adrenal, with circulating
levels rising to a peak at birth (Arai and Widmaier, 1993; Nagaya et al., 1995).
Glucocorticoids are essential for lung development: GRnuli/nu11 mice (section 1.8.2)
die at birth due to lung atelectasis (Finotto et ah, 1999) and CRH' mice develop
cyanosis and die within 24 hours of birth (Muglia et ah, 1999). GR mRNA is mainly
expressed in the lung mesenchyme, although there is some expression in the
bronchial epithelium. Glucocorticoids promote the development of normal lung
architecture: dexamethasone increases alveolar lumen size and type II (surfactant-
producing) pneumocyte density in human foetal lung organ cultures (reviewed in
(Mendelson, 2000)). This may be a partially indirect effect, by inducing the
expression ofmesenchymal factors that act on the epithelium to regulate
morphogenesis and function (Mendelson, 2000). Glucocorticoids also promote
surfactant synthesis. The synthetic glucocorticoid betamethasone increased the
intracellular concentration ofphosphatidyl glycerol and fatty acids (lipid activators
of cholinephosphate cytidyltransferase, the rate-limiting enzyme in surfactant
synthesis) (Mallampalli et al., 1994) and increased the expression of surfactant-
proteins A, B and C (Ballard et al., 1996; McCormick and Mendelson, 1994).
The chromaffin cells of the adrenal medulla synthesise the catecholamines
noradrenaline and adrenaline (Ganong, 1989). Glucocorticoids stimulate the
differentiation of neural crest cells into a chromaffin rather than a neural phenotype
and prevent neural crest cells developing a neural phenotype by reducing the
expression ofneural-specific genes e.g. SCG10 (Stein et al., 1988). Also, they induce
expression of the enzyme phenylethanolamine-N-methyl transferase (PNMT), which
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converts noradrenaline into adrenaline, in neural crest cells that are destined for a
chromaffin phenotype (Jiang et al., 1989; Michelsohn and Anderson, 1992; Ross et
al., 1990; Teitelman et al., 1982) but not those that are destined for a neuronal
phenotype (Jiang et al., 1989). Perplexingly, despite the fact that GRhypo/hypo mice
(section 1.8.1) have a disorganized adrenal medulla and chromaffin cells containing
reduced levels ofPNMT (Cole et al., 1995b; Cole et al., 1995a), GRnull/nu" mice have
normal chromaffin cell numbers (though they lack PNMT expression) (Finotto et al.,
1999). It has been suggested that glucocorticoid signaling may only modulate
chromaffin cell differentiation with spatial restriction ofbiochemical signals
responsible for stabilizing the neuronal phenotype, adrenal inhibitors of neuronal
differentiation or neurite-repulsive cues reaching chromaffin cells being mainly
responsible for differentiation (Finotto et al., 1999).
1.9.2 Central effects of glucocorticoids
Glucocorticoid receptors are widely expressed in the brain (reviewed in (McEwen et
al., 1986)). GR rnRNA is particularly abundant in the hippocampus, with highest
levels in CA1/2 and dentate gyrus and lower levels in CA3 (Herman et al., 1989a;
Sousa et al., 1989). The distribution ofGR binding sites (Gerlach and McEwen,
1972; Sapolsky et al., 1983) and receptor protein (Fuxe et al., 1985) in the brain and
hippocampus is consistent with the mRNA distribution. Evidence suggests that
hippocampal GR mRNA levels vary dynamically during intrauterine development,
with highest levels during the third trimester ofpregnancy (Andrews and Matthews,
2000).GR is also abundant in the cerebellum, especially during development (Pavlik
and Buresova, 1984), amygdala, cortex, thalamus and hypothalamus (Sousa et al.,
1989).
The mineralocorticoid receptor is also expressed throughout the brain (Arriza et al.,
1988) but high levels of expression are mainly restricted to the lateral septum and
hippocampus (Arriza et al., 1988; deKloet et al., 1975; Reul and DeKloet, 1985). In
the hippocampus, MR mRNA is most abundant in the proximal part ofCA3,
followed by CA1/2 and dentate gyrus with lower levels in the distal part ofCA3
(Herman et al., 1989a). MR mRNA is more abundant than GR mRNA in all
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hippocampal subfields (Herman et al, 1989a). The distribution ofMR protein in the
hippocampus is largely similar to that ofMR mRNA with highest levels in CA1 and
dentate gyrus (Reul and DeKloet, 1985). Due to absence of 11P-HSD2 (Robson et
al., 1998), the MR in hippocampus effectively function as glucocorticoid receptors.
1.9.2.1 Central control of glucocorticoid secretion
The secretion of glucocorticoids is controlled by the activity of the hypothalamic-
pituitary-adrenal (HPA) axis (Figure 1.6) via a classical negative feedback loop.
Glucocorticoid secretion follows a circadian rhythm, with the greatest secretion
being just before the beginning of the animal's period of activity (in the morning in
humans and in the evening in rats). This "clock" is ultimately governed by the
suprachiasmatic nucleus of the hypothalamus. Also, glucocorticoid secretion









Figure 1.6: the hypothalamic-pituitary-adrenal axis. Adapted from (Ganong, 1989).
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1.9.2.2 Pituitary control of adrenal activity
Glucocorticoid production in the adrenal cortex is stimulated by adrenocorticotrophic
hormone (ACTH), a 39 amino acid polypeptide produced in the anterior pituitary
from the prohormone proopiomelanocortin (POMC). POMC is the precursor for
several other hormones (including as B-lipotropin, an endorphin/encephalin
precursor) and is secreted from several other tissues e.g. the hypothalamus, lungs,
gastrointestinal tract and placenta (Ganong, 1989).
ACTH rapidly stimulates glucocorticoid synthesis by activating the cyclic AMP
(cAMP) second messenger system via a high-affinity G-protein coupled membrane
receptor. Increased intracellular cAMP activates protein kinase A, which in turn
phosphorylates cholesterol ester hydrolase thus increasing conversion of cholesterol
esters to free cholesterol (Ganong, 1989).
Prolonged exposure to ACTH increases the maximum adrenal secretory capacity by
delayed induction of the 5 cytochrome P450 enzymes involved in glucocorticoid
synthesis (Ganong, 1989) through a poorly-defined signalling cascade (Parker and
Schimmer, 1993).
Corticotrophin-releasing hormone (CRH, a 41 amino acid polypeptide) and arginine
vasopressin (AVP) secreted from projections of the parvocellular neurones of the
medial hypothalamic paraventricular nucleus travel through the hypophyseal portal
circulation to the anterior pituitary where they stimulate POMC production and
ACTH release (Ganong, 1989). Various other peptides e.g. vasoactive intestinal
polypeptide, pituitary AC-activating polypeptide, secretin, glucagon, glucagon-like
peptide, parathyroid hormone and parathyroid hormone related protein may modulate
HPA axis activity (reviewed in (Nussdorfer et al., 2000)).
1.9.2.3 Feedback regulation at the hypothalamus and pituitary
Much evidence supports the hypothalamus as a site of negative feedback via GR,
which is abundant in this area as discussed above. Glucocorticoids regulate CRH
mRNA expression in hypothalamic parvocellular neurons (Herman et al., 1992),
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possibly via GR binding to a negative GRE (Malkoski et al., 1997). Lesions of the
ventromedial hypothalamus disrupt glucocorticoid negative feedback ((Suemaru et
al., 1995), reviewed in (McEwen et al., 1986)). Furthermore, studies using the
chronic hypovolaemia stress model suggest that corticosterone levels mediate CRH
secretion in 2 ways, with inhibition via the GR and facilitation of secretion via MR-
mediated signaling which functions to maintain transcription in the face of chronic
activation (reviewed in (Tanimura and Watts, 2001)). More recently, GRNesCre mice
(section 1.8.2) showed HPA axis hyperactivity with a 5-fold increase in CRH
production (Kretz et al., 1999), increased POMC expression in the anterior pituitary
and increased plasma corticosterone concentration (Tranche et al., 1998) consistent
with impaired glucocorticoid feedback on HPA axis activity. Conversely, YGR mice
show a more than twofold reduction in CRH immunoreactivity in the median
eminence of the hypothalamus (Reichardt et al., 2000b).
The pituitary has been long established as a site of glucocorticoid negative feedback
(Ganong, 1989) which occurs by fast, intermediate and slow mechanisms (reviewed
in (Keller-Wood and Dallman, 1984)). The fast and intermediate mechanisms do not
require changes in gene transcription (reviewed in (Keller-Wood and Dallman,
1984)) and fast feedback was unaffected by the protein synthesis inhibitor
actinomycin D, supporting the hypothesis that it occurs via a nongenomic
mechanism (Hinz and Hirschelmann, 2000). The slow mechanism involves the
classical genomic steroid mechanism of action (reviewed in (Keller-Wood and
Dallman, 1984)); POMC gene transcription and thus ACTH production in the
anterior pituitary are reduced by glucocorticoids (Drouin et al., 1987; Seger et al.,
1988), probably via a negative GRE (Drouin et al., 1987; Riegel et al., 1991). Also,
dexamethasone decreases CRF receptor mRNA in cultured rat anterior pituitary cells
(Sakai et al., 1996).
GR is important in pituitary glucocorticoid feedback. Immuntohistochemistry located
numerous glucocorticoid receptors in the anterior pituitary (Antakly and Eisen,
1984). Dexamethasone suppression ofACTH secretion has been shown to act via
pituitary GR (Cole et al., 2000) and pituitary adenomas that were unresponsive to
dexamethasone suppression had significantly lower GR mRNA than glucocorticoid-
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responsive tumours (Mu et al., 1998). Administration of the GR antagonist RU486 to
patients with pituitary-dependent Cushing's Disease caused an increase in circulating
Cortisol while the same treatment had no effect on patients with non-pituitary
Cushing's Disease (Bertagna et al., 1986). GRhypo/hypo mice show a 20-fold increase
in plasma ACTH and a 2-3 fold increase in plasma corticosterone compared to
normal mice (Cole et al., 1995a) while GRdim/dim mice exhibit elevated POMC
mRNA levels and a 2.2-fold increase in ACTH immunostaining in their pituitary,
indicating that feedback inhibition ofPOMC/ACTH may be abolished at the
transcriptional level in these animals (Reichardt et al., 1998). However, these animals
do not show elevated serum ACTH levels, attributed by the authors to a DNA-
binding independent regulation ofACTH secretion by GR (Reichardt et al., 1998).
Conversely, YGR mice show an approximately threefold reduction in POMC and
ACTH expression in the anterior pituitary, with a fourfold reduction in serum
corticosterone levels compared to wild-type mice (Reichardt et al., 2000b).
Perplexingly, these mice also show elevated plasma ACTH levels, attributed to
developmental influences causing a new equilibrium of basal hormone secretion due
to GR overexpression (Reichardt et al., 2000b).
Inactivation ofGR in the nervous system of GRNesCre mice allows discrimination
between the function of GR in the brain and anterior pituitary (Tronche et al., 1999).
Despite normal GR-mediated negative feedback in the anterior pituitary, these mice
exhibit elevated basal glucocorticoid levels due absent PVN negative feedback
(Tronche et al., 1999) which disinhibits CRH production, leading to increased ACTH
synthesis in the anterior pituitary (Tronche et al., 1999). However, circulating ACTH
levels are slightly reduced, possibly due to the increased corticosterone levels
inhibiting pituitary ACTH secretion (Tronche et al., 1999). The data from the
GRdim/dim^ yGR and GRNesCre mice shows that changes in circulating glucocorticoid
levels are not always accompanied by a parallel change in ACTH levels. Also, the
absence ofGR in the brain leads to an increase in HPA axis activity which pituitary
GR cannot compensate for (Tronche et al., 1999).
Mice ubiquitously expressing a GR antisense transgene exhibit signs ofHPA axis
hyporesponsiveness to glucocorticoids, requiring 1 Ox higher doses of dexamethasone
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to completely suppress corticosterone secretion than controls (Barden et al., 1997;
Stec et al., 1994). Furthermore, the mice show a shorter duration of dexamethasone
suppression ofACTH secretion (Barden et al., 1997), enhanced ACTH responses to
stress (Karanth et al., 1997) and reduced corticosterone negative feedback on CRH
release (Karanth et al., 1997) compared to controls. However, there is some
controversy over the level of basal HPA axis activity in these animals, with initial
findings of increased plasma ACTH and corticosterone concentrations (Pepin et al.,
1992b) being rebutted in a later report (Karanth et al., 1997), suggesting that the high
levels measured initially may not have been representative.
1.9.2.4 Other central influences on HPA axis activity
The hypothalamus receives neuronal inputs from several brain regions and integrates
a variety of complex environmental and emotional influences on HPA axis activity,
e.g. fear (via the amygdala, see below), diurnal rhythm (from the suprachiasmatic
nucleus), nociceptive stimuli (via the reticular formation) and baroceptor inputs
(from the nucleus tractus solitarius) (Ganong, 1989).
The hypothalamus also receives indirect neural inputs from the hippocampus via
inhibitory GABAergic projections from the bed nucleus of the stria terminalis (BST)
and the preoptic nuclei (reviewed in (Herman and Cullinan, 1997)). The
hippocampus has a complex role in HPA axis regulation that is still the subject of
some controversy. Total or dorsal hippocampectomy causes increased CRF and AVP
expression in the hypothalamic paraventricular nucleus and increases circulating
corticosterone levels (Herman et al., 1989b). Also, inhibition of hippocampal GR and
MR using implanted antagonist pellets attenuated the inhibitory effect of
dexamethasone on CRH release from the hypothalamus and increased the CRH
response to auditory and photic stimulation (Feldman and Weidenfeld, 1999). These
data support the hypothesis that the hippocampus has an inhibitory influence on HPA
activity (reviewed in (Jacobson and Sapolsky, 1991)).
Both types of glucocorticoid receptor, MR and GR, are expressed in the
hippocampus (Herman et al., 1989a; McEwen et al., 1986). The MR in brain bind
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corticosterone with high affinity but low capacity, so are largely occupied under
basal conditions, whereas the GR bind corticosterone with lower affinity but higher
capacity (as there are more GR present than MR) and thus become occupied at
higher corticosterone levels e.g. during stress (Reul et ah, 1987b; Spencer et ah,
1990). Indeed, under conditions of basal HPA axis activity the majority of
glucocorticoid signalling in the hippocampus seems to be mediated by MR
signalling, since adrenalectomy-induced elevations in ACTH secretion are
suppressed by corticosterone but not by the predominantly GR ligand dexamethasone
(Kovacs and Makara, 1988) and intracerebroventricular administration of a MR
antagonist increases plasma corticosterone levels at the morning nadir in rats (Ratka
et ah, 1989). Studies using the MR antagonist spironolactone in rats (Bradbury et ah,
1994) and humans (Deuschle et ah, 1998) again suggest that MR activation controls
HPA axis activity at the diurnal trough in glucocorticoid secretion. Interestingly,
there appears to be some cross-talk between the MR and GR signaling pathways
since hippocampal MR signaling appears to potentiate the inhibition of ACTH
secretion by GR activation (Bradbury et ah, 1994).
However, hippocampal GR also seem to be important in controlling HPA axis
activity, especially at higher glucocorticoid levels e.g. during stress or at the diurnal
peak of glucocorticoid secretion. Chronic stress causes downregulation of
hippocampal GR over 7 day (Paskitti et ah, 2000), 14 day (Kitraki et ah, 1999), 18
day (Kim et ah, 1999), 3 week (Sapolsky et ah, 1984b) and 4 week (Mizoguchi et ah,
2001) experimental periods. This effect is likely to be partly mediated by
glucocorticoids (section 1.7.2.1), but probably involves signalling via several
neurotransmitter systems as discussed in section 1.7.2.2. Depletion of hippocampal
GR causes corticosterone hypersecretion after stress, but leaves basal corticosterone
levels unchanged (Sapolsky et ah, 1984a). At glucocorticoid levels above basal, the
GR antagonist RU38486 decreases ACTH secretion (van Haarst et ah, 1997), but has
no effect on basal corticosterone secretion (Ratka et ah, 1989). Evidence from
GRdim/dim mjce suggests that the actions of corticosteroids in the hippocampus require
the DNA binding of GR homodimers (Karst et ah, 2000) and YGR mice show a 60%
increase in hippocampal GR, reduced CRH, POMC and ACTH levels and a fourfold
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reduction in basal serum corticosterone levels (Reichardt et al., 2000b). Additionally,
manipulations that decrease hippocampal GR are consistently associated with
diminished feedback regulation and elevated plasma glucocorticoid levels (Henry et
al., 1994; Jacobson and Sapolsky, 1991) whereas manipulations that increase
hippocampal GR have the opposite effect (Meaney et al., 1988; Meaney et al., 1989;
Meerlo et al., 1999; O'Donnell et al., 1994). However, it has been suggested that
increased hippocampal GR might indirectly improve feedback regulation by altering
behaviour and the animal's ability to cope with stress ((Vallee et al., 1997), reviewed
in (Anisman et al., 1998)).
As mentioned above, other brain regions can influence hypothalamic and hence HPA
axis activity. Like the hippocampus, the medial prefrontal cortex (MpFC) has
inhibitory inputs to the hypothalamus via the BST and preoptic nuclei (Herman and
Cullinan, 1997) and lesions of the MpFC potentiate the increase in ACTH and
plasma corticosterone after restraint stress in rats (Diorio et al., 1993), suggesting
that it modulates glucocorticoid inhibition of stress-induced HPA axis activity.
Data from studies using direct administration of adrenergic and serotonergic agonists
to the amygdala (Feldman et al., 2000) suggest that the amygdala stimulates HPA
axis activity by increasing CRH release from the hypothalamus by increasing
noradrenergic and serotonergic neurotransmission (Feldman et al., 1987; Feldman et
al., 1988). This effect is blocked by neurotoxic lesions of the ventromedial
hypothalamus (Feldman et al., 2000) and HPA axis responses to stimulation of the
amygdala are sensitive to glucocorticoid negative feedback (Weidenfeld et al., 1997).
As well as its neural connections to the hypothalamus, the amygdala inhibits outflow
from the BST (reviewed in (Raber, 1998)). Thus during stress the amygdala
increases HPA axis activity and strengthens fear memory (Raber, 1998).
Endogenous opioid peptide systems may also modulate HPA axis responses to stress.
Opioid receptors are ubiquitously expressed in the CNS and opioids can modulate
the release ofCRH from the hypothalamic parvocellular neurons (reviewed in
(Drolet et al., 2001)).
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1.9.2.5 Neuronal development and survival
In several mammalian species the dentate gyrus of the hippocampus develops new
granular neurons in adulthood. Evidence from studies in rodents and primates
suggests that these late-developing neurons may have an important role in
hippocampal function (reviewed in (Gould and Tanapat, 1999)). For example,
training in a task that requires hippocampal function for acquisition results in an
increase in the number of adult-generated granule cells (Gould et al., 1999).
Glucocorticoids influence this process of adult neurogenesis: experimental elevations
of corticosterone in adulthood reduce dentate gyrus neurogenesis (Cameron and
Gould, 1994) and removal of adrenal steroids stimulates the proliferation of granule
cell precursors (Cameron and McKay, 1999). Since GR and MR are absent from
most adult granule cell precursors (Cameron et al., 1993) this effect is probably via
glutamate receptor mediated excitatory inputs, since blockade of glutamate receptors
enhances granule cell precursor proliferation (Gould et al., 1994) and activation of
glutamate receptors suppresses it (Cameron et al., 1995). However, MR knockout
animals show impaired granule cell neurogenesis and decreased density of granule
cells, suggesting that MR signaling may have long-term trophic effects on these cells
(Gass et al., 2000). Glucocorticoids also regulate the expression of neurotrophic
factors in the hippocampus (Chao et al., 1998b), which may influence neurogenesis.
Perplexingly, glucocorticoids seem to be both neurotoxic and neuroprotective.
Glucocorticoids are essential for neuronal survival: both acute (Gould et al., 1990b;
Hu et al., 1997) and chronic (Sloviter et al., 1989) adrenalectomy cause loss of
hippocampal granule cells. The acute loss is associated with decreases in cell body
area and dendritic branching (Gould et al., 1990b) and can be prevented by
corticosterone replacement (Gould et al., 1990b) or aldosterone replacement
(Woolley et al., 1991), suggesting that occupation of hippocampal MR is sufficient to
prevent cell loss. The dying cells seem to undergo apoptosis, showing chromatin
condensation, nuclear fragmentation, compaction of cytoplasm and pyknosis without
inflammation (Sloviter et al., 1993a; Sloviter et al., 1993b). Indeed, apoptosis may
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represent a common pathway for glucocorticoid-mediated neuronal death (reviewed
in (Reagan and McEwen, 1997)).
Glucocorticoids may also potentiate neuronal damage due to a variety of
pathophysiological insults. Acute administration of dexamethasone has been shown
to induce apoptosis in all regions of the hippocampus (Haynes et al., 2001) and
adrenalectomy reduces ischaemic neuronal damage in the hippocampus (Sapolsky
and Pulsinelli, 1985) and attenuates hippocampal neurotoxicity due to the glutamate
receptor agonist kainic acid(Sapolsky, 1985). Conversely, corticosterone replacement
potentiates both of these toxicities (Sapolsky, 1985; Sapolsky and Pulsinelli, 1985).
Furthermore, glucocorticoids may potentiate neurotoxicity due to excess
neurotransmitter release. Exogenous corticosterone administration causes apical
dendritic atrophy in CA3 pyramidal cells while leaving CA3 basal dendrites, CA1
pyramidal cells and dentate gyrus granule cells unaffected ((Woolley et al., 1990),
reviewed in (McEwen, 1999)). However, CA3 pyramidal neurons have little GR
compared to other hippocampal regions (Herman et al., 1989a; Sousa et al., 1989).
The granule cells of the dentate gyrus are GR- and MR-rich (Reul and DeKloet,
1985) and increased glutaminergic neurotransmission from via their heavy mossy
fibre projections to the CA3 pyramidal neurons (reviewed in (McEwen, 1999))
appears to cause the neurotoxic effect. Indeed, selective blockade of glutamate
receptors prevents it (Magarinos and McEwen, 1995). This atrophy of CA3 neurons
is reversible (reviewed in (Reagan and McEwen, 1997)). However, chronic exposure
to elevated corticosterone levels can cause loss of CA3 neurons in rats (Sapolsky et
al., 1985).
Glucocorticoids also influence hippocampal neuronal survival during aging. Aged
rats show a decrease in CA3 pyramidal cell density (Landfield et al., 1981b).
Adrenalectomy reduces this CA3 neuronal loss (Landfield et al., 1981a).
1.9.2.6 Glucocorticoids, cognition and memory
Glucocorticoid deficiency and excess can both affect cognition. Adrenalectomy
causes memory impairment (Oitzl and DeKloet, 1992; Roozendaal et al., 1996),
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which can be reversed by dexamethasone administration (Roozendaal et al., 1996).
The detrimental effects of chronic stress or pathophysiological conditions (e.g.
affective disorders) on cognition (reviewed in (McEwen and Sapolsky, 1995)) are
probably due to glucocorticoid excess (Arbel et al., 1994; Bodnoff et al., 1995;
Dachir et al., 1993). Furthermore, high levels of glucocorticoids impair memory
retrieval in rats (de Quervain et al., 1998) and may be involved in the development of
traumatic amnesia in human patients (Joseph, 1998).
Interestingly, moderate doses of glucocorticoids or GR agonists enhance memory
when given immediately after training (Flood et al., 1978; Kovacs et al., 1977;
Roozendaal et al., 1999; Roozendaal and McGaugh, 1996a; Roozendaal and
McGaugh, 1996b; Roozendaal and McGaugh, 1997a) and brief periods of stress
usually enhance the formation of new memories (Shors et al., 1992). The above
evidence suggests that the effects of glucocorticoids on memory consolidation show
an "inverted U" dose response, with both high and low levels causing memory
impairment.
Excess glucocorticoids seem to affect cognition in two ways. Firstly, excess
glucocorticoids may alter the electrophysiology of the hippocampus e.g. by
impairing long-term potentiation (Dubrovsky et al., 1987; Pavlides et al., 1993) or
increasing after-hyperpolarisation (Joels and DeKloet, 1989).
Secondly, they cause neuropathological changes, particularly in the hippocampus
(section 1.9.2.1). The hippocampus has an important role in cognition, including
declarative or episodic memory processes (required for event learning and recall),
spatial memory and probably attention, arousal and emotional states (reviewed in
(Lathe, 2001)). Patients with Cushing's syndrome and aged humans with
significantly elevated Cortisol levels show cognitive impairments consistent with
hippocampal dysfunction (reviewed in (Belanoff et al., 2001; Brown et al., 1999;
Sapolsky, 2000)). Also, Cortisol hypersecretion may be implicated in dementia due to
destruction of hippocampal neurons in Alzheimer's disease and hippocampal
sclerosis (reviewed in (Belanoff et al., 2001)).
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Several pieces of evidence suggest that the effects of glucocorticoids on cognition
are mediated by GR. GRAS mice and GRhyp°/hyp° mjce (Oitzl et ah, 1997) have
impaired spatial memory and GRhyp<"'hypo mice show impaired memory consolidation
(Oitzl et ah, 1997). Also, pre or immediately post-training infusions of a GR but not
an MR antagonist impair spatial memory in a water maze (Oitzl and DeKloet, 1992;
Roozendaal et al, 1996), and GR binding capacity correlates with spatial memory
performance following an inverted-U shaped curve while MR occupancy does not
(Conrad et ah, 1999).
Sapolsky has put forward the "glucocorticoid cascade hypothesis" to explain the
hippocampal changes seen in aging and dementia .He has proposed that excessive
glucocorticoid secretion causes downregulation of hippocampal GR and
hippocampal neuron loss, reducing HPA axis negative feedback leading to further
hypersecretion of glucocorticoids and more destruction of hippocampal neurons
(Sapolsky et al., 1986). However, aged rats with impaired ability to perform in a
water-maze test showed similar hippocampal GR and MR levels to young control
animals, suggesting that age-related cognitive deficits are not necessarily related to
altered hippocampal GR levels (Yau et al., 1994). Also, the hypothesis that reduced
hippocampal GR function leads to impaired negative feedback, excessive
glucocorticoid secretion and thus harmful effects via increased GR signalling appears
paradoxical, since ifGR levels are reduced then the amount of GR signalling should
be reduced also. However, there are 3 possible explanations for the deleterious
effects of increased Cortisol levels in the face of reduced GR levels (reviewed in
(McQuade and Young, 2000)). First, the increase in Cortisol levels may be so great
that it overcomes the reduction in GR capacity and increases GR signalling overall.
Second, GR capacity in brain areas not associated with negative feedback may be
normal, giving increased GR signalling in these areas. Third, the damaging effects of
high Cortisol may in part be via increased MR signalling (or a change in the balance
ofMR and GR signalling) or via non-receptor-mediated events.
The modulatory effects of glucocorticoids on cognition are also partly via GR in the
basolateral amygdala: direct administration ofGR agonists there enhances memory
consolidation while administration of antagonists impairs it (Roozendaal and
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McGaugh, 1997b). The enhancing effects of glucocorticoids on memory
consolidation also depend upon the integrity of the amygdala P-adrenergic inputs
from the locus coeruleus and nucleus of the solitary tract, whose cell bodies contain
high densities ofGR (reviewed in (Roozendaal, 2000)). The amygdala may integrate
hormonal and neuromodulatory influences on memory consolidation in other brain
structures, including the hippocampus. The basolateral amygdala projects to the
hippocampus both directly and indirectly via the entorhinal cortex (Racine et al.,
1983; Thomas et al., 1984). Lesions of the basolateral amygdala block the enhancing
effect of post-training administration of glucocorticoids (Roozendaal and McGaugh,
1996a) and the detrimental effects of adrenalectomy on memory consolidation
(Roozendaal et al., 1996): lesions of the stria terminalis (a major afferent-efferent
pathway of the amygdala) have the same effects (Roozendaal and McGaugh, 1996b).
1.9.2.7 Glucocorticoids and mood disorders
Elevations of basal plasma Cortisol levels associated with depression and other mood
disorders have been well-documented (reviewed in (Ehlert et al., 2001; McQuade
and Young, 2000; Pariante and Miller, 2001)). Compared with controls, people with
depression show a loss of the normal circadian rhythm of Cortisol secretion, with
elevated nadir plasma Cortisol concentrations (Deuschle et al., 1997). Furthermore,
depressed patients show increased cerebrospinal fluid CRH concentrations
(Nemeroff et al., 1984), suggesting that their hypercortisolaemia may be due to
hypersecretion of CRH. Patients with unipolar and bipolar disorders show Cortisol
non-suppression in response to dexamethasone (Zhou et al., 1987), suggesting
impaired glucocorticoid negative feedback on HPA axis activity. These effects are
probably mediated via GR. GRNesCre mice show reduced anxiety-related behaviour
compared to wild-type mice (Tranche et al., 1999). Also, reduced GR mRNA is seen
in the hippocampi of patients with the neuropsychiatric disorders mentioned above
(Webster et al., 2000).
Glucocorticoids may also influence the pathogenesis ofmood disorders by altering
the activity of other neurotransmitter systems e.g. by altering GABAa receptor
subtype composition in the hippocampus, which may alter GABAergic
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neurotransmission (Cullinan and Wolfe, 2000). Disturbances of the 5HT system are
consistently associated with depression (Meltzer, 1990) and long-term exposure to
high doses of corticosterone reduces the responsiveness of rat hippocampal CA1
neurones to 5HT (Karten et al., 1999). Glucocorticoids appear to decrease the
expression of the 5HTia (Meijer et al., 1997; Neumaier et al., 2000), 5HT2C (Holmes
et al., 1995a), 5HT6 and 5HT7 receptors (Yau et al., 1997a) in the hippocampus. This
effect seems to be region and receptor subtype-specific, since the magnitude of
changes in 5HTia expression with adrenalectomy and glucocorticoid replacement
varies in different hippocampal subfields (Neumaier et al., 2000), 5HT2c expression
varies throughout the hippocampus with chronic arthritis stress and 5HT6 and 5HT7
expression is regulated by adrenalectomy only in CA1 and CA3 (Yau et al., 1997a).
The effects of glucocorticoids on 5HT receptor expression appear to be mediated by
both GR and MR (Cyr et al., 2001; Holmes et al., 1995a; Meijer et al., 1997;
Neumaier et al., 2000). At least part of the effect of treatments used in mood
disorders may be to normalise GR levels (section 1.7.2.3) and hence glucocorticoid
secretion and 5HT receptor expression. Indeed, the tricyclic antidepressant
desipramine reverses the HPA axis hyperactivity seen in a transgenic mouse model
of the endocrine changes seen in depression (Pepin et al., 1992a).
1.9.2.8 Glucocorticoids and glial cells
The macroglia and microglia are a heterogeneous group of cell types that interact in
many ways with neurones to influence their differentiation, development and
metabolism (reviewed in (Garcia-Segura et al., 1996)), modulate potassium currents
in neuronal membranes (Wu and Barish, 1994), regulate neuronal activity by
regulating glucose metabolism (Pellerin and Magistretti, 1994) and maintain synaptic
transmission in the hippocampus (Keyser and Pellmar, 1994). Glial cells express GR
(Erdeljan et al., 2001; Morita et al., 1999) but not MR (Erdeljan et al., 2001) and
interestingly glial cell GR does not seem to be regulated by glucocorticoids or
serotonin (Erdeljan et al., 2001).
Glucocorticoids, presumably acting via GR, potentiate oligodendrocyte proliferation
by regulating the expression of myelin basic protein, proteolipid protein and glycerol
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phosphate dehydrogenase (Kumar et al, 1989; Tsuneishi et ah, 1991), inhibit
astroglia proliferation in vitro (Kniss and Burry, 1985) and mitosis in vivo (Gould et
ah, 1990a) and enhance death of glial cells deprived of serum (Morita et ah, 1999).
This last effect may be significant in ischaemic insults to the central nervous system.
Neuroactive steroids may also be locally produced and metabolised by glia, which
thus may modulate some of their central effects (reviewed in (Garcia-Segura et ah,
1996)).
1.9.3 The stress response
Acute physical stress (such as illness, trauma or pursuit by a predator) or
psychological stress (such as bereavement, public speaking or a mental illness)
increases HPA axis activity and glucocorticoid secretion. This effect is essential in
the short term to allow the animal to survive the stressor: the glucocorticoid release
affects metabolism, enhancing energy availability, and also inhibits nonessential
processes such as inflammation, growth and reproduction. Also, glucocorticoids
protect the body from overreactivity of the immune system during illness (section
1.9.5.1). The stress response is terminated by the negative feedback effects of
increased circulating levels of glucocorticoids on the HPA axis (section 1.9.2.2). This
feedback control is crucial in preventing the detrimental effects of prolonged
elevations of circulating glucocorticoid levels: these include myopathy, osteoporosis,
hypertension, diabetes and insulin resistance, reproductive failure and infections
(Ganong, 1989).
1.9.4 Glucocorticoids and intermediary metabolism
GR has an important role in metabolic control and is abundant in metabolically
active tissues such as liver (Antakly and Eisen, 1984; Reul et al., 1989), muscle
(Snochowski et al., 1980) and adipose tissue (Feldman and Loose, 1977). Overall,
glucocorticoid release tends to raise blood glucose levels by increasing peripheral
protein catabolism, hepatic uptake of amino acids, deamination and transamination
of amino acids and decreasing peripheral and hepatic glucose utilisation (Ganong,
1989).
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In the liver, GR levels vary with age. In mice, they are higher at 30d postnatally than
at lOd or 60d (Borbhuiya and Sharma, 1995) and in rats they are greater in immature
than mature animals (Sharma and Timiras, 1987). Aged rats also show reduced
hepatic GR (Djordjevic-Markovic et al., 1999). Although hepatic expression ofGR
was initially thought to be homogeneous (Antakly and Eisen, 1984), recent evidence
suggests that there are higher levels of GR mRNA in periportal hepatocytes than in
perivenous hepatocytes (Nyirenda et al., 1998).
GR is central to control of hepatic carbohydrate metabolism, although
glucocorticoids do interact with other hormones controlling intermediary metabolism
(see below). GRhypo/hypo mice show impaired glucocorticoid-mediated induction of
hepatic tyrosine aminotransferase and serine dehydrogenase mRNA expression (Cole
et al., 1995b; Cole et al., 1995a), as do GRdim/dim mice (Reichardt et al., 1998).
ORd'm/dim mjce a|so show impaired glucocorticoid-mediated induction of pyruvate
carboxykinase mRNA expression (Reichardt et al., 1998). Furthermore,
glucocorticoids have been shown to regulate the expression of several other enzymes
of glycolysis and gluconeogenesis, such as 6-phosphofructo-2-kinase/fructose-2,6-
bisphosphatase which controls the level of gluconeogenesis in the cell (reviewed in
(Lemaigre and Rousseau, 1994)), glucose-6-phosphatase (Schmoll et al., 1999) and
phosphoenolpyruvate carboxykinase (in insulin-resistant animals) (Friedman et al.,
1993). Hepatocyte function varies between periportal and perivenous hepatocytes:
this is the basis of the "metabolic zonation" model, according to which
glycogenolysis, gluconeogenesis, amino acid utilization, ammonia detoxification,
protective metabolism (glutathione peroxidation and conjugation), bile formation,
and the synthesis of some plasma proteins such as albumin and fibrinogen occur
mainly in the cells of the upstream or periportal area while glucose utilization,
xenobiotic metabolism, and the formation of other plasma proteins occur mainly in
the cells of the downstream or perivenous zone (reviewed in (Jungermann and
Kietzmann, 1996)). Thus hepatic GR may be higher in the periportal hepatocytes
colocalising with metabolic processes under glucocorticoid control, although this is
as yet unproven.
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GR signalling also affects the rate of lipid synthesis. In the liver, glucocorticoids
increase glucose-6-phosphatase expression and hence increase the phosphorylation
state of the cell, favouring lipogenesis (reviewed in (Berdanier, 1989)) and obese
Zucker rats show increased in hepatic GR levels compared to lean controls (Jenson et
ah, 1996). Furthermore, GRAS mice show greatly increased fat deposition compared
to controls, GRNesCre mice have reduced body fat compared to controls and normal
rats starved then refed a high-glucose diet show a 2-3 fold induction of fatty acid
synthesis, hepatic lipid content and hepatic lipogenic activity that is decreased by
adrenalectomy and restored by glucocorticoid replacement (reviewed in (Berdanier,
1989)). The effects of glucocorticoids on lipid metabolism may be tissue-specific.
Glucocorticoids affect the distribution of body fat; GRNesCre mice showed
redistribution of fat towards the head and neck (Tronche et ah, 1999) and patients
with Cushing's disease showed decreased peripheral and increased central deposition
of fat (Ganong, 1989). This redistribution may be because glucocorticoids acutely
activate lipolysis and increase free fatty acid release in peripheral adipose tissue
(Orth, 1998).
As mentioned above, glucocorticoids interact with other hormones controlling
intermediary metabolism. In cultured rat hepatocytes insulin receptor binding is
increased by dexamethasone in a dose-dependent manner (Fleig et ah, 1985) and
insulin replacement in diabetic rats increases hepatic GR levels (Yourick and
Beuving, 1985). Glucocorticoids potentiate induction of glucokinase expression after
refeeding (Minderop et ah, 1987) and insulin inhibited glucocorticoid induction of 6-
phosphofructo-2-kinase (Pierreux et ah, 1998). Furthermore, GR may interact
directly with other (liver-specific) transcription factors e.g. HNF-4 and FINF-3 to
modulate hepatic gene expression and influence metabolic processes (reviewed in
(Desimone and Cortese, 1992)): the possible mechanism of such interactions is
discussed in section 1.11.
Finally, glucocorticoids are permissive for a number ofmetabolic reactions. These
include the calorigenic effects of glucagon and catecholamines, secretion of aldolase
and the dietary induction of pyruvate kinase (reviewed in (Lemaigre and Rousseau,
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1994)). Glucocorticoids are also required for catecholamines to exert their lipolytic
effects and produce pressor responses and bronchodilation (Ganong, 1989).
1.9.5 Glucocorticoids and the immune system
GR are found at varying levels throughout the immune system. The highest levels of
GR are found in immature thymocytes, followed by mature splenocytes and
peripheral lymphocytes with the lowest levels in neutrophils (Lowy, 1989) (Miller et
ah, 1998). GR in lymphocytes increases if the cells are activated e.g. by a mitogen or
immunogenic stimulation (Munck et al., 1979) and GR is down-regulated as T cells
mature (Miller et al., 1998), which may be related to the role ofGR in thymocyte
selection (section 1.9.5.2).
MR are not detectable in the thymus (Lowy, 1989; Reul et al., 1989) but are found at
low levels in the spleen (Spencer et al., 1993).
1.9.5.1 Effects on inflammatory and immune responses
Both systemic and local release of glucocorticoids can regulate inflammatory and
immune responses (reviewed in (McEwen et al., 1997; Sternberg, 2001)). At
pharmacological doses glucocorticoids are generally immunosuppressive and affect
activation, proliferation, differentiation and distribution of lymphocytes (reviewed in
(McEwen et al., 1997; Sternberg, 2001)) and alter the function of other immune cells
such as monocytes (reviewed in (Cupps and Fauci, 1982; McEwen et al., 1997)). If
inflammatory responses are dominant in the pathogenesis of a disease then high
levels of glucocorticoids may reduce its severity, whereas if pathogen effects
dominate glucocorticoids will increase morbidity (reviewed in (Sternberg, 2001)).
Current evidence suggests that physiological concentrations of glucocorticoids are
immunomodulatory, shifting cytokine production from a pro-inflammatory TH1
pattern ofmainly IL-4 and interferon-y production to an anti-inflammatory TH2
pattern ofmainly IL-4 and IL-10 production (reviewed in (Elenkov and Chrousos,
1999)). Conversely, stress levels of glucocorticoids have distinct effects on
individual cytokines (DeRijk et al., 1997) and HPA axis overactivity can increase
susceptibility to infectious disease (Brown et al., 1993; Glaser and Kiecolt, 1998;
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Hermann et al., 1993). The effects of glucocorticoids on cytokine expression may be
modulated by activated GR interfering with the function of other transcription factors
such as activator protein 1 (AP-1) and nuclear factor kB (NF-kB), which activate
genes coding for many cytokines, cytokine receptors, chemotactic proteins and
adhesion molecules (section 1.11.2, reviewed in (De Bosscher et al., 2000; McEwen
et al., 1997)). Evidence from GRdim/d,m mice suggests that this antagonism may be
independent ofDNA binding in vivo (Reichardt et al., 2000a).
The time of stress relative to exposure to immune stimulation and the type of
stimulus are also important. For example, acute stress early in exposure actually
increases the immune response in contact dermatitis (Dhabhar et al., 2000).
Interestingly, low levels of glucocorticoids due to HPA axis underactivity can
increase susceptibility to autoimmune and inflammatory disease. Lewis rats, which
have a hyporesponsive HPA axis (Oitzl et al., 1995), develop arthritis in response to
injected streptococcal antigen while Fischer rats with normal HPA axis responses do
not (Sternberg et al., 1989). Lewis rats have decreased pituitary GR compared to
Wistar rats (Oitzl et al., 1995) and have larger thymi than Fischer rats (Sternberg et
al., 1989). It is tempting to speculate that the differences in immune responses
between these animals is at least partly due to differences in GR levels in their
immune cells, but these have not yet been measured.
As well as modulating immune function by influencing cytokine production,
glucocorticoids may cause apoptosis of immune system cells. Lymphoid cells,
especially CD4+CD8+ thymocytes, are sensitive to glucocorticoid-mediated
apoptosis, a process that, as discussed below, is of particular relevance in T cell
selection (reviewed in (Ashwell et al., 2000)). Although glucocorticoids are known
to induce an endonuclease-like activity causing rapid cleavage of lymphocyte DNA
(Compton and Cidlowski, 1986) and may stimulate intracellular free fatty acid
release causing nuclear membrane damage (Turnell and Burton, 1975), the exact
mechanism of glucocorticoid-induced apoptosis is unclear. However, most evidence
suggests that they act via GR. GRAS mice show an approximately 50% reduction in
thymocyte GR expression and thymocytes from these animals are unresponsive to
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glucocorticoids (Morale et al., 1995). Thymocytes from GRdim/dim mice were
refractory to glucocorticoid-mediated apoptosis (Reichardt et al., 1998), as were
those from GRAS(Thy) mice (King et al., 1995) whereas mice expressing a GR sense
transgene in the thymus showed a twofold increase in thymocyte apoptosis compared
to controls (Pazirandeh et al., 2002). Also, thymocytes from YGR mice express 20-
24% more GR mRNA than controls and show greatly increased sensitivity to
glucocorticoid-mediated apoptosis (Reichardt et al., 2000b).
Glucocorticoid-mediated apoptosis is ATP-dependent and blocked by protein-
synthesis inhibitors, suggesting that they induce the expression of one or more genes
causing cell death (reviewed in (Ashwell et al., 2000)). Bcl-2 (an inhibitor of
mitochondrial-dependent cell death) inhibits glucocorticoid-mediated apoptosis of
thymocytes and a lack of Bcl-2 expression appears to account for the glucocorticoid-
sensitivity ofCD4+CD8+ thymocytes (reviewed in (Ashwell et al., 2000)). Also,
recent work using DNA chip technology demonstrated that glucocorticoid induction
ofGR expression is a primary phenomenon in glucocorticoid-induced T cell
apoptosis and suggested that consequent GR-mediated repression of various
metabolic pathways might lead to cell cycle arrest and cell death (Tonko et al.,
2001).
The immune system also influences the HPA axis. Inflammatory mediators can
affect central nervous system activity (reviewed in (Sternberg, 2001)). Cytokines can
actively or passively cross the blood-brain barrier and stimulate neurons directly:
intracerebroventricular injection of tumour necrosis factor caused a 51% decrease in
hippocampal GR binding capacity (Betancur et al., 1995). They may also act
indirectly by activating second messenger systems e.g. cyclooxygenase or by
stimulating signaling in peripheral nerves e.g. the vagus (Bluthe et al., 1994; Watkins
et al., 1994). These inputs collectively increase HPA axis activity and hence
glucocorticoid levels, possibly reducing immune system activity and preventing the
immune system from overreacting and causing autoimmunity (Munck et al., 1984).
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1.9.5.2 Glucocorticoids and the thymus
In rats, T cell precursors appear in the thymus from days 13-14 of gestation, with
CD4+CD8+ cells appearing from day 18 and mature thymocytes from day 20
(Vicente et al., 1998). At least 4 T cell receptor (TCR) dependent selection steps
occur in the thymus (reviewed in (Godfrey et ah, 2000) and (Ashwell et ah, 2000)):
(a) T cell receptor-P mediated selection of cells undergoing the transition
between CD4 CD8" (double-negative, DN) and CD4+CD8+ (double positive
or DP) states.
(b) "Death by neglect" of thymocytes bearing TCRs with subthreshold affinity
for self-antigen/MHC (major histocompatibility factor) complexes.
(c) Positive selection leading to rescue from the default death pathway of DP
cells bearing TCRs with intermediate affinity for self-antigen/MHC
complexes, leading to their maturation into single-positive cells and
migration to the periphery.
(d) Negative selection and elimination of thymocytes bearing TCRs with
excessive affinity for self-antigen/MHC complexes, promoting self-tolerance.
The thymic endocrine environment is complex and is influenced by various extrinsic
(e.g. prolactin, thyroxine, androgens and oestrogens) and putative intrinsic (thymosin
a, thymulin and thymopoeitin) hormones as well as locally produced cytokines
(reviewed in (Hadden, 1992)). Many pieces of evidence suggest that GR is crucial
for thymocyte selection, although this area is highly controversial and the subject of
much current debate.
GR levels change during thymocyte selection, since mature T cells possess less GR
than immature thymocytes (Ranelletti et al., 1987) and different T cell subpopulation
possess different levels ofGR (Wiegers et al., 2001).
Glucocorticoids seem to be essential for thymocyte survival through selection. GRAS
mice show a partial blockade of T cell differentiation in the embryo and altered
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thymic stromal architecture in the adult (Sacedon et al., 1999b). GRAS(Thy) mice
showed a thymus-specific 43% reduction in GR expression and impaired
glucocorticoid-mediated gene transcription (King et ah, 1995). These mice showed
reduced thymocyte numbers principally due to a reduction in CD4+CD8+ cells (King
et ah, 1995). They also had increased frequency of CD4 CD8" thymocytes compared
to controls (King et ah, 1995). The reduction in absolute numbers ofCD4+CD8+ is
greater than that of CD4~CD8+/CD4+CD8" thymocytes, with numbers ofCD4 CD8"
cells unchanged (King et ah, 1995). These mice also show increased spontaneous
apoptosis and increased sensitivity to TCR-mediated deletion of CD4+CD8+ cells
(King et ah, 1995). Thymic epithelial cells express steroidogenic enzymes (Lechner
et ah, 2000; Pazirandeh et ah, 1999; Vacchio et ah, 1994) and produce
glucocorticoids in cell culture (Pazirandeh et ah, 1999). Inhibition of glucocorticoid
synthesis by metyrapone in foetal thymus organ culture from non-transgenic mice
blocked the transition of thymocytes from DN to DP, an effect that was reversed by
corticosterone administration (King et ah, 1995). Metyrapone also increased
apoptosis in DP cells with transgenic TCRs which recognized self-antigen/MHC
complexes (Vacchio and Ashwell, 1997). Furthermore, inhibition of thymic
corticosteroid production enhanced TCR-mediated antigen-specific deletion of
immature thymocytes (Vacchio et ah, 1994). These data suggest that glucocorticoids
play a role in the survival of thymocytes during the transition from CD4 CD8" to
CD4+CD8+ cells.
However, glucocorticoids may cause cell death during thymocyte selection.
Glucocorticoids increased thymocyte apoptosis after injection of a suboptimal dose
of anti-CD3 (Jondal et ah, 1993). Glucocorticoids secreted in the thymus induce
apoptosis in cocultured T cells, an effect partially blocked by the glucocorticoid
synthesis inhibitor metyrapone and the GR antagonist RU486 (Miller et ah, 1990)
and may account for persistence of T cell apoptosis after maternal adrenalectomy
(Sacedon et ah, 1999a). Furthermore, in vivo administration of the GR antagonist
RU486 blocked DP thymocyte apoptosis induced by injection of anti-CD3 antibody
(Jondal et ah, 1993) and inhibited TCR-mediated thymocyte apoptosis (Xue et ah,
1996). RU486 also inhibited TCR-mediated thymocyte apoptosis in TCR transgenic
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thymi in vivo and in vitro (Xue et al., 1996). However, RU486 has also been shown
to increase TCR-mediated apoptosis ofDP cells in FTOC (Vacchio et al., 1994):
these different results may be due to variations in the dose of RU486 used (reviewed
in (Godfrey et al., 2000)).
To explain these apparently conflicting roles for glucocorticoids in selection,
Ashwell et al have proposed the "mutual antagonism" model whereby the balance
between glucocorticoid and TCR signaling controls selection (Ashwell et al., 2000).
The model proposes that DP thymocytes with subthreshold avidity for self-
antigen/MHC undergo death by neglect at least partially due to glucocorticoid-
mediated apoptosis, while encounter of self-antigen/MHC by thymocytes with
intermediate-avidity TCRs leads to signaling that would otherwise lead to apoptosis,
but due to glucocorticoid antagonism the cells survive. Also, they propose that
signals leading to apoptosis in thymocytes bearing TCRs with high avidity for self
are too strong to be overcome by ambient glucocorticoids and these cells are deleted
by negative selection. In support of this hypothesis, it is known that TCR signaling
can antagonize glucocorticoid-mediated apoptosis (Iwata et al., 1991; Zacharchuk et
al., 1990) and the TCR and GR signaling pathways are linked via the Ras and MEK
signaling components (Jamieson and Yamamoto, 2000).
However, some evidence suggests that glucocorticoids may not be involved in T cell
selection. Thymocytes from GRdini/dim mice show resistance to glucocorticoid-
mediated apoptosis, but these animals show no difference in their relative abundance
of T lymphocyte subpopulations from control animals (Reichardt et al., 1998).
However, the GR in these animals might still be influencing selection by GR
monomers interacting with other transcription factors (as discussed in section 1.9.5).
Also, GRhypo/hypo mice (Cole et al., 1995a) have T cells unresponsive to
dexamethasone-mediated apoptosis, but normal positive and negative selection
processes occur (Purton et al., 2000). However, since the majority ofmice with this
mutation die at birth due to lung atelectasis (Cole et al., 1995a) all these studies were
carried out in organ culture and therefore do not necessarily represent the situation in
vivo. Also, these mice do express an N-terminus truncated form ofGR which may
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still have DNA-binding ability (Cole et al., 2001; Tranche et ah, 1998), which may
retain sufficient function to allow normal thymocyte selection to proceed.
Despite the evidence presented above, on balance I believe that the evidence favours
a central role for glucocorticoids in thymocyte development. Nevertheless, further
work is required to clarify the exact role of glucocorticoids in the thymus.
1.10 Gene transcription in eukaryotes
Gene expression may be controlled at various stages including transcription, RNA
processing, RNA transport, mRNA degradation, translation and post-translationally.
In most genes transcriptional controls are paramount: these are mediated by the
interactions of gene regulatory proteins with the control region of the gene, changes
in the chromatin structure of the gene and changes in the methylation status of the
gene (Alberts B et ah, 1994).
1.10.1 Control of transcription by gene regulatory proteins
The control region of a eukaryotic gene consists of the DNA sequences required to
initiate transcription and regulate the rate at which this initiation occurs, i.e. the
promoter and various short (<20 nucleotides) regulatory sequences of varying
complexity to which gene regulatory proteins (specific transcription factors) bind
(Figure 1.7).
The majority ofpromoters have the same core sequences, the TATA box and the
initiator, although promoter structure varies widely (reviewed in (Zawel and
Reinberg, 1995)). Various initiator families exist (reviewed in (Weis and Reinberg,
1992)), with an underlying sequence similarity (Javahery et ah, 1994). The initiator
can initiate transcription in TATA-less promoters (reviewed in (Weis and Reinberg,
1992; Zawel and Reinberg, 1995)), as discussed below, and indeed may be the
dominant influence on transcriptional machinery assembly (reviewed in (Zawel and
Reinberg, 1995)).
The transcriptional machinery consists ofRNA polymerase II and the general
transcription factors (Alberts B et ah, 1994). Transcription is initiated by TFIID
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binding to the TATA box via its TATA binding protein subunit (TBP), which is also
required for transcription initiation in TATA-less promoters. Subsequently the rest of
the transcriptional machinery assembles at the transcription start site (reviewed in
(Pugh, 1996; Zawel and Reinberg, 1995)), probably as a PolII holoenzyme (reviewed
in (Maldonado and Reinberg, 1995; Pugh, 1996)) and transcription begins.
Each transcription factor or family of transcription factors (Faisst and Meyer, 1992)
can bind to several of the hundreds of different regulatory sequences (Kel et ah,
1995) via specific protein-DNA interactions (Alberts B et al., 1994). These occur
through several protein motifs, including helix-turn-helix, (3-sheet, zinc finger,
leucine zipper and helix-loop-helix motifs (reviewed in (Garvie and Wolberger,
2001)).
Different combinations of transcription factors (some ofwhich, activators, promote
initiation while others, repressors, inhibit initiation) are present in different cell types
(Alberts B et ah, 1994). This allows cell and tissue-specific regulation of gene
expression. Most transcription factors work as part of a complex of several proteins
whose activator or repressor function depends on the final assembly of all the
individual components, including cofactors (Alberts B et ah, 1994). Two types of
cofactor exist: coactivators that enhance the response of the transcriptional
machinery to activators and corepressors that repress basal transcription (reviewed in
(Zawel and Reinberg, 1995)).
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regulatory sequence spacer DNA promoter transcription machinery
Figure 1.7: the gene control region of a typical eukaryotic gene. Adapted from (Alberts B et al.,
1994).
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1.10.2 Control of transcription by alternate promoter usage
Alternate promoter usage has been observed for many genes. The general consensus
is that by transcribing one gene from multiple promoters the organism gains
additional flexibility in control of expression of the gene. Various patterns of
alternate promoter usage exist of varying complexity (reviewed in (Ayoubi and
VanDeVen, 1996)).
The simplest model has two tandemly arranged promoters closely positioned within
the same exon (coding or noncoding) e.g. in the MYC oncogene (Marcu et al., 1992).
Alternatively, multiple promoter usage may lead to noncoding alternate first exons
spliced onto a common exon 2, as found in the MR (Vazquez et al., 1998; Zennaro et
al., 1995; Zennaro et al., 1996), ER (Flouriot et al., 1998), GR (section 1.6), a-
amylase (Schibler et al., 1983) and HOX5.1 (Cianetti et al., 1990) genes.
In the case of the mineralocorticoid receptor, these alternate promoters show tissue
and region-specific differences in their relative expression. In the hippocampus, the
MR mRNA variant associated with activity of the a promoter is most abundant in
CA2 and dentate gyrus, while the B and y variants are evenly distributed through
CA1-4 (Kwak et al., 1993). Also, these variants are differentially regulated by
glucocorticoids, with the a variant specifically upregulated by adrenalectomy (Kwak
et al., 1993). The activity of these promoters also varies through neuronal
development, with activity of the B promoter associated with synaptogenesis and
activity of the y promoter associated with cell birth and axonal sprouting (Vazquez et
al., 1998).
Likewise, a total of six variant human ERa mRNAs with different 5' untranslated
regions are generated by alternate promoter usage (Flouriot et al., 1998). The
promoters show differential activity; for example, the A and B promoters are active
in the forebrain but the C promoter is not (Osterlund et al., 2000). Six similar ERa
variant mRNAs are found in the mouse, again generated by alternate promoter usage
and splicing (Kos et al., 2000). All these variants show a tissue and sex-specific
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pattern of expression, with the C and F variants predominantly expressed and the H
variant restricted to liver, although female mice produce an approximately five-fold
higher level of this transcript than males (Kos et al., 2000).
Several variations of noncoding alternate first exons spliced onto a common exon 2
occur depending on the arrangement of the promoters and translation start sites. The
most complex models involve multiple promoters which lead to the formation of
mRNAs encoding different protein isoforms (reviewed in (Ayoubi and VanDeVen,
1996)). The distance between these promoters may be large e.g. in the dystrophin
gene, where the alternate promoters are separated by more than 500kb (Nishio et ah,
1994). In the progesterone receptor gene, whose overlapping leader exons contain
multiple promoters, transcription initiation from the upstream promoter leads to
mRNA products encoding a protein with an amino-terminal extension (Kastner et ah,
1990). Proteins with an amino-terminal extension can also be produced from use of
upstream promoters associated with non-overlapping first exons followed by a
splicing event e.g. in the human porphobilinogen deaminase (PBGD) gene (Chretien
et ah, 1988), the glucokinase gene (Iynedjian, 1993), the catecholamine-O-
methyltransferase gene (Tenhunen et ah, 1993) and the c-myb proto-oncogene
(Jacobs et ah, 1994). These different isoforms are sometimes involved in gene
autoregulation e.g. in the CREM inducible cAMP early repressor isoform (Molina et
ah, 1993). Interestingly, transcription initiation at the human GR gene promoter
associated with exon 1A has been suggested to encode membrane-associated GR
(mGR) or direct GR to the plasma membrane (Gametchu et ah, 1999), although it is
unclear how this might occur since the in-frame stop codon at the start of exon 2
should mean that transcripts containing different exons 1 produce identical GR
proteins.
A single promoter is unlikely to contain all the cA-acting control elements needed for
tissue or development-specific expression of a gene and for its response to hormones
or other stimuli. Conversely, use ofmultiple promoters can confer additional
flexibility in the control of gene expression and is likely to have several functions
(reviewed in (Ayoubi and VanDeVen, 1996)). Multiple promoter usage can allow
tissue-specific regulation of gene expression, e.g. in the PBGD gene which possesses
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both an upstream, ubiquitously-active "housekeeping" promoter and a downstream
tissue-specific promoter active only in erythroid cells (Chretien et al., 1988).
Alternate promoters of different strengths may be active in different tissues e.g. in
the a-amylase gene a weak downstream promoter is active in liver and a strong
upstream promoter is active in the parotid gland, giving a 100-fold difference in
expression between these tissues (Schibler et al., 1983). Tissue-specificity may also
be conferred by different responsiveness of promoters to transcription factors e.g. in
the glucokinase gene the downstream promoter is regulated by insulin and glucagon
but the upstream is not (Iynedjian, 1993) and the MR and ER genes (see above).
Alternate promoter usage also enables temporal and spatial regulation of gene
expression during development e.g. in the IGF-II gene, where 3 promoters (P2, P3
and P4) are active in the liver during foetal development but shut off at birth, at
which time the PI promoter is activated (van Dijk et al., 1992).
Production of alternate mRNAs with different stabilities or translational efficiencies
by alternate promoter usage allows post-transcriptional regulation of gene
expression, e.g. in the HOX-5.1 gene where 2 promoters give rise to mRNA isoforms
with different 5'-untranslated regions, tissue and subcellular distributions, induction
by retinoic acid and stability (Cianetti et al., 1990). Some long GC-rich leader exons
produced by alternate promoters are inefficiently translated and many leader exons
contain upstream AUGs which are involved in translation control (Kozak, 1991).
These AUGs are uncommon except in oncogenes (Kozak, 1987), suggesting they
may function to attenuate inappropriate translation (reviewed in (Ayoubi and
VanDeVen, 1996)).
1.10.3 Control of transcription by modifications of chromatin
The degree of compaction of chromatin can affect transcription. Nucleosomes
repress transcription initiation at promoters contained within them (reviewed in (Wu
and Grunstein, 2000)) and higher-order DNA packing (e.g. heterochromatin) renders
the DNA inaccessible for transcription (Alberts B et al., 1994).
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The mechanisms of chromatin decondensation to allow transcription are poorly
understood. However, activator protein binding is thought to recruit several classes
of chromatin-modifying proteins (reviewed in (Sterner and Berger, 2000; Wu and
Grunstein, 2000)):
(a) Switch/sucrose non fermentable (SWI/SNF) and related proteins reposition
nucleosomes in cis, may transfer histone octamers in trans to other DNA
molecules, may also destablise the nucleosome by removing H2A-H2B
dimers and have been shown to create superhelical torsion in DNA in vitro.
(b) Histone acetyltransferases (HATs) including those of the GNAT, MYST and
P300/CBP families, some nuclear receptor cofactors e.g. SRC-1, ACTR and
TIF2 and possibly one subunit ofTFIID all modify the acetylation status of
histones. Their importance is illustrated by HAT mutations being associated
with dysregulation of gene expression in certain tumours and developmental
disorders (reviewed in (Marmorstein and Roth, 2001)). Acetylation reduces
the strength of binding of histones to DNA and each other, thus releasing
DNA from the nucleosome and possibly disrupting higher-order nucleosomal
structures. Histone deacetylation strengthens these interactions and represses
transcription by a poorly defined mechanism. Certain corepressors stabilise
chromatin by targeting histone deacetylases to specific sections ofDNA
(reviewed in (Collingwood et al., 1999)). Genome-wide acetylation and
deacetylation of histones occurs, promoting a rapid turnover of acetyl groups
and preventing targeted acetylation or deacetylation from permanently
affecting chromatin structure.
Binding of some activators is thought to have the net effect of "opening" the
chromatin structure around the promoter allowing access and assembly of the
transcriptional machinery, while others are thought to bind to DNA once the
chromatin has opened (Alberts B et al., 1994). Repressor binding is thought to have
the opposite effect (Alberts B et al., 1994). Other covalent modifications of histones
e.g. phosphorylation, methylation and ubiquitination occur: their effect on chromatin
structure is poorly understood. Methylation of histones may be involved in
97
epigenetic silencing of gene expression and genomic imprinting (reviewed in (Rice
and Allis, 2001)).
1.10.4 DNA methylation and transcription
Methylation ofDNA occurs at the sequence 5'-CpG-3' (or rarely at the sequence 5'-
CpNpG-3') (reviewed in (Newell-Price et ah, 2000)). CpG islands are 500-2000bp
areas of genomic DNA that, unlike bulk DNA, are not deficient in CpG (Bird et al.,
1985). They often lie in the promoter region of genes, but are also found within the
structural gene (reviewed in (Jones, 1999)). Methylation of the cytosine residue is
performed by one of 3 DNA methyltransferases (reviewed in (Newell-Price et al.,
2000)).
The pattern of methylation in the genome is established during embryogenesis. In the
preimplantation embryo the methylation pattern of the gamete is erased, then after
implantation de novo methylation occurs at the vast majority of CpGs (reviewed in
(Jaenisch and Jahner, 1984)). The approximately 60% of promoters that lie within
CpG islands escape de novo methylation (reviewed in (Newell-Price et al., 2000)).
This may be due to binding of the transcription factor SP1, which can bind to
methylated or unmethylated DNA (Silke et al., 1995), at sites in or near the CpG
island. SP1 elements have been shown to protect a CpG island in the adenine
phosphoribosyltransferase (APRT) gene from de novo methylation (Brandeis et al.,
1994) and deletion or mutagenesis of SP1 binding sites causes de novo methylation
of the APRT gene CpG island in a transgenic mouse assay (Macleod et al., 1994). An
embryo-specific element in the sequence of the APRT gene CpG island can protect
itself from de novo methylation and reduce methylation of flanking sequences in
transgenic mice (Siegfried et al., 1999), suggesting that other factors apart from SP1
may help establish methylation patterns in the embryo.
Methylation is involved in gene silencing in several physiological processes e.g. X
chromosome inactivation, parental imprinting and developmental regulation of gene
expression (reviewed in (Newell-Price et al., 2000)). Defects in developmental DNA
methylation are implicated in the pathogenesis of several diseases including the Rett
and fragile X syndromes (reviewed in (Robertson and Wolffe, 2000)).
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Methylation-induced repression of transcription may occur by several mechanisms
(reviewed in (Jones, 1999; Newell-Price et al., 2000)):
(a) The methyl groups protrude into the major groove of the DNA helix, possibly
interfering with transcription factor binding
(b) Methylation recruits CpG binding proteins that mediate repression, such as
MeCp2
(c) Methylation recruits histone deacetylases and corepressors, causing the
formation of condensed, transcriptionally inactive chromatin
(d) Methylation of a promoter may directly interfere with the transcriptional
machinery
Although important in developmental regulation of gene expression, methylation of
promoters in CpG islands may be involved in dynamic regulation of gene expression.
The POMC gene promoter is in a CpG island and is methylated in tissues that do not
express the gene, while methylation in vitro silences POMC gene expression
(reviewed in (Newell-Price et ah, 2000)). Also, methylation of the androgen receptor
promoter CpG island leads to loss of androgen receptor expression in prostatic
tumour cells (Jarrard et al., 1998). These data suggest that methylation may regulate
the tissue-specific expression of genes whose promoter lies in a CpG island.
1.11 Transcriptional regulation by the glucocorticoid receptor
1.11.1 Transcriptional activation
Recent studies utilizing fusions ofGR with green fluorescent protein have shown
that GR interacts dynamically with regulatory elements (a "hit and run" model)
rather than binding to them in a static manner (McNally et al., 2000). When
associated with DNA at a positive GRE (section 1.5.1), GR appears to activate
transcription in two ways.
GR binding causes both chromatin rearrangement and appearance of DNase
hypersensitive sites in the rat tyrosine aminotransferase enhancer (Reik et al., 1991)
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and nucleosome phasing in studies using the mouse mammary tumour virus long
terminal repeat (MMTV LTR) (reviewed in (Beato, 1989)). This suggested that GR
might increase the rate of transcription by remodeling chromatin and improving
access of the transcriptional machinery and other transcription factors to the
promoter (section 1.10.3). Although the mechanism by which GR binding alters
chromatin structure is not fully understood, the extensive recent studies ofGR-
mediated chromatin remodeling on the MMTV LTR (e.g. (Fletcher et al., 2000),
reviewed in (Deroo and Archer, 2001)) suggest that ligand-activated GR enters the
nucleus, recruits various other chromatin-remodelling proteins such as those of the
SWI/SNF family and delivers them to the promoter while transiently interacting with
the GRE (reviewed in (Deroo and Archer, 2001)), also displacing the linker histone
HI (Bresnick et al., 1992). Subsequently the interaction ofDNA with the core
histones is altered, allowing the binding of other transcription factors such as NF-1
and Oct-1 (Archer et al., 1992; Truss et al., 1995), recruitment of the transcriptional
machinery and initiation of transcription (reviewed in (Deroo and Archer, 2001)).
Binding ofGR to the GRE also serves to locate the GR next to the promoter where it
may increase transcription by interacting with the general transcription factors
(section 1.10.1) to increase recruitment of the transcriptional machinery (reviewed in
(Beato et al., 1996)). Evidence suggests that GR usually acts in combination with
other transcription factors to cause transcriptional activation. GR seems to mediate
the assembly of transcription factor complexes on the MMTV promoter (Cordingley
et al., 1987) and various transcription factors including NF1, CP1, SP1 and OTF can
interact synergistically with GR to stimulate transcription when their binding sites lie
within 350bp of the GRE (Schule et al., 1988; Strahle et al., 1988). Also, GR
interacts with HNF-5 on the rat tyrosine aminotransferase gene enhancer (Rigaud et
al., 1991), regulates the binding of CEBPP to the alpha-1-acid glycoprotein promoter
in rat hepatoma cells (Savoldi et al., 1997) and interacts synergistically with STAT5
to induce transcription at the P-casein promoter (Stocklin et al., 1996). Furthermore,
DNA binding ofGR does not seem to be necessary for it to interact with other
transcription factors. In GR dimerisation-deficient GRd,m/d,m mjce glucocorticoid-
induced genes e.g. PNMT and surfactant protein are still expressed, suggesting that
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crosstalk ofGR with other transcription factors may be stimulating their transcription
(Reichardt et ah, 1998).
GR can also facilitate transcription complex assembly by interacting with various
coactivators or transcription intermediary factors (TIFs) e.g. DRIP 150 and DRIP205
(Hittelman et al., 1999), SRC-1, GRIP1/TIF2, ARA70, Rap46 and RSP5 (reviewed
in (Jenkins et al., 2001; Robyr et al., 2000)) and GRIP170, a protein which increases
GR-mediated transcription in a cell-free system through complexing with GR
(Eggert et al., 1995). These coactivators require the presence of a nuclear hormone
receptor for their recruitment to the promoter, enhance the activation function ofGR
and interact with components of the transcription machinery. Additionally, SRC-1
and p/CAF possess histone acetyltransferase activity (reviewed in (Struhl, 1998)). As
yet, the only corepressors shown to interact with GR are calreticulin and TSG101
(section 1.11.2).
GR activation can affect transcription by inducing changes in the methylation status
ofDNA (section 1.10.4). 3d glucocorticoid treatment results in demethylation of all 4
methyl CpGs within the rat TAT gene enhancer, allowing stronger and faster
subsequent responses of the enhancer to glucocorticoids (Thomassin et al., 2001).
The mechanism of GR-induced demethylation is unclear, but the presence ofDNA
strand breaks during the process may suggest an active mechanism involving base
excision (Kress et al., 2001).
The DNA binding and transactivation activity ofmany transcription factors is
affected by their phosphorylation status (reviewed in (Hunter and Karin, 1992)).
Transcriptional activation by GR may be modulated by changes in receptor
phosphorylation. All steroid hormone receptors are phosphorylated and undergo
hormone-dependent hyperphosphorylation; in GR (typically for the receptor family)
this occurs mostly in the transactivation regions of the N-terminal domain (reviewed
in (Bodwell et al., 1998)). GR hyperphosphorylation decreases receptor half-life
(Webster et al., 1997) but strongly enhances transcriptional activation, although this
effect is highly promoter-specific (reviewed in (Bodwell et al., 1998)). For example,
GR-mediated recruitment ofHNF-3 to the rat tyrosine aminotransferase gene
101
enhancer is dependent on protein kinase A signaling and transcriptional activation by
the GR ligand RU486 is enhanced by increased intracellular cyclic AMP or
phosphatase inhibitor administration (reviewed in (Beato et al., 1996)). Also,
phosphorylation enhances transrepression of the GR gene by GR (Webster et ah,
1997). However, GR transactivation of the MMTV promoter in COS-1 cells was not
affected by hyperphosphorylation (Webster et ah, 1997). MR function is also
affected by protein kinase A, probably by an indirect mechanism relieving the effect
of an MR repressor (Massaad et ah, 1999): a similar mechanism may apply to GR.
Inhibition of tyrosine kinase activity using herbimycin A show that phosphorylation
by tyrosine kinase is involved in maintenance of GR protein levels, probably by
increasing receptor stability (Niimi et ah, 1997).
1.11.2 Transcriptional repression
GR downregulates the expression of several genes, such as the POMC gene (section
1.9.2.2) and the genes encoding several cytokines (section 1.9.5.1). Several
mechanisms ofGR repression have been proposed.
GR may repress transcription by binding to negative GREs (nGREs). These were
first discovered in the POMC, prolactin and a-subunit of glycoprotein promoters and
are more variable in sequence than the positive GRE (reviewed in (Beato, 1989;
Karin, 1998)). However, it appears that it is not the precise sequence of the DNA that
makes a GRE negative but rather its particular location in the context of the
regulatory region of the gene (Pearce and Yamamoto, 1993). This is exemplified by
the a-subunit of glycoprotein gene, where the GR binds to a 52 nucleotide region that
also contains elements essential for cAMP responsiveness and placental-specific
expression of the gene and only causes transrepression in tissues where these
elements are functioning as enhancers (Akerblom et al., 1988). When bound to the
nGRE GR may interfere with the function of the transcriptional apparatus e.g. in the
POMC gene where GR binds to the nGRE at -60 (Drouin et al., 1993). It has been
suggested that GR binds as a trimer (Drouin et al., 1993) and prevents TFIID binding
to the TATA box (Drouin et al., 1987). GR may also interfere with the binding of
other transcription factors e.g. in the proliferin promoter and glutamine synthase
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enhancer where it may interfere with AP-1 binding (reviewed in (Beato et al., 1996)),
the CRH (Malkoski et al., 1997) and a-subunit of glycoprotein (Akerblom et ah,
1988) promoters where it may interfere with the function of a cyclic AMP response
element and the globin gene ofmouse erythroleukaemia cells where it can block
GATA-1 binding (reviewed in (Beato et ah, 1996)).
GR may also repress transcription by direct interaction with other transcription
factors in the nucleus, e.g. HSF1 (Wadekar et ah, 2001), AP-1, NF-kB, GATA-1 and
CREB (reviewed in (Beato et ah, 1996; Reichardt and Schutz, 1998)). Studies
showing that GR can inhibit AP-1 mediated induction of genes lacking GREs e.g. the
collagenase gene (reviewed in (Beato et ah, 1996)) and that an activation-deficient
GR mutant with no dimerisation ability can repress AP-1 activity in cultured Jurkat
cells (Heck et ah, 1994; Helmberg et ah, 1995) suggest that this interaction does not
require DNA binding by GR. These interactions may involve masking of
transactivation domains, post-translational modifications or conformational changes
in the proteins (reviewed in (Beato et ah, 1996; Reichardt and Schutz, 1998)) and are
likely to be complex with crosstalk between transcription factor systems e.g. AP-1
signaling can lead to increased circulating levels of glucocorticoids and eventual
down-modulation ofAP-1 signaling in a negative feedback loop (reviewed in (Karin
and Chang, 2001)). Also, the activity ofGR may be repressed by protein-protein
interactions. For example, calreticulin binds to the GR DBD and prevents its binding
to GREs (Burns et ah, 1994; Dedhar et ah, 1994) and tumour susceptibility gene 101
(TSG101) represses the transactivation activity of the AF-1 domain ofGR
(Hittelman et ah, 1999).
As well as interacting with them directly, GR may compete with other transcription
factors e.g. NF-kB for binding to HAT coactivator proteins (section 1.10.3) such as
CREB binding protein (CBP) or steroid receptor coactivator-1 (Sheppard et ah,
1998). However, although there is evidence that coactivators may be limiting in the
process of transactivation, this is not the case for GR-mediated transrepression in a
model combining p65, CBP and GR (De Bosscher et ah, 2000) so the physiological
relevance of this model is uncertain.
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Finally, GR may interfere with the action of other transcription factors by increasing
the synthesis of inhibitor proteins which bind them and maintain them in an inactive
state. An example of this is IkB-cc, which binds NF-kB in an inactive complex in the
cytoplasm (Auphan et al., 1995; Scheinman et al, 1995). This induction of IkB-cx is
not seen in all cell types, however, and the mechanism by which it might occur is
unclear since the IxB-a promoter does not contain a GRE (De Bosscher et al., 2000).
These various models are not mutually exclusive and it seems likely that GR
transrepression is due to a combination of the above effects.
1.12 Aims
This thesis examines the tissue-specific expression and glucocorticoid autoregulation
of variant exons 1 of the GR gene. GR is widely expressed in the body and has
important physiological effects. In particular, GR is highly expressed in the
hippocampus, where changes in GR levels alter HPA axis regulation and hence affect
all physiological processes that are mediated by glucocorticoids. GR is also highly
expressed in the thymus, where it is important in the development and function of the
immune system and in the liver, where it modulates the effects of glucocorticoids on
hepatic metabolism.
Although glucocorticoid autoregulation ofGR levels is well-recognised and is almost
certainly fundamentally important in both dynamic and programmed changes in GR
expression, surprisingly little is known about the mechanisms of transcriptional
regulation of the GR gene. The GR gene is large and complex; multiple 5'
untranslated exons 1 have been identified in the rat, mouse and human GR genes.
These variant exons 1 are thought to arise from transcription initiation at alternate
promoters. Furthermore, both tissue-specific control ofGR levels and perinatal
programming ofGR expression may involve changes in alternate promoter usage
(e.g. prenatal dexamethasone exposure has been shown to affect the expression of
exons \^ and 1 io of the rat GR gene).
The work described in this thesis was designed to further investigate whether tissue-
specific changes in alternate promoter usage have an important role in transcriptional
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control of the GR gene. In order to do this, the work planned to test 3 main
hypotheses. The first was that there were widespread tissue and region-specific
differences in the pattern of expression of variant exons 1 of the GR gene (and hence
possibly alternate promoter usage), with the expression of certain exons 1 being
restricted to specific tissues. The second hypothesis was that changes in the pattern
of variant exon 1 expression would be associated with tissue and region-specific
differences in GR expression. To investigate these hypotheses, the pattern of variant
exon 1 expression and the distribution of variant transcripts relative to that of the
total pool of GR mRNA were characterized in a range of tissues.
The third hypothesis arose from the evidence suggesting a role for alternate promoter
usage in perinatal programming of GR levels. It was proposed that changes in
alternate promoter usage were the mechanism by which glucocorticoids autoregulate
GR levels in adult animals; specifically, that glucocorticoid-induced changes in the
activity of several tissue-specific promoters (e.g. those associated with exons 11 and
I7) but not those thought to be ubiquitously active (e.g the promoter associated with
exon 110) might be the mechanism of autoregulation. To investigate this, this work
studied the effects of glucocorticoid manipulations on expression of total GR mRNA
and variant exons 1 in hippocampus, liver and thymus, where glucocorticoids are
known to have important physiological effects.
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2 Materials and Methods
2.1 Materials
2.1.1 Chemicals
All chemicals were obtained from one of the following two suppliers unless listed
specifically below:
BDH Chemicals Ltd, Magna Park, Lutterworth, Leicestershire, LEI7 4XN.
Sigma Chemicals Ltd, Fancy Road, Poole, Dorset, BH17 7NH.
Chemical
Nucleotide triphosphates





Amfix High Speed Fixer
Ethanol
Agarose/low melting point agarose
Caesium chloride
Supplier
Amersham Pharmacia Biotech UK Ltd,
Little Chalfont, Buckinghamshire, HP7
9NA.
Becton Dickinson, Between Towns
Road, Cowley, Oxford, 0X4 3LY.
H.A.West Ltd, 41, Watson Crescent,
Edinburgh, EH 11 1ES.
Hayman Ltd, 70, Eastways Industrial
Park, Witham, Essex, CM8 3YE.
Life Technologies Ltd, 3, Fountain
Drive, Paisley, PA3 9RF.
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2.1.2 Radiochemicals







Deoxyribonuclease I, Proteinase K, RNase A and RNase T1 were supplied by Roche
Diagnostics Ltd, Bell Lane, Lewe, East Sussex, BN7 1LG. All other enzymes were




Sephadex G-50 grade ("Nick") columns Amersham Pharmacia Biotech UK Ltd
Hybspeed RPA Kit II
Century RNA Marker Set
Cryo-M-Bed embedding compound
Kodak autoradiographic film
AMS Biotechnology, Milton Park,
Abingdon, Oxfordshire.
Bright Instrument Co. Ltd, St Margaret's
Way, Huntingdon, PE18 6EB.
H.A.West Ltd
Hybaid Recovery DNA Purification Kit Hybaid Ltd, Action Court, Ashford
II Road, Ashford, Middlesex, TW15 1XB.
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Item Supplier
DNA size markers (1Kb DNA ladder) Life Technologies Ltd
TRIzol reagent
Fluothane Merial Animal Health Ltd, Sandringham
house, Harlow Business Park, Harlow.
Reverse Transcription System Promega Ltd
Vetergesic Reckitt & Colman Products Ltd, Dansom
Lane, Hull, HU8 7DS.
2.1.5 Solutions and buffers
2.1.5.1 General
Deionised water was used to make all solutions unless otherwise stated or if solutions
were for RNA work, in which case ultrapure water was used. Solutions marked 1
were not autoclaved before use: all others were. Solutions marked 2 were treated with
diethylpyrocarbonate (DEPC) (see section 2.1.5.1, DEPC water) before autoclaving
if they were to be used for RNA work.
Solution Composition
Alkaline SDS 0.2M NaOH, 1% SDS
Borate buffer 0.13M boric acid, 46mM NaCl and 0.5%
(w/v) bovine serum albumin. pH adjusted
to 7.4 with conc. HC1.
"Box buffer" for in situ mRNA
hybridization
20ml 20 x SSC, 50ml deionised
formamide (not molecular biology




Buffer I for nuclei preparation




0.5M EDTA pH 8.02
50%, 70% and 90% ethanol in
ammonium acetate1
Composition
0.32M sucrose, 0.1mM EDTA, lOmM
Tris-HCl pH 8.0 and ImM EGTA. Just
before use, 0.1% Triton X-100, ImM
spermidine, l.OmM DTT and O.lmM
PMSF were added.
2.0M sucrose, 5.0mM Mg acetate,
O.lmM EDTA and lOmM Tris-HCl pH
8.0. Just before use l.OmM DTT and
O.lmM PMSF were added.
150ml formamide was mixed with 15g
Amberlite mixed bed ion-exchange resin
for lhr at room temperature then filtered
twice through Whatman No. 1 filter
paper and stored at -20°C (for molecular
biology grade) or room temperature (for
non molecular biology grade).
0.5ml DEPC in 500ml ultrapure water.
Leave for 1-24 hours, autoclave.
0.25% (w/v) bromophenol blue, 0.25%
(w/v) xylene cyanol, 30% glycerol.
186.1 g Na2EDTA.2H20 was dissolved in
800ml water, pH was adjusted to 8.0
with NaOH and volume was adjusted to
1L.
11.55g of ammonium acetate was mixed




Glycerol tolerant buffer (20x)
GTE
Hybridization buffer for in situ mRNA
hybridisation (2x)'
MEA buffer (1 Ox)
Northern blot hybridisation buffer
4% paraformaldehyde in 0.1M phosphate
buffer1
Composition
appropriate and the volume was adjusted
to 500ml with water.
34.03% (w/v) bromophenol blue, 0.03%
(w/v) xylene cyanol, 20mM EDTA in
deionised formamide.
216g Trizma base, 72g taurine and 4g
Na2EDTA.2H20 were dissolved to a
final volume of 1L.
50mM glucose, 25mM Tris-HCl ph 8.0,
lOmM EDTA
1.2M NaCl, 20mM Tris-HCl pH 7.5, 2 x
Denhardt's solution, 2mM EDTA,
0.2mg/ml sonicated single-stranded
salmon testes DNA, 0.2mg/ml yeast
tRNA, 20% dextran sulphate.
200mM MOPS acid, 50mM sodium
acetate and lOmM EDTA with pH
adjusted to 7.2
0.13M NaH2P04, 0.4M Na2HP04,
3.3mM EDTA, 6.6% SDS and lOpg/ml
sonicated single-stranded salmon testes
DNA (denatured for 2min at 100°C
before adding to the buffer).
Dissolve 20mM NaH2P04 and 80mM
Na2HP04 in 1L DEPC water, heat to




5M potassium acetate (5M with respect
to acetate, 3M with respect to potassium)
Prehybridization buffer for in situ mRNA
hybridisation (2x)1
RNase buffer for in situ mRNA
hybridization
SSC (20x)2
Storage buffer for nuclei
5M sodium chloride2
Composition
Stir for 1 hour, cool, then store at 4°C.
80g NaCl, 2g KC1, 2g KH2P04, 29g
Na2HP04.2H20 were dissolved in 800ml
water. PH was adjusted to 7.4 and the
volume adjusted to 1L.
245.6g potassium acetate was dissolved
in 300ml water. Volume was adjusted to
500ml by adding 142.5ml water and
57.5ml glacial acetic acid.
1,2M NaCl, 20mM Tris-HCl pH 7.5, 2 x
Denhardt's solution, 2mM EDTA,
lmg/ml sonicated single-stranded salmon
testes DNA, 0.2mg/ml yeast tRNA.
0.5M NaCl, lOmM Tris-HCl pH 7.5 and
ImM EDTA.
Mix 175.32g 3M NaCl and 88.23g 0.3M
trisodium citrate. Adjust pH to 7 with
10M NaOH and volume to 1L with
water.
25% glycerol, 5.0mM Mg acetate,
O.lmM EDTA and 50.0mM Tris-HCl pH
8.0. Just before use l.OmM DTT and
O.lmM PMSF were added.








1M Tris-HCl pH 8.0 or pH 7.5
Tris-saturated phenol
Composition
10% dextran sulphate, 6 x SSC, 1% SDS
and O.lmg/ml salmon testes DNA
(denatured for 2min at 100°C before
adding to the buffer).
108g Trizma base, 55g boric acid, 20ml
0.5M EDTA were dissolved in water to a
final volume of 1L.
lOmM Tris-HCl pH 8.0, ImM EDTA
13.3ml triethanolamine was added to
800ml DEPC water, pH was adjusted to
8.0 with HC1 then volume was adjusted
to 1L with DEPC water.
121.1 g Trizma base was dissolved in
800ml water, pH was adjusted with
concentrated HC1 as required and the
volume adjusted to 1L.
Phenol was thawed from -20°C with a
small amount of H2O added.
Hydroxyquinoline was added to a
concentration of 0.1% (w/v) to prevent
oxidation and the phenol was
equilibrated twice each with 0.5M, 0.2M
and 0.1M Tris pH 8. The Tris-saturated
phenol was stored at 4°C under a layer of
0.1M Tris pH8.
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2.1.5.2 Molecular biology buffers
All buffers were provided by Promega Ltd.
Buffer
PCR buffer (lx)
Reverse Transcription Buffer (lx)
T4 DNA ligase buffer (lx)
Transcription optimised buffer (lx)
Composition
20mM Tris-HCl, 50mM KC1
lOmM Tris-HCl pH 8.8, 50mM KC1,
0.1% Triton X-100.
30mM Tris-HCl pH 7.8, lOmM MgCl2,
lOmM DTT, ImM ATP.
40mM Tris-HCl pH 7.9, 6mM MgCl2,
2mM spermidine, lOmM NaCl.
2.1.5.3 Restriction enzyme buffers
All buffers were supplied by Promega Ltd, apart from universal restriction buffer
which was prepared in our laboratory.
Buffer
Universal restriction buffer (lx)
AvaUPvuII buffer (1 x)
EcoRl/PstI buffer (1 x)
Hindlll buffer (1 x)
Composition
500mM NaCl, 500mM Tris-HCl pH 8.0,
llOmM MgCl2, 60mM p-
mercaptoethanol, lmg/ml bovine serum
albumin
6mM Tris-HCl, 6mM MgCl2, 50mM
NaCl, ImM DTT (pH 7.5 at 37°C).
90mM Tris-HCl, lOmM MgCl2, 50mM
NaCl (pH 7.5 at 37°C).
6mM Tris-HCl, 6mM MgCl2, lOOmM
NaCl, ImM DTT (pH 7.5 at 37°C).
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Buffer Composition
KpnI/Smal buffer (1 x) lOmM Tris-HCl, 7mM MgCl2, 50mM
KC1, ImM DTT (pH 7.5 at 37°C).
Ncol/Sall buffer (1 x) 6mM Tris-HCl, 6mM MgCl2, 150mM
NaCl, ImM DTT (pH 7.9 at 37°C).
SphI buffer (lx) lOmM Tris-HCl, lOmM MgCl2, 150mM
KC1 (pH 7.4 at 37°C).
2.1.6 Animals and cells
2.1.6.1 Animals
Wistar rats were supplied by Charles River UK Ltd, Margate, Kent, UK.
2.1.6.2 Bacterial cells
E. coli strains used were HB101 and JM109. Competent JM109 cells were supplied
by Promega Ltd.
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1% (w/v) bactotryptone, 0.5% (w/v)
yeast extract, 0.5% (w/v) NaCl.
LB broth with 1.5% (w/v) agar. For
pouring culture plates, LB-agar was
melted in a microwave, allowed to cool
then poured into 10cm petri dishes. If
required, ampicillin was added to a
concentration of lOOpg/ml before
pouring.
2.1.8.1 Primers for use in semi-quantitative RT-PCR.

































Exon 15 5 '-AAGAGGGTTTTGCATTCG-3' Exon 15, 364
55°C anneal
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2.1.8.2 Primers for generation of templates for riboprobes used for in situ
mRNA hybridisation.




Exon 1 5' -TCTGAAACATCTTCCTGGCT-3' Exon 1, 3', 58°C anneal.
P17 5'-CCAAAGAGGAGTCACTGTA-3' Exon 1, 5', 58°C anneal.
V6895 5' -ATAATACGACTCACTATAGGGCTTTGGAGTCCA Exon 110 3\ 65.5°C anneal.
TTGGCA-3'
W6489 5'-TTAATACGACTCACTATAGGGCCAGCGCGCTCA Exon 15 3\67.7°C anneal.
CACT-3'
W6490 5 '-TATTAACCCTCACTAAAGGGTAAGAGGAGGGC Exon 15 5\66.6°C anneal.
GGACT-3'
V6896 5' -TTAATACGACTCACTATAGGGCAGCGTGTGCC Exon 17 3', 67.7°C anneal.
GACCT-3'
V6897 5'-CATTAACCCTCACTAAAGGGCACCGTTTCCGTG Exon 17 5', 66.7°C anneal.
CAT-3'
Y3011 5'-CTACTACTACTAGGCCACGCGTCGACTAGTAC-3' Exon 110 5', 65.6°C anneal.
Y3012 5' -TATTAACCCTCACTAAAGGGAGCGGCGTCTGGA Exon 1 „ 5', 67.9°C anneal.
CC-3'




Exon 2 3', 64.4°C anneal.
Z3343 5' -AATTAACCCTCACTAAAGGGCCAATGGACTCC
AAAGA-3'
Exon 2 5', 64.4°C anneal.
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2.1.8.3 Primers for cycle sequencing.
Primer annealing temperatures are those determined under conditions of 0.1M Na'.
Primer Sequence Description
D3720 5'-GATTTAGGTGACACTATAG-3' SP6 promoter sequencing primer, 44.5°C anneal.
T7 5'-GTAATACGACTCACTATAG-3' T7 promoter sequencing primer, 52°C anneal.
2.1.8.4 Plasmid constructs
pVL constructs were a kind gift from Mrs Val Lyons in our laboratory. pJIM
constructs were a kind gift from James McCormick in our laboratory. pNNCAT was
a kind gift from M.D.Jacobson. pGR9 was a kind gift from Mrs June Noble in our







pGEM-T 367bp rat 5'-RACE clone containing exon 11




228bp rat 5'-RACE clone containing exon 14
290bp rat 5'-RACE clone containing exon 15
5-6kb EcoRI fragment from >.208 (rat clone containing
exon 2 and approximately 15kb of the rat GR gene
flanking the 5' end of exon 2 (M.D.Jacobson,
unpublished data), containing exon 1 n
pVL166
pNNCAT
pGEM-T Easy 276bp rat 5'-RACE clone containing exon 1 ]
pUCOOcO 2.2kb Ncol fragment from rat GR promoter upstream of
exon 1)0.




pJIM2 pGEM-T Easy 414bp rat 5'-RACE clone containing exon 110.
pJIM5 pGEM-T 269bp rat liver RT-PCR product containing exon 16
pTRI-Beta-actin- pTRI 126 bp cDNA fragment of the rat p-actin gene derived
125-Rat from exon 5
pALl pGEM-T Easy 430bp Exon 1 j RT-PCR product from mouse thymus
RNA.
pAL3 pGEM-T Easy 250bp Exon 15 PCR product from rat genomic clone.
pAL4 pGEM-T Easy 300bp Exon 17 PCR product from rat genomic clone.
pAL5 pGEM-T Easy 250bp Exon 1,0 PCR product from rat 5'-RACE clone.
pAL6 pGEM-T Easy 250bp Exon ln PCR product from rat 5'-RACE clone.
pAL7 pGEM-T Easy 300bp Exon 2 PCR product from rat 5'-RACE clone.
pAL9 pUC18 250bp SphHSall recovery of insert from pAL3 (Exon 15).
pALlO pUC18 250bp Sphl/Sall recovery of insert from pAL6 (Exon
1.,).
pALl 1 pUCl 8 300bp Sphl/Sall recovery of insert from pAL7 (Exon 2).
pAL13 pGEM3 430bp EcoRI recovery of insert from pALl (Exon 1,).
pAL14 pGEM3 300bp EcoRI recovery of insert from pAL4 (Exon 17)





Animals were maintained under controlled lighting (lights on from 0700 to 1900
hours) and temperature (22°C) with water and food available ad libitum.
2.2.1.2 Adrenalectomy
This procedure was performed by Mrs. June Noble (for the short-term adrenalectomy
experiment) or Mr. Mark Cleasby (for the long-term adrenalectomy experiment).
Anaesthesia was induced and maintained using halothane (Fluothane, Merial) in a
Perspex anaesthetic chamber (constructed in-house). Intraoperative analgesia was
provided with buprenorphine 0.05mg/kg s/c (Vetergesic, Reckitt & Colman). A 1-
2cm transverse incision was made through the skin, subcutis and abdominal
musculature approximately 1cm caudal to the last rib, then the adrenal gland was
located in the perirenal fat and removed. The abdominal muscle and subcutis were
closed with simple continuous sutures of 2/0 braided silk. The skin was closed with
stainless steel Michel clips. Sham-operated animals underwent the same procedure,
except the adrenal glands were left intact.
2.2.1.3 Short-term (ST) glucocorticoid replacement
4 groups of 6 animals were used to study the effect of short-term (72h)
adrenalectomy and subsequent glucocorticoid replacement on GR expression in the
hippocampus.
The groups were:
(a) Sham-operated controls that received injections of com oil vehicle only
(Sham).
(b) Adrenalectomised animals that received injections of com oil vehicle only
(Adx).
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(c) Adrenalectomised animals that received "physiological" corticosterone
replacement (Adx/phys), administered as a daily injection of 0.2mg/kg
corticosterone acetate in vehicle at 4pm.
(d) Adrenalectomised animals that received "supraphysiological" corticosterone
replacement (Adx/supra), administered as a daily injection of 2mg/kg
corticosterone acetate in vehicle at 4pm.
A time-course of 3 days was chosen because previous work from this laboratory had
shown significant changes in hippocampal glucocorticoid receptor mRNA levels 2
days after adrenalectomy (Holmes et al., 1995b). Injections of vehicle or
corticosterone acetate were given on days 0, 1 and 2. Injections were performed by
Mr. Keith Chalmers.
Daily injections of corticosterone acetate were chosen rather than implantation of
subcutaneous pellets principally to mimic the natural diurnal afternoon/evening peak
of corticosterone release in the rat. Second, corticosterone pellets display rapidly
changing release kinetics in the initial period after implantation, with a high initial
rate of release falling off sharply to a steady rate of release. The animals would thus
be experiencing a variable dose of corticosterone for the majority of the experimental
period: this variation was considered a potential source of experimental error.
2.2.1.4 Long-term (LT) glucocorticoid replacement
3 groups of animals were used to study the effect of long-term (3 weeks)
adrenalectomy and subsequent glucocorticoid manipulations on GR expression in the
hippocampus. The experimental animals were part of a study being performed by Mr
Mark Cleasby. For details of experimental procedures see section 2.2.1.
The groups were:
(a) Sham-operated controls (Sham).
(b) Adrenalectomised animals (Adx).
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(c) Adrenalectomised animals implanted with pellets containing corticosterone
(Adx/cort).
In this case subcutaneous pellets were used to provide corticosterone replacement
because the longer experimental period made daily injections impractical.
Subcutaneous pellets contained corticosterone 21-acetate in carrier. The
corticosterone content of the pellets was calculated to provide a dose of lmg/kg/day.
Sham-operated and vehicle groups received pellets of carrier alone. Pellet
implantation was performed by Mr. Mark Cleasby at the time of adrenalectomy.
Trunk blood was obtained for plasma corticosterone assays (section 2.2.13). Animals
in both studies were weighed before surgery and again at the time of death.
2.2.1.5 Harvesting of tissues
In both experiments animals were killed by decapitation l-2h after the beginning of
the light period. Trunk blood samples were collected as described in section 2.2.13.
The liver, brain and thymus were harvested from both sets of experimental animals.
When tissues were harvested care was taken to ensure that an animal was killed from
each experimental group in turn to minimise any effect of time of death on GR
levels. Tissues were removed, quick-frozen on dry ice and stored at -80°C until
required.
2.2.2 Agarose Gel Electrophoresis
2.2.2.1 Analytical DNA gels
These were prepared by mixing solid agarose with 0.5x TBE to give a final agarose
concentration of 0.8-2.5% (w/v) depending on the molecular weight of the DNA of
interest and boiling in a microwave oven until the agarose was completely dissolved.
50pg/ml of ethidium bromide was added, the solution was thoroughly mixed then the
gel was cast using an appropriately-sized gel mould and comb. After setting the gel
was placed in a Biorad Sub-Cell GT electrophoresis tank and 0.5x TBE was added
until the gel was just submerged, lkb DNA ladder markers and experimental samples
(with lpl DNA loading buffer added) were then loaded into the wells and
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electrophoresed at 100-200V to resolve the DNA fragments. These were visualized
on a UV transilluminator at 254nm and imaged using an Appligene Imager. Images
were recorded as TIFF files on 1,44Mb floppy disc or on Seikosha video printer
paper.
2.2.2.2 Preparative DNA gels
1-1.5% (w/v) agarose gels were used for gel purification ofDNA fragments. Low
melting point agarose was used and the gel was cast in a cold room at 4°C.
Electrophoresis at 150V was performed to separate out the fragment of interest,
which was visualized using a UV transilluminator at 365nm to avoid UV light-
induced damage to the DNA. The band of interest was excised with a sterile scalpel
and the DNA purified (section 2.2.5.2).
2.2.2.3 Analytical RNA gels
Integrity of total RNA was assessed by electrophoresis through a denaturing agarose
gel. Gel trays, combs and tank were cleaned with detergent then soaked in 0.1M
NaOH for 30min and rinsed several times with ultrapure H2O before use. 50ml 1.3%
(w/v) agarose gels were prepared: 0.6g agarose was dissolved in 36ml DEPC H2O by
boiling in a microwave. After allowing the mix to cool slightly, 9ml 40% (w/v)
formaldehyde solution and 2.5ml lOx MEA were added, the solution was mixed
thoroughly and the gel was cast. Before use the set gel was aged in a Biorad Sub-Cell
GT gel tank in lx MEA buffer for 15-30min.
2pl ofRNA sample was mixed with 2.5pl 40% (w/v) formaldehyde solution, 2.5pl
lOx MEA and lOpl deionised formamide. After incubation at 65°C for 15min, 2pl of
a 1:5 mix of lOmg/ml ethidium bromide and gel loading buffer was added to the
denatured samples. These were loaded on the gel and resolved for 20-3Omin at 100V.
RNA was visualized as described for analytical DNA gels.
2.2.3 Denaturing polyacrylamide gel electrophoresis
Different percentage polyacrylamide gels were used depending on their application.
For electrophoresis of cycle sequencing reactions a 6% acrylamide gel was used, for
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determination of the quality of cRNA probes a 5% gel was used and in RNase
protection analysis a 4% gel was used. Before use, all glass plates were scrubbed
with detergent, rinsed in deionised water then rinsed with absolute ethanol and
allowed to dry before assembly.
For 6% gels, two 45cm x 35cm glass plates were cleaned, assembled with 0.3mm
spacers between them and clamped with bulldog clips. The edges of the plates were
sealed with 2-3% (w/v) agarose. 42g urea was dissolved in 15ml 40%
acrylamide:bis-acrylamide (19:1), 4ml glycerol tolerant buffer and 600pl 10% (w/v)
ammonium persulphate made up to a total volume of 100ml with DEPC water. After
filtration through Whatman No. 1 filter paper, 40pl TEMED was added to initiate
polymerization and the gel was poured immediately. The flat side of a comb was
inserted to allow use of a shark-tooth comb once the gel had set. The gel was left to
polymerize overnight, wrapped in Clingfilm to prevent desiccation. Electrophoresis
was performed in a Kodak Biomax STS45i vertical tank in 0.8x glycerol tolerant
buffer. The gel was prerun at 1800V for 30min, then the wells were flushed with
buffer to remove accumulated urea and the samples, denatured in formamide loading
buffer at 95°C for 5min, were loaded. The gel was run at 1800V until the
bromophenol blue had reached the bottom of the gel. At this point, if reading of
sequence far from the sequencing primer position was required, a second loading of
sample was performed and the gel run until the bromophenol blue of this loading
reached the bottom of the gel. The gel was then transferred to Whatman 3MM paper
and dried under vacuum at 80°C using a Biorad 583 gel drier. The dried gel was
exposed to Kodak Biomax MR film overnight, then re-exposed for longer if
necessary.
For 5% gels a 10-tooth comb and two 8cm x 10cm glass plates were cleaned. The
plates were assembled with 1mm spacers. 3.6g urea was dissolved in 1.25ml 40%
acrylamide:bis-acrylamide (19:1) and 1ml lOx TBE made up to a total volume of
10ml with DEPC water. lOOpl 10% (w/v) ammonium persulphate and 10pl TEMED
were added, the gel was immediately poured and the comb was inserted. The gel was
allowed to polymerize for at least 30min before use. Electrophoresis was performed
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in lx TBE buffer using a vertical electrophoresis tank. Samples were denatured in
formamide loading buffer for 5min at 95°C before loading. The gel was run at 15mA
for 20-25min then transferred to Whatman 3MM paper, wrapped in Clingfilm and
exposed against either a phosphor screen for 15min or against Kodak Biomax MR
film. The phosphor screen was read using a Fujifilm FLA-2000 phosphoimager.
For 4% gels 2 15 x 17cm glass plates were cleaned then assembled with 0.8mm
spacers and sealed with 2-3% (w/v) agarose. 21 g urea was dissolved in 5ml 40%
acrylamide:bis-acrylamide (19:1), 5ml lOx TBE and 300pl 10% (w/v) ammonium
persulphate made up to a total volume of 50ml with DEPC H2O. 1 OOjul TEMED was
added to begin polymerization, the gel was immediately poured and a 20-tooth comb
was inserted. At least 2h were allowed for polymerization before the gel was used.
Electrophoresis was performed in a Model 16 vertical gel electrophoresis system
(Life Technologies) in lx TBE buffer. Wells were flushed before loading of samples
(for treatment of samples see section 2.2.11.2). The gel was run at 30mA until the
bromophenol blue just ran off the bottom of the gel then was transferred to Whatman
3MM paper and dried under vacuum at 80°C using a Biorad 583 gel drier. The dried
gel was exposed to Kodak Biomax MR autoradiography film overnight then
developed. The gel was then exposed to a phosphor screen for l-7d depending on the
autoradiography result. If necessary the gel was then reexposed to autoradiography
film.
2.2.4 Ribonucleic acid (RNA) extraction
Tissues were obtained from animals killed by decapitation or cervical dislocation (in
rats and mice respectively) and immediately snap-frozen on dry ice, then stored at -
80°C until required. 50-100mg of tissue was taken, 1ml of TRIzol reagent was added
and the tissue was homogenised with an IKA Labortechnik Ultra-Turrax T8 electric
homogeniser. Care was taken that the sample did not exceed 10% of the volume of
TRIzol reagent used, as use of too much tissue could lead to protein or genomic
DNA contamination of the extracted RNA. The homogenised sample was incubated
for 5min at room temperature to allow complete dissociation of nucleoprotein
complexes, then 0.2ml chloroform was added to each tube. The tube was shaken
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vigorously by hand for 15s then incubated at room temperature for 2-3min. The
sample was then centrifuged in a microcentrifuge at 12,000g for 15 minutes at 4°C to
separate the aqueous and organic phases. The upper aqueous phase was removed to a
fresh tube and the RNA precipitated by adding 0.5ml isopropanol and incubating for
lOmin at room temperature. The RNA was then pelleted by centrifuging the sample
at 12000g for lOmin at 4°C. The supernatant was carefully removed and the pellet
washed by adding 1ml ice-cold 75% ethanol and vortexing. The sample was then
centrifuged at 7500g for 5min at 4°C and the supernatant was removed with a drawn-
out glass Pasteur pipette. The RNA pellet was air-dried for 5-10min at room
temperature until the edges were just translucent, then dissolved in 10-150ptl of either
DEPC-treated water or 100% deionised formamide (if for use in RNase protection
analyses) by heating to 55-60°C for lOmin and repeatedly passing through a pipette
tip. Samples were then stored at -80°C until required.
2.2.5 Manipulation of DNA
2.2.5.1 Restriction digests
Plasmid DNA (approximately 0.5pg for screening of "minipreps", 5jig for
subcloning or linearisation ofDNA templates) was digested at 37°C for 60-90min in
a mixture containing 1 x restriction buffer (either commercially-bought buffer
supplied with the enzyme or our own lab universal restriction buffer) and 5-15U of
restriction endonuclease made up to a final volume of 15-30pl with ultrapure H2O.
Digestion was verified by agarose gel electrophoresis of the whole digest (for
minipreps) or a 1 pi aliquot.
Genomic DNA was digested at 37°C for 12-18h in a similar mixture with a final
volume of 50-100pl. A second aliquot of 5-15U restriction endonuclease was added
after approximately 12h of incubation.
If the DNA fragment was for ligation and both the insert and vector had been cut
with the same enzyme (generating an overhanging end), an equal volume of TE and
1U calf intestinal phosphatase was added followed by incubation for a further 60min
at 37°C then 15min at 65°C to inactivate the phosphatase. If a blunt 5' end was
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required for ligation this was created from a 5' overhang by adding 5U Klenow
fragment and 1/10 vol 2mM dNTPs then incubating at 37°C for lOmin followed by
65°C for lOmin.
2.2.5.2 Purification of digested plasmid DNA
For subcloning, DNA fragments of greater than 200bp in size were purified using the
Hybaid Recovery DNA Purification Kit II. Fragments were resolved by
electrophoresis at 120V on a 1.5% low melting point agarose gel. The gel was
examined on a UV transilluminator at 365nm (to avoid DNA damage) to identity the
bands of interest, which were then excised. Linearized plasmid DNA was purified
directly from the restriction digest reaction. Either the entire restriction digest or the
excised gel slice was placed in a spin filter tube to which 400pl of the supplied
binding buffer had been added. The mixture was incubated at 55°C for 5min, agitated
then centrifuged in a microcentrifuge at 14000rpm for 30s. Two washes were
performed with 500pl of supplied Wash Solution being added each time followed by
centrifugation as before. The pellet was dried by centrifuging for lmin, then the
purified DNA was eluted into a fresh catch tube by adding 15-25pl of Elution
Solution, vortexing briefly then centrifuging as before.
DNA fragments of less than 200bp were recovered using the High Pure PCR Product
Purification Kit. Fragments were resolved by electrophoresis and gel slices were
excised as described above. Gel slices were placed in a preweighed Eppendorf tube
and weighed. 300pl of supplied binding buffer per lOOmg agarose was added, the
sample was vortexed and heated to 56°C for lOmin, vortexing every 2-3min. After
the agarose had completely dissolved, 150pl isopropanol/lOOmg agarose was added
and the mixture was vortexed thoroughly. The entire mixture was then placed in the
High Pure filter tube and centrifuged for 30-60s in a microcentrifuge at maximum
speed. The flowthrough solution was discarded and 500pl supplied wash buffer was
added to the filter. The tube was centrifiiged as above, the flowthrough was discarded
and the wash step was repeated with 200pi wash buffer. The filter was attached to a
fresh collecting tube, 50-1 OOpl supplied elution buffer was added to the filter and the
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tube was centrifuged as above. The eluted DNA was retained and stored at -20°C
until required.
In both cases, DNA recovery was checked by electrophoresis of a lpl aliquot on a 1-
1.5% agarose gel.
2.2.6 DNA cloning
2.2.6.1 Ligation of DNA
DNA fragments were purified and recovered as described in Section 2.2.5.2, then
ligated in a mixture containing 1 x ligation buffer, 1-5U T4 DNA ligase,
approximately 50ng insert DNA and approximately lOOng vector DNA. The mix was
incubated at 4°C overnight then used for transformation of bacterial cells (section
2.2.6.3).
2.2.6.2 Preparation of competent bacterial cells
For cloning of PCR products, supercompetent E.coli JM109 were purchased. For
other cloning procedures the recA-HB101 strain ofE.coli was used. Transformation-
competent cells of this strain were produced as follows. 1ml of LB was inoculated
with a single colony of cells and incubated in a shaking incubator at 37°C overnight,
then used to inoculate 50ml of LB. This was incubated as before for 1.5-2h until the
cells were in the late log phase ofmultiplication. The culture was centrifuged in a
Beckman J2-MC centrifuge with a JA-14 rotor at 4700g for 5min. Pelleted cells were
resuspended in 20ml ice-cold 0.1M CaCl2, incubated for 10min-2h on ice,
centrifuged as before then resuspended in 2ml ice-cold 0.1M CaCE. Competent cells
thus prepared were stored on ice at 4°C for up to 4d with daily changes of ice.
2.2.6.3 Transformation of bacterial cells
Supercompetent JM109 cells were transformed as follows. Cells were allowed to
thaw from -80°C on ice, mixed gently then 100pi of suspension was transferred to a
prechilled 1.5ml Eppendorf tube. 200-500ng of DNA was added, mixed gently then
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incubated on ice for lOmin. Cells were then subjected to 50s heat shock at 42°C
followed by 2min recovery on ice. 400pl ofLB broth at room temperature was added
and the cells were placed in a shaking incubator at 37°C for 30min. 200pl of
suspended cells was plated on a LB agar plate containing 40pl 50mg/ml 5-bromo-4-
chloro-3-indolyl-fl-D-galactoside (X-GAL), 40pl 0.1M isopropyl-13-
thiogalactopyranoside (IPTG) and lOOpg/ml ampicillin. Plates were allowed to dry
for lOmin before incubation at 37°C overnight.
2.2.6.4 Screening of transformants: "minipreps"
Single transformant colonies were picked and inoculated into 2ml LB containing
lOOpg/ml ampicillin then incubated at 37°C in a shaking incubator overnight.
Cultures were decanted into 1.5ml Eppendorf tubes then centrifuged at 14000rpm for
lmin in a microcentrifuge. Pelleted cells were resuspended in lOOpl GTE, 200pl
fresh alkaline SDS was added, then the tubes were vortexed and placed on ice for
5min. 150pl 5M potassium acetate pH 4.8 was added, then the tubes were vortexed
and placed on ice for 5min. Tubes were centrifuged for 5min as before and the
supernatant was removed to fresh Eppendorf tubes containing 225pi
chloroform:isoamyl alcohol (24:1) and 225pl Tris-saturated phenol. Tubes were
vortexed and centrifuged for 2min as above. The supernatant was transferred to fresh
Eppendorfs containing 2 vol ethanol, vortexed and incubated at room temperature for
5min. Tubes were centrifuged for 5min as above, the supernatant was completely
removed and the DNA pellet was allowed to air dry for lOmin. The DNA was
resuspended in 50pl TE containing 50ng RNase A and stored at -20°C. Appropriate
restriction enzyme digests and agarose gel electrophoresis were performed to identify
colonies containing plasmids with the desired insert.
2.2.6.5 Preparation of large quantities of plasmid DNA
A single transformed colony was used to inoculate 2ml of LB broth containing
lOOpg/ml ampicillin then incubated overnight at 37°C in a shaking incubator. This
culture was used to inoculate 500ml of LB broth containing lOOpg/ml ampicillin
which was incubated overnight at 37°C in a shaking incubator. Cells were pelleted by
centrifugation for 5min at 3500g and 4°C in a Beckman J2-MC centrifuge with a JA-
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14 rotor, then resuspended in 12ml GTE. 24ml of fresh alkaline SDS was added and
the mix incubated on ice for at least lOmin. 16ml cold 5M potassium acetate was
added. The sample was mixed thoroughly, incubated on ice for 1 Omin then
centrifuged for lOmin as above. The supernatant was filtered through gauze into
fresh centrifuge pots containing 32ml isopropanol and left at room temperature for
30min. DNA was pelleted by centrifugation for 3min at 9600g and 4°C. The pellet
was briefly air-dried then resuspended in 2.2ml TE. 3g of CsCl and lOOpl of
ethidium bromide was added then the solution was transferred into 3ml Beckman
Quickseal tubes and centrifuged for either 16-20h at 70000rpm or 4h at lOOOOOrpm
in a Beckman Optima TLX ultracentrifuge using a TLA100.3 rotor. The band of
ethidium-stained plasmid DNA was removed and transferred to a fresh tube using a
sterile needle and syringe. TE with lg CsCl added per ml TE was used to fill the tube
and the centrifugation was repeated. The ethidium-stained DNA was removed as
above and repeated isopropanol extractions were performed to remove the ethidium
bromide. The DNA solution was then dialysed overnight against 3 changes of 2L TE
solution at 4°C. Concentration and quality (measured by A280/A260 absorbance ratio)
of the recovered DNA was determined using a Pharmacia Biotech GeneQuant
spectrophotometer. Samples were then stored at -20°C.
2.2.7 Polymerase Chain Reaction techniques
2.2.7.1 Semiquantitative reverse transcriptase polymerase chain reaction (RT-
PCR)
Single-stranded cDNA was synthesized using the Reverse Transcription System kit
(Promega). Reactions contained 5mM MgCE, 1 x reverse transcription buffer, ImM
each dNTP, 40U RNasin ribonuclease inhibitor, 30U AMV reverse transcriptase,
lpg oligo(dT)i5 primer, 2jug total RNA and nuclease-free water to a final volume of
40pl. Control reactions were identical in all respects except that no reverse
transcriptase was added. Reactions were incubated at 42°C for 30min, 95°C for 5min
then 4°C for 5min. Products were stored at -20°C until required. 2pl of either neat or
diluted (1/5, 1/25, 1/125 in DEPC water) product was used in a PCR reaction
containing 1 x PCR buffer, 1.5mM MgCh, 200pM each dNTP, 40pM each primer
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(section 2.1.8) and nuclease-free water to a final volume of 50pl. Reactions were also
set up for each primer pair containing either 2pl control reaction without reverse
transcriptase or 2pl nuclease-free water. 1 TAQbead (Promega) was added to each
tube followed by 2 drops ofmineral oil to prevent evaporation. PCR amplification
(95°C 5min followed by 35 cycles of 95°C 50s, 50°C 45s, 72°C 90s then 72°C for
5min) was performed in an EppendorfMastercycler Gradient thermal cycler. A 10pl
aliquot of each product was run on a 1.5% analytical agarose gel and amplified DNA
fragments were visualized as described in section 2.2.2.1.
2.2.7.2 Cycle sequencing
This was performed using the Thermo Sequenase radiolabelled terminator cycle
sequencing kit (Amersham). Reactions were prepared containing 2pl dGTP
nucleotide master mix, 0.5pl [a33P]-dNTP (A, C, G or T with only 1 being added per
sequencing reaction) and 4.5pi reaction master mix (2pl reaction buffer, 1 pi DNA
solution, 0.05pM primer (section 2.1.8.3), 13pl ultrapure water and 8U Thenno
Sequenase polymerase). Tubes were placed on a preheated thermal cycling block and
40 cycles ofPCR amplification (95°C 30s, 45°C 30s, 72°C lmin) were performed.
4pl of stop solution was added and the reactions were resolved on a 6% glycerol
tolerant sequencing polyacrylamide gel.
2.2.7.3 General PCR protocol
A reaction mix was prepared containing 1 x PCR buffer, 0.5mM MgCh, 40pM each
primer (section 2.1.8), 200pM each dNTP and approx. lOOng ofDNA template. The
reactions were overlaid with 2 drops ofmineral oil and denatured at 95°C for 5min
before adding 2.5U Taq DNA polymerase and beginning cycling. Appropriate
cycling conditions were used for the primer pair in use (section 2.1.8).
2.2.8 Southern blot analysis
2.2.8.1 Restriction enzyme digestion
50pg of genomic DNA was digested overnight as described in section 2.2.5.1.
Enzymes used are described in Chapter 5.
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2.2.8.2 Electrophoresis of samples and transfer to nylon membrane
After restriction enzyme digestion DNA samples were electrophoresed overnight at
15-20V on a 0.8% analytical agarose gel as described in section 2.2.2.1. Towards the
end of the running time the DNA was visualised as described in section 2.2.2.1 to
ensure that the smallest fragments ofDNA were not lost from the end of the gel. Gels
were treated by shaking in 0.125M HC1 for 15min, 1.5M NaCl/0.5M NaOH for
30min and 1.5M Tris pH 7.5/1.5M NaCl for 30min on a Bellco Biotechnology
orbital shaker. DNA was transferred to a positively-charged nylon membrane
(Hybond N Plus, Amersham) by capillary transfer. The gel was inverted and placed
on a wick ofWhatman 3MM paper soaked in 20 x SSC. The nylon membrane was
applied to the gel, with care being taken to ensure no air bubbles lay between it and
the gel. 3 layers ofWhatman 3MM paper cut to the same size as the membrane and a
2-3 inch layer of paper towel (Wypall, Kimberley-Clark) folded to the same size as
the membrane were layered on top. A glass plate was applied to the top of the towel
stack and weighted with approximately 150g. The plate was levelled with a spirit
level, then the whole assembly was covered with Clingfilm and left at room
temperature overnight. The towels etc. were then removed and the blot was washed
in fresh 20 x SSC to remove any agarose sticking to it. The blot was allowed to air
dry, then the DNA was crosslinked to the nylon membrane by exposing it to
120mJ/cm2 ofultraviolet radiation in a "Spectrolinker" XL-1500 ultraviolet
crosslinker (Spectronics Co.).
2.2.8.3 Preparation of cDNA probe
Probes were prepared using the Random Primed DNA Labeling Kit (Roche
Diagnostics). l-2pg ofDNA template was denatured at 100°C for lOmin, then
cooled on ice for 5min. A reaction mixture was prepared containing this DNA, 75pM
each of dATP, dGTP and dTTP, 1 x reaction mixture containing hexanucleotide
primers (supplied with kit), 1.85MBq [a32P]-dCTP, 2U Klenow fragment ofDNA
polymerase I and H2O to a final volume of 20pl. The reaction was incubated at 37°C
for 60-90min then the probe was purified using a Sephadex G-50 grade ("Nick")
column. The column was first equilibrated with 3ml TE, then the reaction mix was
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added and allowed to soak into the gel bed. 400pl TE was added and the eluate
discarded. A further 2 elutions were performed with 200pl ofTE each and the
eluates collected. The specific activity of probe in the eluates was assayed by adding
a ljul aliquot to 1ml of Aquasafe 300 Plus scintillant fluid and counting on a Wallac
1450 Microbeta Plus scintillation counter. The eluate with the highest activity was
retained for use in hybridisation and stored at -20°C for a maximum of 48h until
required.
2.2.8.4 Hybridization
This was performed in glass hybridisation bottles in a Techne Hybridizer HB-1D
hybridisation oven. Two methods of hybridisation were used, employing different
buffers. In the first method, the blot was prehybridized for 3-4h at 65°C in 20-25ml
of Southern blot hybridization buffer. The probe was denatured at 95°C for lOmin
and immediately added to the hybridisation bottle. The volume of buffer used was
calculated so that the final specific activity of probe would be approximately
lxl06cpm/ml. The blot was hybridised for 14-16h, then the buffer was removed and
the blot was quickly washed in room temperature 2 x SSC followed by 2 washes of
15min in 0.1 x SSC/1% SDS at 65°C. In the second method the blot was
prehybridized at 42°C in a commercially-available hybridisation buffer (Ultrahyb,
Ambion Inc.). The probe was denatured and added as above, then the blot was
hybridised for 14-16h at 42°C. The buffer was removed and the blot was washed for
2 x 15min in 2 x SSC/0.1% SDS at 42°C, then for 2 x 15min in 0.1 x SSC/0.1% SDS
at 42°C. In both cases after washing the blot was wrapped in Clingfilm, examined
with a Geiger-Muller counter and exposed to a phosphor screen for 2-8h depending
on the amount of radioactivity detected. The bands were visualized using a Fujifilm
FLA-2000 phosphoimager. The blot was then exposed to autoradiography film for 1-
14d depending on the strength of signal observed on the phosphoimager.
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2.2.9 Northern blot analysis
2.2.9.1 Electrophoresis of samples and transfer to nylon membrane
RNA samples were electrophoresed at 150V on a 1.3% analytical RNA gel as
described in section 2.2.2.3. The gel was run until the bromophenol blue dye front
was l-2cm from the end of the gel. RNA was transferred to a positively-charged
nylon membrane (Hybond N Plus, Amersham) as described for Southern blot
analysis in section 2.2.8.2.
2.2.9.2 Hybridization
This was performed in glass hybridisation bottles in a Techne Hybridizer HB-1D
hybridisation oven. Blots were prehybridised at 55°C in Northern blot hybridisation
buffer (section 2.1.5.1) for at least 3h before probes, prepared as described in Section
2.2.8.3, were denatured for lOmin at 95°C and immediately added to the bottle.
Hybridization was performed for 14-16h at 55°C. After hybridisation the buffer was
removed and the blot was washed for 3 x 20min in a solution of 0.1 x SSC/0.1 % SDS
at room temperature. The radioactivity levels on the blot were assessed with a
Geiger-Muller counter and if necessary the blot was then washed for 30min in a
solution of 0.3 x SSC/0.1% SDS at 55°C. From this point the blot was treated as
described for Southern blot analysis in section 2.2.8.4.
2.2.10 In situ mRNA hybridization
2.2.10.1 Preparation of slides
Glass microscope slides were prepared by submersion in 0.2M hydrochloric acid for
3min, submersion for 3min in DEPC H20, dipping in 2% silane in acetone,
submersion for 2 x 3min in acetone then submersion for 3min in DEPC H20. Slides
were briefly air-dried at room temperature then baked at 50°C overnight in a size 2
Gallenhamp Hotbox oven.
2.2.10.2 Sectioning of tissues
Tissues were cut at -20°C into 15pm sections using a Bright Model OTF cryostat.
Tissues were removed from storage at -80°C and mounted for sectioning using Cryo-
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M-Bed embedding compound, then allowed to warm to -20°C for 15-20min. Glass
microscope slides prepared as described above were pre-chilled to -20°C before use.
3 sections of tissue were collected onto each slide and fixed in place by brief melting.
Sections were stored at -80°C until required.
2.2.10.3 Preparation of cRNA probes
Probes for in situ hybridization were prepared using either PCR products or their
subclones as templates. Initially, DNA templates for the synthesis of cRNA probes
for exons 15, 17, 110, In and 2 were generated by PCR amplification from various 5'-
RACE and genomic clones using exon-specific primers (Table 2.1: for details of
primer positioning on the genomic sequence see section 2.1.8.2 and Appendix A, for
details of 5'-RACE and genomic clones see 2.1.8.4). All these PCR product
templates used phage T7 polymerase to generate the antisense probe: all but the 110
template (whose 5' primer had no phage polymerase recognition sequence) used




5' primer 3' primer Product length
2 pVL131 Z3343 Z3342 200bp
Is pNNCAT W6490 W6489 228bp
I7 pNNCAT V6897 V6896 290bp
110 pVL131 Y3011 V6895 290bp
In pVL154 Y3012 Y3021 290bp
Table 2.1: primers and plasmid constructs used to generate PCR product templates for cRNA
probes.
The probe for exons 5-9 was generated from plasmid construct pGR9 (section
2.1.8.4) linearised with Aval to generate the antisense probe and EcoRl to generate
the sense probe.
Subsequently, plasmid constructs pAL2 to pAL7 (section 2.1.8.4) were created by
subcloning the PCR product templates into the pGEM-T Easy vector system. Also,
plasmid construct pALl (section 2.1.8.4) was generated by subcloning a RT-PCR
product (generated from mouse thymus RNA using primers PI7 and 11) into the
same vector. Orientation of inserts was determined by cycle sequencing (section
2.2.7.2). Plasmid templates were linearised with the appropriate enzyme and probes
transcribed with phage T7, T3 or SP6 RNA polymerase (Table 2.2).
Further subcloning was undertaken into the pUC 18 and pGEM3 vectors to create
plasmids pAL9 to pAL15 (section 2.1.8.4). Orientation of inserts was determined and
probes were generated as described in the preceding paragraph.
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Exon Plasmid Restriction enzymes/phage polymerase
1. pALl NcollSP6 AS, Sail111 S
Is pAL3 Sail111 AS, NcollT3 S
h pAL4 Sail/T7 AS, Ncoim S
110 pAL5 Salim AS, SphllSP6 S
1.1 pAL6 Salim AS, NcollT3 S
2 pAL7 Ncoim AS, Sail/T3 S
Is pAL9 Sail/J7 AS, Hindllim S
ln pALlO Sall/Tl AS, Hindllim S
2 pALll Hindllim AS, Salim S
1. pAL13 Smal/Tl AS, PvuIIISP6 S
17 pAL14 Pvw///SP6 AS, Smaim S
110 pAL15 PvuIHSP6 AS,Hindllim S
Table 2.2: restriction enzymes and phage polymerases used with plasmid templates for
generation of RNA probes. AS = antisense, S = sense.
A reaction was set up containing lx transcription optimized buffer, 0.3mM each of
ATP, CTP and GTP, 5.92MBq [oc35S]-UTP, lOmM DTT, 40U RNasin RNase
inhibitor, approximately 1 pg linearised DNA template and 15U of the appropriate
phage polymerase. The reaction was incubated for 60-90min at 37°C (40°C if phage
SP6 polymerase was being used), then 1U of RNase-free DNase was added and the
mixture was incubated for a further 15min at 37°C. Probes were purified using
Sephadex G-50 grade ("Nick") columns. The column was first equilibrated with 3ml
TE, the reaction mix was then added and allowed to soak into the gel bed. 400pl TE
was added and the eluate discarded. A further elution was performed with 400pl of
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TE and the eluate collected. The activity of probe in this eluate was measured
(section 2.2.8.3) and the integrity of the probe was verified by electrophoresing
lxlO5 cpm of probe on a 5% denaturing polyacrylamide gel (section 2.2.3).
2.2.10.4 Fixation of tissues
All solutions for fixation were prepared using sterile glassware and DEPC H2O.
Sterile glass troughs were used for all incubations. Experimental slides were fixed by
lOmin in 10% paraformaldehyde in phosphate buffer at 4°C, 2 x 5min washes in 1 x
PBS, lOmin in a solution of 0.25% acetic anhydride and 0.1M triethanolamine, 5min
in 1 x PBS then dehydration by passing through 70%, 80% and 95% ethanol for
2min each. Slides were briefly air dried before use.
2.2.10.5 Hybridization
Hybridization was performed in Perspex hybridization boxes whose bases were lined
with a double layer ofWhatman 3MM paper soaked in box buffer. Sections were
prehybridized in 200pl of 1 x prehybridization solution then incubated for 2-3h at
50°C in a size 2 Gallenhamp Hotbox oven. Sections were then incubated at 50°C for
16h in 200li1 of lx hybridization solution containing lxlO6 cpm probe. cRNA probes
were denatured for lOmin at 75°C before adding to the hybridization mix. Slides
were washed for 3 x 5min in 2 x SSC then coated with 200ul ofRNase buffer
containing 30ug/ml RNase A. Slides were incubated at 37°C for lh in Perspex
hybridization boxes lined with a single layer of Whatman 3MM paper soaked in
RNase buffer. Washes were performed in a Hybaid Omnislide wash module. Slides
were washed for lh in 2 x SSC at room temperature, lh in 0.1 x SSC at 60°C and lh
in 0.1 x SSC cooling to room temperature from 60°C. Slides were dehydrated by
passing through 50%, 70% and 90% ethanol in ammonium acetate for 2min each,
then air dried.
2.2.10.6 Autoradiography
Slides were exposed to a Fuji phosphor screen for 24h and visualized in a Fujifilm
FLA-2000 phosphoimager to ascertain if the hybridisation had been successful.
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Slides were then exposed to Kodak Biomax MR autoradiography film for 7-14d
depending on the strength of signal observed on the phosphoimager. Slides were then
dipped in a 50% solution ofKodak NTB2 photographic emulsion, air dried and kept
at 4°C for 2-6 weeks depending on the strength of signal observed on the
autoradiography film. Slides were developed by immersion for 4min in a 1:1 dilution
of Kodak D19 developer and water, followed by 10s in water, 5min in a 1:4 dilution
ofAmfix High Speed Fixer and water then 5min in water. Slides were then air-dried
before staining.
2.2.10.7 Staining of slides
Sections were stained with either haematoxylin and eosin (for liver and thymus) or
pyronin (for brain). Haematoxylin and eosin staining was performed by immersing
slides for 80s in Meyer's haematoxylin, 20s in H20, lmin in alkaline H20, lmin in
H20, lmin in 70% ethanol, lmin in eosin, 2 x lmin in 95% ethanol, 2 x lmin in
100% ethanol then 2 x lmin in Histoclear solution. Pyronin staining was performed
by immersing the slides for 3min in l%(w/v) pyronin (filtered through Whatman No.
1 filter paper before use), washing in deionised water then immersing for 2min in
acetone, 2min in 50% acetone/50% xylene and 2 x 2min in xylene. After staining
slides were mounted using DPX mounting fluid and glass cover slips, then allowed
to dry overnight. Stained emulsion was removed from the non-section side of the
slides by scraping with a scalpel.
2.2.10.8 Data analysis
Autoradiographs were examined on a Northern Light B95 Precision Illuminator
(Imaging Research Ltd, St. Catharine's, Ontario, Canada) with a MTI CCD725 video
camera. 2D densitometry was performed using MCID-M4 version 3.0 (revision 1.5)
software (Imaging Research Ltd).
After dipping in photographic emulsion and staining, sections were examined using a
Carl Zeiss GmbH Axioskop microscope with a Zeiss Plan-Neofluar 40x objective
lens and a Zeiss lOx eyepiece lens. Images were captured using a JVC 3-CCD C-
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mount video camera and silver grains counted using Zeiss KS300 v3.0 image
analysis software.
Statistical analysis was performed by 1-way ANOVA and Tukey's HSD Test or
Fisher's LSD Test using the Statistica software package (version 5), with p<0.05
taken as indicating significance.
When examined microscopically, the emulsion-dipped slides from the experiment
investigating expression of exon 15 in the hippocampus showed marked variability in
the number of silver grains present. Approximately 50% of the slides had virtually no
silver grains present while the other 50% had comparable amounts to those seen with
the other exon 1 probes. The most likely cause for this was a fault in the developing
process which rendered it impossible to perform grain counting analysis for this
experiment.
2.2.11 Ribonuclease Protection Analysis
2.2.11.1 Synthesis of cRNA probes
Templates for cRNA synthesis were 5'-RACE clones previously generated in this
laboratory (section 2.1.8.4), except for the rat P-actin template (pTRI-Beta-actin-125-
Rat, section 2.1.8.4) which was supplied by AMS Biotechnology and the exon 16
template (pJIM5) which was a subcloned RT-PCR product generated from total rat
liver RNA in this laboratory. The templates were linearised with Ncol and
transcribed with the phage SP6 RNA polymerase, except for the actin probe where
the template was linearised by the manufacturer using Xbal and Hindlll. The
predicted sizes of protected fragments containing both exon 2 and the specific exon 1
of interest are shown in Table 2.3 along with the predicted size of the rat P-actin
protected fragment.
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Table 2.3: predicted sizes of cRNA probe fragments protected by GR mRNA containing
alternate exons 1 in RNase protection analysis.
For probe synthesis a reaction was prepared containing approximately lpg linearised
DNA template, lx transcription optimised buffer, 0.26mM ATP/CTP/UTP, 3.5mM
DTT, 20U RNasin RNase inhibitor and 0.5pi lOmg/ml bovine serum albumin. 5pl of
[a32P]-GTP (3000Ci/mmol) was added followed by 20U of the appropriate
polymerase. After incubation for 2h at 37°C, 1U of RNase-free DNase was added
and the mixture was incubated for a further 15min at 37°C. cRNAs were purified
using Sephadex G-50 grade ("Nick") columns. The column was first washed then
equilibrated with 3ml TE, then the reaction mix was added and allowed to soak into
the gel bed. 400pl TE was added and the eluate discarded. A further elution was
performed with 400pl ofTE and the eluate collected. The radioactivity of probe in
this eluate was measured (section 2.2.8.3) and the integrity of the probe was verified
by electrophoresing lxl 05 cpm of probe on a 5% denaturing polyacrylamide gel
(section 2.2.3). Several bands (corresponding to truncated products) were often
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observed on autoradiography, probably due to the high GC content of the DNA
templates causing "stalling" and dissociation of the phage polymerase. Probes were
only used in assays if the full-length product was the dominant band on the
autoradiograph.
2.2.11.2 Ribonuclease protection analysis
These were performed using the HybSpeed RPA Kit (Ambion). In all assays 2 cRNA
probes were used, one for actin mRNA (as an internal control) and one for the exon 1
of interest. 50pg of either total RNA (experimental samples) or yeast tRNA (positive
or negative controls) was coprecipitated with lxlO5 cpm cRNA probe by adding 1/10
vol 5M ammonium acetate and 2.5 vol ethanol then placing at -20°C for 20min. The
coprecipitate was pelleted by centrifugation in a microcentrifuge for 15min at 4°C.
The supernatant was carefully removed with a drawn-out Pasteur pipette and the
pellet resuspended in 20pl hybridisation buffer (provided in kit) by incubating at
95°C and vortexing each sample for 3x10s. Successful resuspension was confirmed
by pipetting each sample and holding it next to a Geiger-Muller counter: if > 70% of
the total counts were in the pipette tip then resuspension was regarded as satisfactory.
Samples were incubated for 2min at 95°C then quickly transferred to 68°C for lh.
lOOpl of a 1/25 dilution of a RNase A/Tl mix was added to all tubes except the
positive controls which received lOOpl digestion buffer without RNase A/Tl. Tubes
were vortexed, incubated at 37°C for 15min, vortexed again then incubated at 37°C
for a further 15min. 150pl of the supplied RNase inactivation/precipitation mix was
added, then tubes were vortexed and placed at -20°C for 20min. RNA was pelleted
by centrifugation in a microcentrifuge at 14000rpm for 15min then resuspended in
8pl of the supplied gel loading buffer. Resuspension was verified as detailed above.
Samples were then electrophoresed on a 4% denaturing polyacrylamide gel: positive
control samples were diluted with additional loading buffer so that the amount of
radioactivity loaded on the gel was comparable to that loaded in the experimental
samples. As a typical assay required the use of 2 polyacrylamide gels, half of the
samples from each experimental group were loaded on each gel.
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2.2.11.3 Data analysis
Dried polyacrylamide gels were exposed to autoradiography film overnight then to a
phosphoimager screen for l-7d depending on the strength of signal on the
corresponding autoradiograph. Quantitative analysis of bands was carried out using a
Fujifilm FLA-2000 phosphoimager and Aida v2.0 software (Raytest GmbH) by
enclosing them within a rectangle and measuring the intensity of signal within this
area by 2D densitometry. Background for each band was determined by placing a
similar rectangle just above it. The background value was subtracted and the values
for each band corrected for the differences in size of the protected fragment. Each
exon 1 probe contains a section complementary to the 5' end of exon 2, so is
predicted to give 2 protected fragments, one representing the exon 1 and exon 2 and
one representing exon 2 alone. The abundance of each exon 1 was expressed as a
proportion of total GR mRNA transcripts and as an absolute value relative to actin:
0/. . 1 r-T> DAT A exon 1 & 2 band intensity . An ..%total GR mRNA = r— - -xlOO %
(exon 1 & 2 band intensity)+ (exon 2 band intensity)
. . . , ■ • exon 1 & 2 band intensity
Absolute quantity of exon 1 - containing GR mRNAs = —
actin band intensity
The abundance of total GR mRNA transcripts was expressed as an absolute value
relative to actin:
., . _ exon 2 band intensityAbsolute quantity of GR mRNA =
actin band intensity
Statistical analysis was performed by 1-way ANOVA and Tukey's HSD Test or
Fisher's LSD Test using the Statistica software package (version 5), with p<0.05
taken as indicating significance.
2.2.12 DNase I hypersensitive site mapping
2.2.12.1 Preparation of nuclei
All buffers, centrifuge rotors and other equipment were chilled to 4°C before use and
experimental samples were kept on ice throughout the procedure. Liver tissue was
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finely chopped while still frozen, rinsed in 0.1M NaCl, lOmM Tris pH 8.0 and
homogenised in 10ml Buffer I/g tissue using a Wheaton 15ml glass homogeniser and
loose-fitting pestle. The homogenate was filtered through gauze and then
homogenised again with a tight-fitting pestle. Lysis of hepatocytes was verified by
microscopic examination of 25 pi of homogenate. The homogenate was then diluted
by addition of 1.6 volumes of Buffer II. Nuclei were purified by density gradient
centrifugation through Buffer II in a Beckman J2-MC centrifuge with a JA-21 rotor
at 36000G for 45min at 4°C. Supernatant was removed by suction then nuclei were
resuspended in 0.5ml storage buffer per pellet. A 1:200 dilution of the nuclei
suspension in storage buffer was counted using an Improved Neubauer
Haemocytometer and the suspension diluted to give a final concentration of lxlO7-
1x10s nuclei/ml. Prepared nuclei were used immediately.
2.2.12.2 DNase I digestion
DNase I digestions were performed on ice. 15ml Corex tubes were prepared, each
containing 0-200U of DNase I in a total volume of 60pl 1 x PBS. 300pl of nuclei
suspension was added, mixed and left to incubate for lOmin on ice. The reaction was
stopped by adding EDTA to 20mM. Nuclei were pelleted by centrifugation at 600 x
g in a Heraeus Labofuge 400R centrifuge at 0°C. The supernatant was carefully
removed and the nuclei resuspended in 1.9ml 50mM Tris pH 8.0, lOmM EDTA.
SDS was added to a final concentration of 5% and proteinase K to a final
concentration of lOOpg/ml. The samples were incubated at 37°C overnight then the
genomic DNA was purified.
2.2.12.3 Purification of genomic DNA
Genomic DNA was purified by phenol/chloroform extraction. An equal volume of
Tris-saturated phenol was added to the sample and mixed by inversion for 1 minute.
The sample was centrifuged for 5min at 1500g in a Heraeus Labofuge 400R
centrifuge and the supernatant transferred to a fresh tube, taking care to avoid the
interface. This procedure was repeated once more with an equal volume of Tris-
saturated phenol, then with 0.5 vol of Tris-saturated phenol and 0.5 vol of
chloroforrmisoamyl alcohol (24:1), then with an equal volume of chloroforrmisoamyl
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alcohol. 1/10 vol of 5M NaCl and 2.5 vol of ethanol were added to the final
supernatant which was then placed at -20°C overnight. The DNA was pelleted by
centrifiiging at 3900g in a Heraeus Labofuge 400R centrifuge for 25min at 0°C. The
supernatant was completely removed and the pellet briefly air-dried. The pellet was
resuspended by adding 0.5-2ml TE (depending on DNA yield) and standing at 4°C
for 3-4 d, gently mixing daily. Integrity of the recovered DNA was checked by
electrophoresis on a 0.8% analytical agarose gel. Only samples where agarose gel
electrophoresis showed no evidence of an excessive amount of low-Mr DNA
fragments were used in subsequent experiments.
2.2.13 Plasma corticosterone assay
Trunk blood samples were collected immediately after decapitation into 15ml
universal tubes containing 1ml 5% (w/v) EDTA solution. Samples were placed on
ice, centrifuged for lOmin at 1200g and 4°C in a Heraeus Labofuge 400R centrifuge
to remove blood cells. Plasma was removed into fresh 1.5ml Eppendorf tubes and
stored at -80°C until required. For the assay, 25pi aliquots of plasma were diluted
with 225pl borate buffer and denatured at 75°C for 30min. A mixture of 2pl
[l,2,6,7]3H-corticosterone (2.59TBq/mmol), and 9ml borate buffer was prepared: the
specific activity of 50pl of this was measured (section 2.2.8.3) and the concentration
of 3H-corticosterone adjusted to give a final activity of approximately 2xl03cpm/pl.
Rabbit anti-corticosterone antiserum (raised by and a gift from Dr C.Kenyon in our
laboratory) was added to a final dilution of 1 in 10000. Standard solutions of
corticosterone 21-acetate were prepared to concentrations of 320nM, 160nM, 80nM,
40nM, 20nM, lOnM, 5nM, 2.5nM, 1.25nM, 0.625nM and OnM. 50pl of 3H-
corticosterone/antibody mix was added to the appropriate number of wells of a 96-
well microplate, with each sample and standard being loaded in duplicate. 20pl of
either sample of standard was added to each well, the plate was covered with
Parafilm and left to incubate at room temperature for lh. 50pi of scintillation
proximity assay reagent was added to each well, the wells were covered with sealant
film and the samples thoroughly mixed. Samples were incubated at room
temperature for 24h then counted in a Wallac 1450 Microbeta Plus scintillation
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counter. Results were analysed using the Statistica software package (version 5) by
ANOVA and Fisher's LSD Test, with p<0.05 being taken to indicate significance.
2.2.14 Sequence analysis
Sequence analysis was performed using the Wisconsin Sequence Analysis Package
(GCG) (Genetics Computer Group, 1991).
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3 Tissue and region-specific distribution of variant
glucocorticoid receptor mRNA transcripts
3.1 Introduction
Glucocorticoid receptors are widely expressed in many tissues (section 1.4).
However, levels of GR expression vary between tissues (Kalinyak et al., 1987) and
even between different regions of the same tissue (Herman et al., 1989a). GR levels
also vary developmentally in the hippocampus (Andrews and Matthews, 2000) and
with changes in the environment of the organism e.g. during stress (section 1.9.2.4).
The GR gene is large and complex. Strahle et al provided the first evidence for the
existence ofmultiple GR mRNA variants in the mouse (Strahle et al., 1992). In the
rat, there are at least 11 potential alternate exons 1, at least 6 ofwhich are expressed
in vivo (McCormick et al., 2000). Previous work from this laboratory has shown that
these exons 1 vary in their tissue and region-specific relative expression, especially
in the hippocampus. Furthermore, their existence might reflect the use of alternate
promoters for transcription initiation (McCormick et al., 2000). If these exons 1 also
exist in the mouse, this might indicate that alternate promoter usage is likely to be of
wider importance in other species and would lay the groundwork for future
manipulation of the GR promoter region in transgenic animals.
The series of experiments described in this chapter were designed to further
investigate the tissue and region-specific distribution of variant exons 1 in rodent
tissues, which might provide a mechanism for the sensitive control of GR levels.
Specifically, we wished to address the following questions:
1. To what extent is the expression of GR mRNA containing alternate exons 1
tissue-specific?
2. Is there additional region-specific expression of these variant transcripts
beyond that already described in the hippocampus?
3. Is alternate GR exon 1 usage conserved in mice?
147
In the rat, the brain, liver and thymus were investigated due to the known distinct
physiological roles ofGR in these organs and our previously published data on the
existence of variant exons 1 in these tissues. In the mouse a wide range of tissues
were investigated to establish the existence and possible tissue-specific expression of
alternate exons 1 in this species.
3.2 Experimental design
3.2.1 Semiquantitative RT-PCR
To provide a rapid and sensitive method of detection of alternate GR mRNA
transcripts we adopted a RT-PCR approach.
Sequence comparison of the rat and mouse GR gene promoter region sequences
revealed 91.4% identity between the sequences, with all the known alternate exons 1
conserved in the mouse together with their splice sites (Appendix A). PCR primers
were designed to be complementary to the rat GR gene sequence for exon 11, to the
rat and mouse GR gene sequences individually for exon U and to both the rat and
mouse GR gene sequence for exons, 15, 16, I7, 110 and In (section 2.1.8.1, Figure
3.1). However, as the original primers for exons 11 and I4 led to production of
multiple PCR products, a primer complementary to the sequence of a 5'-RACE clone
of the rat exon 1, (McCormick et al., 2000) was designed and another primer
complementary to both the mouse and rat GR gene sequences was designed for exon
I4 (section 2.1.8.1). Exons 12 and I3 were not investigated as their exact positioning
on the genomic GR gene sequence is not known. Furthermore, exon 12 was not
present at detectable levels in rat liver, hippocampus or thymus (McCormick et ah,
2000). Exons lg and I9 were not analysed. They are unlikely to be present at
significant levels in vivo under basal conditions since they were poorly represented in
the 5'-RACE PCR from rat hippocampus (McCormick et ah, 2000). A single 3'
primer was used, complementary to the 5' end of exon 2 of the GR gene (Figure 3.1).
The design of these primers allowed PCR products generated from a reverse
transcribed cDNA to be distinguished from those generated from genomic DNA
contamination of the RT reaction, which would result in the formation ofmuch
larger products (>2kb). Also, with the Taq DNA polymerase used here, these
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products would be less likely to be produced as the efficiency of PCR reactions is
dramatically reduced if the products are greater than 2kb in size.
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"U 15 "U 17 18 19 110 1-11 2-9
Exon 1 specific (5') primers
Exon 2 specific (3') primer
Figure 3.1: diagrammatic representation of the positions of exon 1-specific primers on the GR
gene promoter region. For further details see section 2.1.8.1.
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3.2.2 In situ mRNA hybridisation
cRNA probes used to detect GR mRNA transcripts containing exons 15, I7, 110, 111
and 2 have been previously described ((McCormick et al., 2000), section 2.2.10.3)
and were generated directly from PCR product templates. To be able to detect GR
mRNA transcripts containing exon 11, a similar cRNA probe was designed (section
2.2.10.3). Briefly, extended primers containing a T7 polymerase site (3' primer) or
T3 polymerase site (5' primer) were designed based on the sequences for mouse
exon 1A published by Chen et al (Chen et ah, 1999a). These primers were used to
PCR amplify exon 11 from cDNA produced from mouse thymus total RNA as a
template. Expression ofGR mRNA transcripts containing exon ^ was not examined,
despite previous data showing their presence in rat hippocampus, liver and thymus
(McCormick et ah, 2000). Due to the highly GC-rich nature of the DNA within and
surrounding exon U (see Appendix A) it was not possible to design a specific cDNA
probe with a sufficiently low annealing temperature to allow specific hybridisation.
In situ mRNA hybridization with a riboprobe specific for exon 2 of the GR gene
(common to all GR mRNA variants) was performed to reveal the distribution of the
total population ofGR mRNA transcripts. This probe is similar in size to the exon 1
probes (section 2.2.10.3) and was previously shown to give an identical distribution
ofbinding (McCormick et ah, 2000) to the standard GR probe complementary to
exons 5-9 of the GR gene (Holmes et ah, 1995b; Holmes et ah, 1995a; Yau et ah,
1994; Yau et ah, 2001a; Yau et ah, 1997b) used in our laboratory. The cRNA probe
complementary to exons 5-9 was also used in some experiments to validate the data
provided by the exon 2 probe.
3.3 Results
3.3.1 Variant GR mRNA transcripts are expressed in a wide range of rat tissues
and vary in their tissue-specific relative expression.
RT-PCR demonstrated the presence of all exon 1 variants in rat tissues. Exons I5, U,
I7, 110 and 111 appeared to be ubiquitously present while exons 11 and I4 were not
(Table 3.1, Figure 3.2 and Figure 3.3). The specificity of the observed bands was
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confirmed by a comparison of the observed and expected product sizes. Negative
controls without the use of reverse transcriptase produced no bands after PCR
amplification (data not shown). Semiquantitative analysis showed tissue-specific
differences in relative expression levels (Table 3.1). For example, transcripts
containing exon I4 appeared relatively scarce in cerebellum and thymus but
relatively abundant in hippocampus (Table 3.1). GR mRNA containing exon 15 was
expressed at low levels in cerebellum, hippocampus and thymus but was more
abundant in liver (Table 3.1, Figure 3.3). In contrast, transcripts containing exon 16,
















Cerebral cortex ND ND + +++ + +++ +++
Cerebellum ND + + 1 1 1 1 + ++++ +++
Hippocampus +
Liver +++
+++ + + , , M + ++ ++
Table 3.1: distribution and relative amounts of variant exons 1 in tissues from control rats.
Each assay was performed twice.
Key: ND not detected I I I I present at 1/125 dilution
present at 1/25 dilution ++ present at 1/5 dilution
present only in neat RT product
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Figure 3.2: representative gel showing PCR products obtained after amplification of serial
dilutions of cDNA made from rat cerebral cortex RNA.
The exon 1-specific primer used to generate the product in each lane is indicated at the top of
the figure and the dilution of RT product used for each reaction is indicated at the left-hand
side.
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Figure 3.3: representative gel showing PCR products obtained after amplification of serial
dilutions of cDNA made from rat liver RNA.
The exon 1-specific primer used to generate the product in each lane is indicated at the top of
the figure and the dilution of RT product used for each reaction is indicated at the left-hand
side.
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3.3.2 Variant GR mRNA transcripts are conserved in the mouse and also show
tissue-specific variation in expression levels.
RT-PCR showed the presence of all the predicted bands in a variety ofmouse tissues,
demonstrating that use of alternate exons 1 is conserved between rat and mouse
(Table 3.2).
The original rat and mouse-specific exon I4 primers produced multiple bands in
mouse PCRs. Despite designing a replacement primer complementary to both
sequences, multiple bands were still obtained in mouse RT-PCRs using this primer.
To determine which band was specific for exon I4, Southern blotting was performed
on 14 PCR products from a selection of rat and mouse tissues with a cDNA probe
specific for exon I4. The results indicated that the specific band was approximately
450bp in rat and 350bp in the mouse (data not shown).
The exon 11 primer produced a single product in mouse PCRs, but the product was
larger than expected (~800bp compared to ~200bp). Initially, the most likely reason
for this difference was thought to be a sequence difference between the rat and
mouse exons 1 \. However, after the publication of the mouse exon 1A sequence
(Chen et al., 1999a) it was found that the 11 primer was complementary to a section
of sequence whose 3' end was 3 nucleotides from the 3' end of exon 1A (Chen et al.,
1999a). It is possible that the amplified mouse exon 1A cDNA was reverse
transcribed from a mRNA transcript spliced from a downstream splice donor site
similar to those reported for the human exon 1A (Breslin et al., 2001) and thus
produced a longer PCR product. However, it was also possible that the longer PCR
product was due to the primers amplifying cRNA from another gene. The sequences
of the exon 11 and exon 2 primers were compared with the mouse genome using
BLAST (Altschul et al., 1997). The primers matched 36 and 20 mouse genomic
sequences respectively, although none of the sequences were matched by both
primers. Southern analysis of PCR products using a probe complementary to exon 11
or sequencing of the PCR product could resolve whether the product is indeed exon
1>.
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In the range of tissues used for semiquantitative analysis, exons I5, U, I7, lioand In
appeared to be ubiquitously expressed while exons 11 and I4 did not (Table 3.2,
Figure 3.4 and Figure 3.5). Exon 110 was relatively abundant in all tissues examined
and in most tissues could be readily detected in a 1/25 dilution ofRT product (Table
3.2). In contrast, whilst ubiquitously expressed, the other exons 1 showed marked
variability in their tissue-specific relative expression. Exon I4 is not detectable in fat,
lung and heart and appears relatively scarce in kidney (Table 3.2, Figure 3.4 and

















Lung ND ND ++ ++ ++ +++ +++
Heart ND ND + + + +++ +
Kidney ND ++ +++ ++ ++ +++ 1 1 1 1
Thymus D ++ +++ ++ ++ +++ ++
Spleen + +++ 1 1 1 1
Fat (abdominal) ND ND +++ +++ + +++ ++++
Testis ND +++ ++++ +++ ++ +++ I I I I
Table 3.2: distribution and relative amounts of variant exons 1 in tissues from MF1 mice.
Key: ND not detected ++++ present at 1/125 dilution
present at 1/25 dilution ++ present at 1/5 dilution
present only in neat RT product
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Figure 3.4: representative gel showing PCR products obtained after amplification of serial
dilutions of cDNA made from mouse spleen RNA.
The exon 1-specific primer used to generate the product in each lane is indicated at the top of
the figure and the dilution of RT product used for each reaction is indicated at the left-hand
side.
The larger of the 2 bands in the 14 lane is a non-specific band with the true band of
approximately 400bp only visible with the neat RT reaction (see text for details of how the
specific band was identified).
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Figure 3.5: representative gel showing PCR products obtained after amplification of serial
dilutions of cDNA made from mouse kidney RNA.
The exon 1-specific primer used to generate the product in each lane is indicated at the top of
the figure and the dilution of RT product used for each reaction is indicated at the left-hand
side.
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3.3.3 Alternate exons 1 and exon 2 of the GR gene show different region-
specific distributions in rat brain.
GR mRNAs containing exons 15, U, I7, and 110 have all been shown to be present in
rat hippocampus (McCormick et al., 2000). To indicate whether these transcripts
were differentially expressed within the brain, in situ mRNA hybridization with
riboprobes specific for exons 15, I7 and 110 of the GR gene was performed on serial
sections obtained from the brain of a single control Wistar rat as a follow-up to the
RT-PCR experiments described in section 3.3.1.
Expression of total GR mRNA (detected by the probe specific for exon 2) appears
relatively uniform through the brain, with slightly higher expression in the lateral
ventricle walls, septal hypothalamic nuclei, subfornical organ, paraventricular
hypothalamic nucleus and cerebellar grey matter (Table 3.3, Figure 3.6). No specific
hybridization was seen in the cerebellar white matter; densitometric analysis showed
very similar signal with the corresponding sense control probe.
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Table 3.3 (facing page): summary of mapping of expression of exon 2 and alternate exons 1 of
the glucocorticoid receptor gene in the brain.
Results were derived from 156 sections derived from a single rat brain. Approximate estimation
of the level of expression of each exon in different brain areas was provided by densitometric
analysis, taking the average of 4-5 measurements from a single section on which each
anatomical structure was clearly visible. The optical density reading was then compared to the
slide background density to give a measure of relative expression in each area.
Key: + = weak hybridisation of probe ++ = moderate hybridisation of probe
+++ = strong hybridisation of probe I I I I = very strong hybridisation of probe
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Region Exon 2 Exon ls Exon 17 Exon 110
Anterior olfactory nucleus ++ + +++ ++
Piriform cortex ++ ++ I I I I +++
Cortex layers 1 -2 ++ + ++++ +++
Cortex layers 3-4 ++ + +++ ++
Cortex layers 5-6 -H- + +++ +++
Lateral ventricle walls +++ + +++ ++
Preoptic nuclei ++ + ++ +++
Septal hypothalamic nuclei +++ + + II I I
Subfornical organ +++ ++ +++ ++++
Periventricular hypothalamic nucleus ++ + ++ ++
Paraventricular hypothalamic nucleus +++ + ++ +++
Thalamic nuclei ++ ++ ++ ++
CA1 ++ ++ +++ +++
CA2 ++ ++ +++ +++
CA3/4 + ++ ++++ ++
Dentate gyrus ++ +++ 1 1 1 1 1 1 1 1
Amygdala ++ + ++ +++
Cerebellum (grey matter) ++++ I I I I 1 1 1 1 ++++
Cerebellum (white matter) + + + +
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Figure 3.6 (facing page): representative autoradiographs of rat brain showing in situ mRNA
hybridisation to a probe specific for exon 2 of the GR gene.
Panels 1-8 show binding of the antisense probe; panel 9 shows binding of the sense control probe
to hippocampus.
AON = anterior olfactory nucleus, LV = walls of lateral ventricle, SHN = septal hypothalamic
nuclei, SFO = subfornical organ, PaVN = paraventricular hypothalamic nuclei, PeVN =
periventricular hypothalamic nuclei, AMY = amygdaloid nuclei, CA1/2 = cornu ammonis
regions 1 and 2 of hippocampus, CA3/4 = cornu ammonis regions 3 and 4 of hippocampus, DG =






















In the sections derived from the single Wistar control brain used in this experiment,
all the exons 1 studied showed differences in their region-specific pattern of
expression compared to the pattern of binding detected for the probe specific to exon
2 of the GR gene. Expression of exon 11 was studied since RT-PCR had
demonstrated expression ofGR mRNA containing this exon in the hippocampus
(section 3.3.1). However, no specific hybridization was seen with the exon 11 probe.
Although it bound weakly throughout the brain, similar binding was seen with the
corresponding sense control probe (Figure 3.7). In contrast,G R mRNA containing
exons I5, I7 and 110 was expressed in the rat brain. In this brain, the distribution of
GR mRNA containing exons I5 and I7 was similar. Expression of exon 15 was
slightly higher in piriform cortex, subfornical organ, thalamus, hippocampus and
cerebellar grey matter than the rest of the brain (Table 3.3, Figure 3.8). Exon I7
showed lower relative expression in the preoptic and septal hypothalamic nuclei,
hypothalamic nuclei, thalamus, amygdala and cerebellar white matter than in the
other areas studied (Table 3.3f igure 3.9). The distribution ofGR mRNA containing
exon 110 was more homogeneous than that of exon 17: interestingly, exon li0 was
generally more highly expressed in the same areas that exon 2 was more highly
expressed. Exon Ho also showed the same distribution as exon 2 in hippocampus
(Table 3.3, Figure 3.10).
In this brain, the distribution of the alternate GR exons 1 seemed to be particularly
distinct in the hippocampus. Exon 110 hybridisation mirrored the distribution of total
GR mRNA, with higher expression in CA 1/2 and the dentate gyrus than in CA 3 and
4 (Figure 3.6, Figure 3.10). In contrast, hybridization of the exon 15 and 17 probes
showed a more homogeneous distribution of binding through all the hippocampal
subfields (Figure 3.8, Figure 3.9).
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3
Figure 3.7: representative autoradiographs demonstrating a lack of expression of exon 1] of the
GR gene in rat brain. Panels 1 and 2 show hybridisation of the antisense probe; panel 3 shows
binding of the sense control probe to caudal hippocampus.
CA1/2 = cornu ammonis regions 1 and 2 of hippocampus, CA3/4 = cornu ammonis regions 3
and 4 of hippocampus, DG = dentate gyrus of hippocampus, CeGM = cerebellar grey matter,
CeWM = cerebellar white matter.
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Figure 3.8 (facing page): representative autoradiographs showing expression of GR mRNA
containing exon 15 in rat brain.
Panels 1-8 show in situ mRNA hybridisation of the antisense probe; panel 9 shows binding of the
sense control probe to caudal hippocampus.
AON = anterior olfactory nucleus, LV = walls of lateral ventricle, SHN = septal hypothalamic
nuclei, SFO = subfornical organ, PaVN = paraventricular hypothalamic nuclei, PeVN =
periventricular hypothalamic nuclei, AMY = amygdaloid nuclei, CA1/2 = cornu ammonis
regions 1 and 2 of hippocampus, CA3/4 = cornu ammonis regions 3 and 4 of hippocampus, DG =




Figure 3.9 (facing page): representative autoradiographs showing expression of GR mRNA
containing exon 17 in rat brain.
Panels 1-8 show in situ mRNA hybridisation of the antisense probe; panel 9 shows binding of the
sense control probe to cranial hippocampus.
AON = anterior olfactory nucleus, LV = walls of lateral ventricle, SHN = septal hypothalamic
nuclei, SFO = subfornical organ, PaVN = paraventricular hypothalamic nuclei, PeVN =
periventricular hypothalamic nuclei, AMY = amygdaloid nuclei, CA1/2 = cornu ammonis
regions 1 and 2 of hippocampus, CA3/4 = cornu ammonis regions 3 and 4 of hippocampus, DG =

















Figure 3.10: representative autoradiographs showing expression of GR mRNA containing exon
110 in rat brain. No sense control probe was available for use in this study (see Section 2.2.10.3
for details). For key to labels see Figure 3.9.
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3.3.4 Total GR and GR transcripts containing exon 1™ show a similar
distribution of binding in rat liver.
Detected using a probe specific for exons 5-9, total GR mRNA shows a striking
zonal distribution in rat liver (Figure 3.11). The areas expressing GR mRNA most
highly are the periportal regions, while the perivenous regions show lower
expression (Figure 3.11 and Figure 3.12). Transcripts containing exon 110 show a
similar distribution to total GR, while those containing exon 111 show a more
homogeneous distribution (Figure 3.11 and Figure 3.12). However, binding of the
exon 111 antisense probe is very similar to that of the sense probe, indicating a low




Figure 3.11: representative autoradiographs showing distribution of total GR mRNA and GR
mRNA containing exons 1 (u and ln of GR in rat liver.
Total GR mRNA and GR mRNA containing 1]0 show a similar distribution, while exon In
shows a more homogeneous distribution (similar to that of the corresponding sense control).
AS = antisense probe, S = sense probe.
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Figure 3.12 (facing page): representative photomicrographs showing in situ mRNA
hybridisation to fresh frozen sections of the periportal and perivenous areas of rat liver.
Note higher density of silver grains in the periportal area compared to the perivenous area for
GR mRNA and GR mRNA containing exon 110, while GR mRNA containing exon ln shows a
more homogeneous distribution.
Magnification x 400.





3.3.5 Total GR and GR transcripts containing alternate exons 1 are distributed
similarly in rat and mouse thymus
To establish conditions for in situ mRNA hybridisation on thymus, two methods of
fixing fresh frozen sections of rat thymus were tested; with and without partial
acetylation by immersion in a solution of acetic anhydride (section 2.2.10.4). A
preliminary experiment revealed that the acetylation step gave much better results
with an exon 2-specific cRNA probe (Figure 3.13), so this method of fixation was
used for all subsequent experiments.
Total GR mRNA was detected using the exon 2 probe. Expression of exons 11, and
1 io was also examined. Expression of other exons 1 was not examined as they were
not previously detected in thymus by RNase protection analysis (McCormick et al.,
2000). All probes showed greater binding in the thymic cortex than in the thymic
medulla (Figure 3.14 and Figure 3.15).
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Figure 3.13: representative autoradiographs showing in situ mRNA hybridisation of an exon 2-
specific probe to sections of rat thymus fixed with (C, D) and without (A, B) acetylation step.
Sections A and C were hybridised to the antisense probe, while sections B and D were
hybridised to the sense probe. Sections were exposed to the same piece of autoradiography film
for the same length of time (5d).
Note the better resolution of thymic cortex and medulla and greater difference between the
hybridisation of the sense and antisense probes in the sections fixed with acetylation.
Images are taken from a 7d exposure
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Figure 3.14: representative autoradiographs showing in situ mRJNA hybridisation of probes
complementary to exons 2,110 and l! of the GR gene to rat thymus.
Panel A = exon 2 antisense probe, B = exon 2 sense probe, C = exon 110 antisense probe, D =
exon 11 antisense probe, E = exon lt sense probe.





Figure 3.15: representative autoradiographs showing in situ mRNA hybridisation of probes
complementary to exons 2,110 and li of the GR gene to mouse thymus.
Note the similar distribution of binding for all the antisense probes.
A = exon 2 antisense probe, B = exon 2 sense probe, C= exon li0 antisense probe, D - exon 1]






The experiments described in this chapter were designed to further investigate
whether the previously-identified variant exons 1 of the rat GR gene (McCormick et
al., 2000) were conserved in the mouse and whether they were differentially
expressed between and within tissues.
The sequences of all the exons 1 studied that were previously identified in the rat
were conserved in the mouse GR promoter genomic DNA and were identified in
mouse tissues by RT-PCR. Exons 1A (equivalent to rat exon 11), IB (equivalent to
rat exon L) and 1C (equivalent to rat exon 1 io) had been previously identified in a
limited number of tissues and cell lines (Strahle et al., 1992). Also, exons ID
(equivalent to rat exon I5) and IE (equivalent to rat exon In) have recently been
shown to be present in S-49 mouse T-lymphoma cells (Chen et al., 1999b). However,
this is the first time that expression of exons I4 and I7 has been reported in the
mouse.
In both the rat and mouse, most of the variant exons 1 studied were ubiquitously
expressed and showed tissue-specific differences in their relative expression. It
should be noted that the results of separate RT-PCR experiments from different
tissues are not directly comparable. However, comparisons of the relative level of
expression of each exon with those of the others within the same tissue may be made.
The RT-PCR data from rat tissues are largely consistent with previous studies.
McCormick et al used RNase protection analysis to identify GR mRNA containing
exons 11, 15, 16, I7, 110 and In in rat tissues and demonstrated tissue-specific
differences in their relative expression (McCormick et al., 2000). Furthermore, exon
\(, is present in the published rat GR cDNA sequence (Miesfeld et al., 1986) and
together with exon 110 was identified by 5'-RACE PCR in rat liver GR mRNA
(Gearing et al., 1993). Two other putative exon 1 sequences were identified in the
same study, but in fact one of them corresponds to genomic sequence immediately
upstream of exon 2 while the other lies within exon I4.5 (V.Lyons and K.Chapman,
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unpublished data). Interestingly, those transcripts displaying the greatest differences
in relative expression between tissues (I4 and I5) are those that appear less abundant
when examined by RNase protection analysis (forming less than 1% and up to 8.1%
of total GR mRNA transcripts respectively (McCormick et al, 2000)). In contrast,
the exons displaying less variability in relative expression here tend to be those
which are more abundant (McCormick et al., 2000). An exception to this is exon In,
which has relatively low abundance (forming approximately 12% of the total GR
mRNA population in the hippocampus and approximately 2% in the liver
(McCormick et al., 2000)) yet shows little variability in its relative expression.
Interestingly, GR mRNA transcripts containing exon I7 were clearly detectable in all
the tissues studied despite previous data from RNase protection analysis suggesting
that it was hippocampus-specific (McCormick et al., 2000). In contrast to the other
exons 1, exons f and I4 were definitely not detectable in some tissues by RT-PCR
but were easily detectable in others. Although Chen et al demonstrated expression of
GR mRNA transcripts containing exon 11 in all the tissues they studied, with high
levels of expression in liver and muscle (Chen et al., 1999b), the balance of evidence
from other studies is that expression of exon 11 is restricted to the immune system
(McCormick et al., 2000) and is specific to T lymphocytes (Strahle et al., 1992). In
the experiments described here the greater sensitivity ofRT-PCR (compared to
RNase protection analysis) may have allowed the detection of extremely small
numbers of transcripts containing exon 11 in immune cells contaminating the tissues.
These could be in blood or in the tissues themselves, such as the Kupffer cells of the
liver. In future experiments the possibility of blood contamination could be reduced
by saline-perfusion of the animals before harvesting of tissues for RT-PCR.
Some exons 1 were readily detected by RT-PCR in tissues where RNase protection
analysis failed to detect their presence (exon 14 in hippocampus, liver and thymus,
exon 15 in liver and thymus, exon 1 ^ in liver and thymus and exon 111 in thymus)
(McCormick et al., 2000). These data suggest that, in the tissues where they are
detectable by RT-PCR but not by RNase protection analysis, the transcripts are either
present at a low level (1-2% of the total GR mRNA) in all cells or are present at
higher levels in a subpopulation of cells.
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Although the tissues used in these experiments were derived from a single control
animal (and hence the results should be regarded as an indication of expression rather
than a quantitative measure and should be interpreted with caution, particularly with
regard to whether they are representative of the population at large), it appears that
there may be qualitatively different expression of the variant exons 1 studied within
the rat brain. In situ mRNA hybridisation did not detect exon 11 in any of the regions
studied. Thus the RT-PCR product demonstrated in hippocampal RNA is likely to be
due to blood contamination. Exon 15 was largely absent also, apart from in the
piriform cortex, subfornical organ, hippocampus and cerebellum. Interestingly, RT-
PCR also demonstrated relatively low expression of transcripts containing exon I5
compared to other GR mRNA transcripts in cerebellum, cerebral cortex and
hippocampus. These observations are in agreement with previous data showing that
exon I5 comprised ~8% ofGR mRNA in rat hippocampus and showed a
homogeneous distribution throughout this structure (McCormick et al., 2000). GR
mRNA transcripts containing exon I7 were detected by in situ mRNA hybridisation
in all brain areas, in agreement with the RT-PCR data, and were distributed in
hippocampus as reported previously (McCormick et al., 2000). GR mRNA
transcripts containing exon 110 have been shown to be similarly distributed to total
GR mRNA in hippocampus (McCormick et al., 2000): this study shows that this is
likely to be the case throughout the brain, probably reflecting their predominance in
the total GR mRNA population in all tissues studied so far (McCormick et al., 2000).
Total GR mRNA was expressed in all brain areas studied with a distribution
similar/identical to that reported previously (Herman et al., 1989a; Sousa et al.,
1989). Minor differences in results are likely to be due to specificity of probes (both
the above studies used considerably longer riboprobes of 1155 and 452 nucleotides
respectively that were targeted towards the 3' end of the GR gene) or subjective
assessment of the relative GR mRNA expression. Also, since all the tissues used in
this experiment were derived from a single brain, it is possible that there is some
individual variation in the distribution of total GR mRNA and variant exons 1.
Further experiments would be required to determine if this is the case.
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The differences in the pattern of distribution of the different exons 1 and total GR
mRNA suggests that the different exons 1 form different proportions of the total GR
mRNA population in different brain areas, again suggesting there is region-specific
differential expression of exon 1 variants in brain. The high level of hybridisation of
all the antisense probes seen in the cerebellar grey matter was most probably due to
the extremely high density of cells in the granular cell layer which can also cause
higher hybridisation of the sense probe (Sousa et al., 1989).
In the liver, GR mRNA containing exon 1 j i does not appear to be highly expressed
and shows no region-specific distribution. This data is consistent with RNase
protection analysis that found exon 111 present in only 2% of total GR mRNA in liver
(McCormick et al., 2000). As in the hippocampus, transcripts containing exon Go
have a similar distribution to total GR mRNA, which is strongly expressed in the
liver with higher expression periportally as shown previously (Nyirenda et al., 1998).
The relevance of this striking zonal distribution ofGR may be that the distribution of
a number ofmetabolic functions (carbohydrate metabolism, lipid metabolism,
xenobiotic metabolism and amino acid metabolism) and the enzymes involved in
them varies between the periportal and perivenous hepatocytes (Jungermann and
Kietzmann, 1996). Enzymes and proteins involved in gluconeogenesis, urea
formation, cholesterol synthesis, oxidative metabolism and bile formation are
expressed mainly in the periportal region, while those involved in glucose uptake,
glutamine formation and xenobiotic metabolism occur mainly in the perivenous
region. The expression of several enzymes that are more highly expressed
periportally is regulated by glucocorticoids. Activity of phosphoenolpyruvate
carboxykinase (PEPCK) is higher periportally (Jones and Titheradge, 1996) and
expression of PEPCK is upregulated by glucocorticoids (Brien et al., 1990; Sasaki et
al., 1984). The expression of glucose-6-phosphatase is also upregulated by
glucocorticoids (Argaud et al., 1996). Expression of fructose-2,6-bisphosphatase is
under indirect control by glucocorticoids via glucocorticoid regulation of levels of
fructose-2,6-bisphosphatase (Marker et al., 1989), which catalyses its synthesis and
degradation (Jungermann and Kietzmann, 1996). Expression of tyrosine
aminotransferase (Ganss et al., 1994) and carbamoyl phosphate synthetase (Gautier
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et al., 1977; Nebes and Morris, 1988) is also upregulated by glucocorticoids, while
expression of HMG CoA reductase is upregulated by glucocorticoids in cultured
cells (Cavenee and Melnykovych, 1977). Thus it seems plausible that the reason for a
higher level ofGR in the periportal region is that it will confer greater sensitivity on
the glucocorticoid control of these metabolic processes.
In the thymus, total GR mRNA was more abundant in thymic cortex than medulla,
consistent with maturing thymocytes migrating to the medulla (Sprent et al., 1988)
where their GR expression is reduced to a low level similar to that found in
peripheral blood lymphocytes (Ranelletti et al., 1987). GR mRNA transcripts
containing exons 11 and 1 io were also more abundant in thymic cortex than medulla.
Transcripts containing exon 11 form approximately 20% of the total GR mRNA in
thymus total RNA (McCormick et al., 2000) and RNA isolated from thymocytes,
thymic epithelium and spleen (Dammerman A., unpublished observations).
Transcripts containing exon lio are reported to form -50% of the total GR mRNA in
thymus ((McCormick et al., 2000) and Dammerman A., unpublished observations).
Thus we would expect to find higher levels ofmRNAs containing these alternate
exons 1 in the immature thymocytes of the cortex than in the mature cells in the
medulla, in line with the level of total GR mRNA. The density of cells in the thymic
medulla might be lower than in the cortex (Chapter 6), which could at least partly
account for the lower density of autoradiographic signal in the medulla. Also, there
could be developmental regulation of variant exons 1 e.g. exon 1| could be
downregulated during thymocyte maturation, accounting for the reduction in total
GR expression.
The tissue and region-specific variations in their relative expression suggest that the
mechanisms that contribute to differential expression of variant GR mRNAs are not
absolute, but rather apply to a greater or lesser extent in all tissues (with the possible
exceptions of exons 11 and I4). In the case of exon 11, it is plausible that its position
on the genomic DNA at least 15kb 5' of the CpG island containing the other exons 1
means that its associated promoter is controlled differently to those associated with
the other exons 1. In addition, although exon 14 is located in the CpG island it lies
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towards the 5' end, so it is possible that its promoter also behaves differently from
those of the exons 1 lying further 3'.
The conservation of these exon 1 variants in rat and mouse and recent work
demonstrating the presence of human equivalents of some (Breslin et al., 2001) or all
(Reynolds, R, unpublished observations) of the alternate exons 1 studied here
suggests that they are likely to be of physiological relevance. The tissue-specificity
of exon 11 and I4 expression, the evidence demonstrating that exon I7 shows its
highest associated promoter activity in CNS-derived cells (McCormick et al., 2000)
and the changes in relative expression of exon I7 after neonatal handling and exon
110 after prenatal dexamethasone exposure (McCormick et al., 2000) further support
this hypothesis.
These data are consistent with variant exons 1 of the GR gene reflecting the tissue-
specific use of alternate promoters, which led to the hypothesis that changes in
alternate promoter usage (and hence exon 1 expression) might provide a mechanism
for tissue-specific regulation ofGR levels. One of the main regulators of GR levels,
at least in adult animals, is levels of glucocorticoids themselves. The investigation of
regulation of these alternate exons 1 in brain, liver and thymus by manipulations of
glucocorticoid levels is described in the following chapters.
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4 The effect of glucocorticoid manipulation on the
expression of alternate exons 1 of the GR gene in the rat
hippocampus
4.1 Introduction
The hippocampus contains the highest concentration ofGR in the brain (section
1.9.2). Levels ofGR in the hippocampus can be permanently "programmed" by
early-life events. Hippocampal GR levels are increased by neonatal handling
(O'Donnell et al., 1994), associated with increased expression of GR mRNA
containing exon I7 in hippocampus but not of that containing exon 110 (McCormick
et al., 2000). Similar programming effects are seen in the liver after prenatal
treatment with dexamethasone, where an increase in hepatic GR levels is associated
with a decrease in the proportion of the total GR mRNA population containing exon
110 (McCormick et al., 2000), implying an increase in expression ofmRNAs
encoding another exon 1 variant. GR levels are also dynamically regulated by
glucocorticoids in a region and tissue-specific manner (section 1.7.2.1). The data
from programmed animals (McCormick et al., 2000) led to the hypothesis that
glucocorticoid-induced changes in alternate promoter usage (and consequently in
expression ofGR mRNAs containing different exons 1) was the mechanism by
which tissue-specific glucocorticoid autoregulation ofGR levels occurred.
The experiments described in this chapter were designed to test this hypothesis by
examining glucocorticoid regulation of variant exon 1 expression in the
hippocampus. The hippocampus was chosen (rather than other brain areas involved
in control of HPA axis activity) for several reasons. Most importantly, glucocorticoid
regulation of hippocampal GR levels had been previously demonstrated and was
well-characterised (section 1.7.2.1). Also, most variant exons 1 are expressed in the
hippocampus (chapter 3 and (McCormick et al., 2000)) and differential regulation of
variant exons 1 in hippocampus by neonatal handling had already been demonstrated
(McCormick et al., 2000). Finally, the hippocampus contains a high concentration of
GR mRNA (Herman et al., 1989a; Sousa et al., 1989) and hence relatively abundant
expression of variant exons 1. Since transcripts containing each exon 1 form only a
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proportion of the total population of GR mRNA, this would facilitate the detection of
individual exon 1 variants.
4.2 Experimental design
4.2.1 Adrenalectomy and glucocorticoid replacement
The effects of glucocorticoids on variant exon 1 expression were examined over two
experimental periods. Short-term adrenalectomised animals (ST) underwent
glucocorticoid manipulations over a period of 72h. This period was chosen because
previous work from this laboratory had shown significant changes in hippocampal
glucocorticoid receptor mRNA levels 2 days after adrenalectomy (Holmes et al.,
1995b). Long-term adrenalectomised animals (LT) underwent glucocorticoid
manipulations over a period of 3 weeks to determine the effects of these
manipulations on variant exon 1 expression over a longer time period. For details of
experimental procedures and animal groups see section 2.2.1.
4.2.2 In situ mRNA hybridisation
This technique was used for analysis ofmRNA containing exon 1 variants. Although
RNase protection analysis would have allowed more precise quantitation ofmRNAs,
it does not provide any information on the anatomical distribution of the transcripts,
which is important in a heterogeneous structure like the hippocampus. Total GR
mRNA levels were also assessed by in situ mRNA hybridisation to determine if
glucocorticoid manipulations had affected hippocampal GR expression.
4.3 Results
4.3.1 Experimental manipulations significantly alter corticosterone levels in ST
and LT animals.
In the ST animals, all the experimental groups showed at least an 8-fold reduction in
their plasma corticosterone levels compared to the sham-operated controls (Figure
4.1 A). In this analysis (Figure 4.1 A), Adx animals had significantly lower
corticosterone levels than Adx/supra animals. Despite a relatively large difference in
the mean levels for the Adx and Adx/phys groups (0.78nM and 42nM respectively)
the difference failed to reach statistical significance.
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In the LT animals, Adx animals had significantly lower corticosterone levels than
sham-operated controls, while Adx/phys animals showed no difference in
corticosterone levels from sham-operated controls (Figure 4.1 B).
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Figure 4.1 (facing page): radioimmunoassay of plasma corticosterone levels in trunk blood.
Blood samples were taken 17h after the final injection of corticosterone acetate. Data (presented
as meanSE M) were analysed by ANOVA and Tukey's HSD test.
A: ST animals. As the corticosterone levels for the sham group were so much higher than those
for the experimental groups, the data for the experimental groups were analysed
separately.There was a significant effect of treatment (p<0.05), with all other groups showing a
significantly lower corticosterone concentration than sham-operated controls (p<0.05, indicated
by *). Additionally, Adx animals had significantly lower corticosterone levels than Adx/supra
animals (p<0.05, indicated by x).
B: LT animals. There was a significant effect of treatment, with Adx animals having a lower
plasma corticosterone concentration than sham-operated controls and Adx/cort animals
(p<0.05, indicated by *).
ST = short-term adrenalectomised. LT = long-term adrenalectomised.
ST n=6 per group, except sham n=8. LT n=8 except Adx n=7.
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4.3.2 Adrenalectomised animals and animals adrenalectomised with
supraphysiological glucocorticoid replacement lose significantly more
weight than sham-operated controls over the experimental period.
Both the ST and LT animals lost weight over the course of the experiments.
However, the groups differed in the amount ofweight lost. In the ST animals, all the
treatment groups tended to lose more weight than the controls although when
analysed using Tukey's HSD Test the differences between individual groups did not
reach statistical significance. However, analysis using Fisher's LSD test showed that
the Adx and Adx/phys animals lost significantly more weight than sham-operated
controls (Figure 4.2 A). In the LT experiment, the Adx animals lost significantly
more weight than sham-operated controls (Figure 4.2 B).
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Figure 4.2: weight loss of rats over the experimental period.
Data (presented as mean ± SEM) were analysed by ANOVA and Tukey's HSD test.
A: ST animals. There was a significant effect of treatment (p<0.05). Post-hoc analysis using
Tukey's HSD Test failed to reveal significant differences between individual groups, but
Fisher's LSD Test showed that Adx and Adx/supra animals lost significantly more weight than
sham-operated controls (p<0.05, indicated by *). n=6 except sham n=8.
B: LT animals. There was a significant effect of treatment, with Adx animals losing significantly
more weight than sham-operated controls (p<0.05, indicated by *). n=8 except Adx n=7.
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4.3.3 RNA probes generated from the GR exon 2 template in different vectors
give qualitatively different results in in situ mRNA hybridisation.
The in situ mRNA hybridisation experiments described in Chapter 3 were performed
using probes generated directly from PCR product templates. However, it was noted
that the yield (measured in disintegrations/second/pl of eluted probe) ofRNA probe
obtained by in vitro transcription using these templates was quite variable and was
frequently low. In order to increase the reliability and yield of probe synthesis, the
PCR products were subcloned into pGEM-T Easy as described in section 2.2.10.3.
However, the probes produced from the constructs utilising the pGEM-T Easy vector
system gave variable results. In pailicular, the exon 2 cRNA probe synthesised using
the subcloned PCR product as template gave a different distribution of binding in
hippocampus to that of the probe synthesised directly from the PCR product template
(Figure 4.3). This distribution did not agree with the previously published
distribution ofGR in hippocampus (Herman et al., 1989a). On further investigation,
it was discovered that if the transcribed antisense probe contained the region of the
pGEM-T Easy polylinker sequence between the T7 polymerase recognition site and
the insert, it gave an abnormal distribution of antisense binding. If this section of
polylinker was present in the sense probe, it caused abnormally high binding of the
sense probe (data not shown). To eliminate this possible source of error for exon 1
probes, the PCR product templates for the variant exons 1 were recloned as described
in section 2.2.10.3, which resolved the problem. In situ mRNA hybridisation
experiments to detect total GR mRNA were subsequently performed using a probe
complementary to exons 5-9 of the GR gene.
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Figure 4.3: representative autoradiographs showing in situ mRNA hybridisation of probes
specific for exon 2 of the GR gene to rat hippocampus.
A: hybridisation of a probe transcribed from the exon 2 PCR product subcloned into pGEM-T
Easy. 21d exposure.
B: hybridisation of a probe transcribed directly from the PCR product. 21d exposure.
Identical specific activities of probe were added to each section (section 2.2.10.5). Note the even
distribution of binding of probe throughout the hippocampus in A compared to the pattern of
binding in B, which shows greater binding in CA1/2 and DG than in CA3/4.
CA1/2 = cornu ammonis regions 1 and 2, CA3 = cornu ammonis region 3, CA4 = cornu
ammonis region 4, DG = dentate gyrus.
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4.3.4 Both adrenalectomy and supraphysiological corticosterone replacement
significantly increase glucocorticoid receptor mRNA in hippocampus of
ST animals.
Both autoradiographs and dipped slides revealed obvious differences in total GR
mRNA between the experimental groups (Figure 4.4, Figure 4.5). Adrenalectomy
significantly increased GR mRNA by at least 30% in all hippocampal subfields while
physiological corticosterone replacement restored levels to those of sham-operated
controls (Figure 4.6).
In CA1 of the hippocampus, supraphysiological corticosterone replacement had no
effect on GR mRNA levels. Interestingly, in CA2-CA4 and the dentate gyrus
supraphysiological corticosterone replacement significantly increased GR mRNA
compared to sham-operated controls (Figure 4.6).
In CA2-CA4 of hippocampus there are approximately 2-fold differences in GR
mRNA between groups, whereas in CA1 or dentate gyrus the differences are
approximately 30-40% (Figure 4.6).
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Figure 4.4 (facing page): representative autoradiographs showing in situ mRNA hybridisation of
a probe complementary to exons 5-9 of the GR gene to hippocampus of ST animals.
Binding of antisense probe appears greater in all hippocampal subfields in Adx and Adx/supra
animals than in Adx/phys and Sham animals.
ST = short-term adrenalectomised. CA1/2 = cornu ammonis regions 1 and 2, CA3 = cornu
ammonis region 3, CA4 = cornu ammonis region 4, DG = dentate gyrus. Sham = sham-operated
control, Adx = adrenalectomised, Adx/phys = adrenalectomised with physiological
corticosterone replacement by daily injection, Adx/supra = adrenalectomised with
supraphysiological corticosterone replacement by daily injection.
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Figure 4.5 (facing page): representative photomicrographs showing in situ mRNA hybridisation
of a probe complementary to exons 5-9 of the GR gene to DG of ST animals.
More silver grains are present in Adx and Adx/supra animals than in Adx or Sham animals.
Only a small amount of non-specific binding is seen with the corresponding sense control.
ST = short-term adrenalectomised, DG = dentate gyrus, Sham = sham-operated control, Adx =
adrenalectomised, Adx/phys = adrenalectomised with physiological corticosterone replacement
by daily injection, Adx/supra = adrenalectomised with supraphysiological corticosterone
replacement by daily injection.
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Figure 4.6: grain counting analysis of in situ mRNA hybridisation of a probe complementary for
exons 5-9 of the GR gene to hippocampus of ST animals.
Data (presented as mean ± SEM) were analysed by ANOVA and Tukey's HSD test.
There was a significant effect of treatment, with Adx animals (in all hippocampal subfields) and
Adx/supra animals (in ca2-4 and dg) having significantly higher GR mRNA levels than sham-
operated controls (p<0.05, indicated by *). Densitometric analysis of autoradiographs gave very
similar results (data not shown). n=6 except sham n=7.
ST = short-term adrenalectomised. CA1/2 = cornu ammonis regions 1 and 2, CA3 = cornu
ammonis region 3, CA4 = cornu ammonis region 4, DG = dentate gyrus. Sham = sham-operated
control, Adx = adrenalectomised, Adx/phys = adrenalectomised with physiological
corticosterone replacement by daily injection, Adx/supra = adrenalectomised with
supraphysiological corticosterone replacement by daily injection.
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4.3.5 Adrenalectomy increases glucocorticoid receptor mRNA expression in
CA2 and CA4 of hippocampus in LT animals.
Quantitative analysis of silver grain distribution (Figure 4.7) showed a significant
increase in GR mRNA in CA2 and CA4 of LT adrenalectomised animals compared
to sham-operated controls (Figure 4.8 A). Analysis of autoradiographs (Figure 4.9)
by densitometry (Figure 4.8 B) showed a very similar trend, although the differences
did not reach statistical significance.
There appeared to be a trend in both the grain counting and densitometry data for
adrenalectomy to increase GR mRNA levels in CA1 and CA3 (Figure 4.8).
Conversely, there was no such trend in dentate gyrus (Figure 4.8). When analysed
using Tukey's HSD Test the differences in CA1 and CA3 did not reach statistical
significance. However, analysis using Fisher's LSD Test showed that in CA3 Adx
animals had significantly higher GR mRNA than sham-operated controls (Figure
4.8).
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Figure 4.7 (facing page): representative photomicrographs showing in situ mRNA hybridisation
of a probe complementary to exons 5-9 of the GR gene to CA2 of LT animals.
More silver grains are present in sections from adrenalectomised animals.
LT = long-term adrena)ectomised.CA2 = cornu ammonis region 2, Sham = sham-operated
control, Adx = adrenalectomised, Adx/cort = adrenalectomised with physiological corticosterone
replacement by subcutaneous pellet.
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Figure 4.8 (facing page): analysis of in situ mRNA hybridisation of a probe specific for exons 5-9
of the GR gene to hippocampus of LT animals. Data (presented as mean ± SEM) were analysed
by ANOVA and Tukey's HSD test.
A: grain counting analysis. There was a significant effect of treatment, with Adx animals having
significantly higher GR mRNA levels in ca2 and ca4 than sham-operated controls (p<0.05,
indicated by *). Also, when analysed by Fisher's LSD Test Adx animals had significantly higher
GR mRNA levels in ca3 than sham-operated controls (p<0.05, indicated by x).
B: densitometric analysis. There was no significant effect of treatment.
LT = long-term adrenalectomised.CAl/2 = cornu ammonis regions 1 and 2, CA3 = cornu
ammonis region 3, CA4 = cornu ammonis region 4, DG = dentate gyrus. Sham = sham-operated
control, Adx = adrenalectomised, Adx/cort = adrenalectomised with physiological corticosterone
replacement by subcutaneous pellet.
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Figure 4.9: representative autoradiographs showing in situ mRNA hybridisation of a probe
complementary to exons 5-9 of the GR gene to hippocampus of LT animals.
Binding of antisense probe appears similar in all 3 groups in all hippocampal subfields.
LT = long-term adrenalectomised.CAl/2 = cornu ammonis regions 1 and 2, CA3 = cornu
ammonis region 3, CA4 = cornu ammonis region 4, DG = dentate gyrus. Sham = sham-operated
control, Adx = adrenalectomised, Adx/cort = adrenalectomised with physiological corticosterone
replacement by subcutaneous pellet.
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4.3.6 Exon I5 of the GR gene is expressed in all hippocampal subfields but its
expression is not significantly altered by changes in glucocorticoid
levels.
As shown previously (Chapter 3 and (McCormick et al., 2000) GR mRNA
containing exon 15 is evenly distributed throughout the hippocampus (Figure 4.10,
Figure 4.11).
In ST animals, although the means for the Adx and Adx/supra groups trend to be
higher than the Sham and Adx/phys groups, mimicking the pattern of changes in
total GR, expression of exon 15 was not significantly altered in any hippocampal
subfield by glucocorticoid manipulation (Figure 4.12). Similarly, expression of exon
I5 was not significantly altered by glucocorticoid manipulations in the LT animals
(Figure 4.12).
Unfortunately, grain counting of the exon 15 experimental slides was not possible
(section 2.2.10.8) and it was not possible to repeat the adrenalectomy experiments






Figure 4.10: representative autoradiographs showing in situ mRNA hybridisation of a probe
complementary to exon 15 of the GR gene to hippocampus of ST animals.
Similar binding of antisense probe is seen in all hippocampal subfields.
ST = short-term adrenalectomised. CA1/2 = cornu ammonis regions 1 and 2, CA3 = cornu
ammonis region 3, CA4 = cornu ammonis region 4, DG = dentate gyrus. Sham = sham-operated
control, Adx = adrenalectomised, Adx/phys = adrenalectomised with physiological
corticosterone replacement by daily injection, Adx/supra = adrenalectomised with





Figure 4.11: representative autoradiographs showing in situ mRNA hybridisation of a probe
specific for exon 15 of the GR gene to hippocampus of LT animals.
Similar binding of antisense probe is seen in all hippocampal subfields. Representative sense
control is shown in Figure 4.10.
LT = long-term adrenalectomised.CAl/2 = cornu ammonis regions 1 and 2, CA3 = cornu
ammonis region 3, CA4 = cornu ammonis region 4, DG = dentate gyrus. Sham = sham-operated
control, Adx = adrenalectomised, Adx/cort = adrenalectomised with physiological corticosterone
replacement by subcutaneous pellet.
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Figure 4.12 (facing page): densitometric analysis of in situ mRNA hybridisation of a probe
complementary to exon 15 of the GR gene to rat hippocampus.
Data (presented as mean ± SEM) were analysed by ANOVA and Tukey's HSD test.
A: ST animals. There was no significant effect of treatment. Adx/phys n=5, Adx/supra n=6, Adx
n=6, Sham n=7.
B: LT animals. There was no significant effect of treatment. n=7 except sham n=8.
ST = short-term adrenalectomised. LT = long-term adrenalectomised. CA1/2 = cornu ammonis
regions 1 and 2, CA3 = cornu ammonis region 3, CA4 = cornu ammonis region 4, DG = dentate
gyrus. Sham = sham-operated control, Adx = adrenalectomised, Adx/phys = adrenalectomised
with physiological corticosterone replacement by daily injection, Adx/supra = adrenalectomised
with supraphysiological corticosterone replacement by daily injection, Adx/cort =
adrenalectomised with physiological corticosterone replacement by subcutaneous pellet.
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4.3.7 Exon I7 of the GR gene is expressed in all hippocampal subfields but its
expression is not significantly altered by changes in glucocorticoid
levels.
GR mRNA containing exon I7 appears to be evenly distributed throughout the
hippocampus (Figure 4.13, Figure 4.14).
In both the ST and LT animals, the expression ofGR mRNA containing exon 17 was
not significantly altered by glucocorticoid manipulation (Figure 4.15, Figure 4.16)
although in the ST animals there was a trend for the Adx and Adx/supra groups to
have higher exon I7 expression than the Sham and Adx/phys groups in 3 out of the 4
hippocampal subfields, mimicking the pattern of changes in total GR mRNA (Figure
4.15). The densitometric analysis was repeated using a larger number of sample
zones for each of these regions. This confirmed the previous results with no
significant effect of treatment, although the observed trend persisted (data not
shown).
Grain counting analysis gave similar results (data not shown).
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Figure 4.13 (facing page): representative autoradiographs showing in situ mRNA hybridisation
of a probe complementary to exon 17 of the GR gene to hippocampus of ST animals.
Similar binding of antisense probe is seen in all hippocampal subflelds.
ST = short-term adrenalectomised. CA1/2 = cornu ammonis regions 1 and 2, CA3 = cornu
ammonis region 3, CA4 = cornu ammonis region 4, DG = dentate gyrus. Sham = sham-operated
control, Adx = adrenalectomised, Adx/phys = adrenalectomised with physiological
corticosterone replacement by daily injection, Adx/supra = adrenalectomised with















Figure 4.14: representative autoradiographs showing in situ mRNA hybridisation of a probe
complementary to exon 17 of the GR gene to hippocampus of LT animals.
Similar binding of antisense probe is seen in all hippocampal subfields in all experimental
groups.
Representative sense control is shown in Figure 4.13
LT = long-term adrenalectomised.CAl/2 = cornu ammonis regions 1 and 2, CA3 = cornu
ammonis region 3, CA4 = cornu ammonis region 4, DG = dentate gyrus. Sham = sham-operated
control, Adx = adrenalectomised, Adx/cort = adrenalectomised with physiological corticosterone
replacement by subcutaneous pellet.
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Figure 4.15: densitometric analysis of in situ mRNA hybridisation of a probe complementary to
exon 17 of the GR gene to hippocampus of ST animals.
Data (presented as mean ± SEM) were analysed by ANOVA and Tukey's HSD test.
There was no significant effect of treatment. n=6 except Adx/supra n=5.
ST = short-term adrenalectomised. CA1/2 = cornu ammonis regions 1 and 2, CA3 = cornu
ammonis region 3, CA4 = cornu ammonis region 4, DG = dentate gyrus. Sham = sham-operated
control, Adx = adrenalectomised, Adx/phys = adrenalectomised with physiological
corticosterone replacement by daily injection, Adx/supra = adrenalectomised with
supraphysiological corticosterone replacement by daily injection.
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Figure 4.16: densitometry analysis of in situ mRNA hybridisation of a probe complementary to
exon 17 of the GR gene to hippocampus of LT animals.
There was no significant effect of treatment. n=8 except Adx n=7.
LT = long-term adrenalectomised.CAl/2 = cornu ammonis regions 1 and 2, CA3 = cornu
ammonis region 3, CA4 = cornu ammonis region 4, DG = dentate gyrus. Sham = sham-operated
control, Adx = adrenalectomised, Adx/cort = adrenalectomised with physiological corticosterone
replacement by subcutaneous pellet.
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4.3.8 Exon 110 of the GR gene is expressed in all hippocampal subfields but its
expression is not significantly altered by changes in glucocorticoid
levels.
As described previously (Chapter 3 and (McCormick et al., 2000) GR mRNA
transcripts containing exon 110 are distributed similarly to the total population of GR
mRNA transcripts in hippocampus (Figure 4.17f igure 4.18). Densitometric analysis
indicated a trend in the ST animals for the Adx and Adx/supra groups to have higher
levels of exon 110 expression than the Sham and Adx/phys groups, mimicking the
pattern of changes in total GR (Figure 4.19). Flowever, these differences did not
reach statistical significance (Figure 4.19) and there were no differences in exon li0
expression in the LT animals (Figure 4.20).













Figure 4.17: representative autoradiographs showing in situ mRNA hybridisation of a probe
complementary to exon 1]0 of the GR gene to hippocampus of ST animals.
Greater binding of antisense probe is seen in CA1/2 and DG than in CA3 and CA4 in all
experimental groups.
ST = short-term adrenalectomised. CA1/2 = cornu ammonis regions 1 and 2, CA3 = cornu
ammonis region 3, CA4 = cornu ammonis region 4, DG = dentate gyrus. Sham - sham-operated
control, Adx = adrenalectomised, Adx/phys = adrenalectomised with physiological
corticosterone replacement by daily injection, Adx/supra = adrenalectomised with




Figure 4.18: representative autoradiographs showing in situ mRNA hybridisation of a probe
complementary to exon l™ of the GR gene to hippocampus of LT animals.
Greater binding of antisense probe is seen in CA1/2 and DG than in CA3 and CA4.
LT = long-term adrenalectomised.CAl/2 = cornu ammonis regions 1 and 2, CA3 = cornu
ammonis region 3, CA4 = cornu ammonis region 4, DG = dentate gyrus. Sham = sham-operated
control, Adx = adrenalectomised, Adx/cort = adrenalectomised with physiological corticosterone
replacement by subcutaneous pellet.
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Figure 4.19: densitometric analysis of in situ mRNA hybridisation of a probe complementary to
exon 1 io of the GR gene to hippocampus of ST animals.
Data (presented as mean ± SEM) were analysed by ANOVA and Tukey's HSD test.
There was no significant effect of treatment. n=6 except sham n=7.
ST = short-term adrenalectomised. CA1/2 = cornu ammonis regions 1 and 2, CA3 = cornu
ammonis region 3, CA4 = cornu ammonis region 4, DG = dentate gyrus. Sham = sham-operated
control, Adx = adrenalectomised, Adx/phys = adrenalectomised with physiological
corticosterone replacement by daily injection, Adx/supra = adrenalectomised with
supraphysiological corticosterone replacement by daily injection.
222
\
GR mRNA containing exon 1-|0 in LT animals
ca1 ca3 ca4 dg
Hippocampal subfield
Figure 4.20: densitometric analysis of in situ mRNA hybridisation of a probe specific for exon
lio of the GR gene in hippocampus of LT animals.
Data (presented as mean ± SEM) were analysed by ANOVA and Tukey's HSD test.
There was no significant effect of treatment. n=8 except Adx n=7.
LT = long-term adrenalectomised.CAl/2 = cornu ammonis regions 1 and 2, CA3 = cornu
ammonis region 3, CA4 = cornu ammonis region 4, DG = dentate gyrus. Sham = sham-operated
control, Adx = adrenalectomised, Adx/cort = adrenalectomised with physiological corticosterone
replacement by subcutaneous pellet.
223
4.3.9 Exon 1n of the GR gene is expressed in all hippocampal subfields but its
expression is not significantly altered by changes in glucocorticoid
levels.
Examination of autoradiographs revealed that exon 111 was evenly distributed in all
hippocampal subfields (Figure 4.2If igure 4.22). Densitometric analysis of
autoradiographs showed no significant effect of glucocorticoid manipulation on
expression of GR mRNA transcripts containing exon In in ST and LT animals
(Figure 4.23, Figure 4.24). However, there was a trend for ST Adx and Adx/supra
animals to have higher levels of exon 111 expression in the hippocampus than
Adx/phys animals or sham operated controls (Figure 4.23).
Grain counting analysis gave similar results (data not shown).
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Figure 4.21 (facing page): representative autoradiographs showing in situ mRNA hybridisation
with a probe specific for exon ln of the GR gene in hippocampus of ST animals.
Similar binding of antisense probe is seen in all hippocampal subfields.
ST = short-term adrenalectomised. CA1/2 = cornu ammonis regions 1 and 2, CA3 = cornu
ammonis region 3, CA4 = cornu ammonis region 4, DG = dentate gyrus. Sham = sham-operated
control, Adx = adrenalectomised, Adx/phys = adrenalectomised with physiological
corticosterone replacement by daily injection, Adx/supra = adrenalectomised with
supraphysiological corticosterone replacement by daily injection.
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Figure 4.22: representative autoradiographs showing in situ mRNA hybridisation with a probe
specific for exon In of the GR gene in hippocampus of LT animals.
Similar binding of antisense probe is seen in all hippocampal subfields. Representative sense
control is shown in Figure 4.21.
LT = long-term adrenalectomised.CAl/2 = cornu ammonis regions 1 and 2, CA3 = cornu
ammonis region 3, CA4 = cornu ammonis region 4, DG = dentate gyrus. Sham = sham-operated
control, Adx = adrenalectomised, Adx/cort = adrenalectomised with physiological corticosterone
replacement by subcutaneous pellet.
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Figure 4.23: densitometric analysis of in situ mRNA hybridisation of a probe complementary to
exon ln of the GR gene to hippocampus of ST animals.
Data (presented as mean ± SEM) were analysed by ANOVA and Tukey's HSD test.
There was no significant effect of treatment. n=6 except Adx/supra n=4 and Adx n=5.
ST = short-term adrenalectomised. CA1/2 = cornu ammonis regions 1 and 2, CA3 = cornu
ammonis region 3, CA4 = cornu ammonis region 4, DG = dentate gyrus. Sham = sham-operated
control, Adx = adrenalectomised, Adx/phys = adrenalectomised with physiological
corticosterone replacement by daily injection, Adx/supra = adrenalectomised with
supraphysiological corticosterone replacement by daily injection.
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Figure 4.24: densitometry analysis of in situ mRNA hybridisation of a probe complementary to
exon lu of the GR gene to hippocampus of LT animals.
Data (presented as mean ± SEM) were analysed by ANOVA and Tukey's HSD test.
There was no significant effect of treatment. Adx n=6, Adx/cort n=7, Sham n=8.
LT = long-term adrenalectomised.CAl/2 = cornu ammonis regions 1 and 2, CA3 = cornu
ammonis region 3, CA4 = cornu ammonis region 4, DG = dentate gyrus. Sham = sham-operated
control, Adx = adrenalectomised, Adx/cort = adrenaiectomised with physiological corticosterone
replacement by subcutaneous pellet.
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4.4 Discussion
It is well established that glucocorticoids are a major regulator of GR expression in
the hippocampus (section 1.7.2.1) and that this regulation is likely to be at the level
of transcription (Herman and Spencer, 1998; Rosewicz et al., 1988), although some
post-translational regulation may also occur (Dong et al., 1988). Therefore, changes
in the rate of GR gene transcription will be reflected in changes in mRNA levels.
Here, I have examined whether hippocampal variant GR mRNA transcripts
containing alternate exons 1 are differentially regulated by glucocorticoids. Although
ST glucocorticoid manipulation significantly altered total GR mRNA levels (which
were increased by adrenalectomy and supraphysiological glucocorticoid replacement
and normalized by physiological glucocorticoid replacement), no significant changes
were seen in GR mRNA containing any of the variant exons 1. However, for all the
exons 1 a similar trend to the changes in total GR mRNA was noted. In contrast, LT
glucocorticoid manipulation had a much smaller effect on total GR mRNA levels and
also had no effect on levels ofGR mRNA transcripts containing any of the variant
exons 1.
The observed changes in total GR mRNA could not be accounted for by changes in
expression of any of the variant GR mRNA transcripts studied here. There are three
possible reasons why this might be so.
Firstly, the in situ mRNA hybridisation experiments might have failed to detect a
genuine effect of changes in glucocorticoid levels on variant exon 1 expression. The
riboprobes specific for the different exons 1 were relatively short, which means that
the ratio of true signal to background "noise" due to non-specific binding of probe
will be less than with a longer probe. This hypothesis is supported by the fact that
although the densitometry data for all the individual exons 1 showed similar trends to
the changes in total GR mRNA, these changes were not present in the grain counting
data. Since densitometry examines a larger area of hippocampus than does grain
230
counting it assesses the overall changes in a large number of cells which will reduce
the variability of the data.
Secondly, it is possible that this study was statistically underpowered. The number of
animals in each group was chosen based on those used in previous experiments from
our laboratory that had detected changes in total GR mRNA with adrenalectomy
(Holmes et ah, 1995b). Indeed, changes in total GR mRNA were demonstrated here.
However, any glucocorticoid-induced changes in expression of the exons 1 studied
here must be much smaller than those in total GR mRNA and thus would require a
larger number of animals in each group to detect. Another, more quantitative
technique such as RNase protection analysis might have been more appropriate than
in situ hybridisation for this study. However, such techniques do not offer any
anatomical detail. Ideally, one would like to repeat this series of experiments with a
larger number of animals in each group and perhaps with redesigned probes (e.g.
with higher specific activity) to overcome some of the problems discussed above.
Another possible approach would be to split the hippocampus in half longitudinally
when harvesting the tissue and use half of it for in situ mRNA hybridisation and half
of it for total RNA extraction and RNase protection analysis.
Thirdly, the increase in GR mRNA levels seen with adrenalectomy may be due to an
increase in expression of transcripts containing another variant exon 1 not studied
here (known or novel) or to small changes in expression of all the individual exons 1
that are not significant when analysed in isolation. Either of these possibilities is
intriguing, since the hippocampus specific exon I7 is specifically upregulated by
neonatal handling. However, the results presented here suggest that none of the
exons 1 studied is dramatically regulated by glucocorticoids. It is possible that
changes in expression of transcripts containing exon lf) might account for the
changes as they make up 17-20.7% of the hippocampal GR mRNA population
(McCormick et al., 2000). Unfortunately it is not possible to generate a probe for in
situ mRNA hybridisation to detect this exon (section 3.2.2), so it could not be
included in this study. Changes in the expression of exon U with glucocorticoid
manipulation could be investigated by RNase protection analysis and this would be
an interesting line of future enquiry.
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It is interesting to compare the above results with those from studies on other nuclear
receptors. The rat mineralocorticoid (Kwak et ah, 1993; Zennaro et ah, 1995) and
human (Flouriot et ah, 1998) and mouse (Kos et ah, 2000) oestrogen receptors
express multiple variant mRNAs with alternate 5' untranslated exons 1. Variant
human (Flouriot et ah, 1998; Osterlund et ah, 2000) and mouse (Kos et ah, 2000)
oestrogen receptor mRNAs are expressed in a tissue and region-specific manner. In
the case of the mineralocorticoid receptor, variant exons 1 are associated with the
activity of alternate promoters (Zennaro et ah, 1995; Zennaro et ah, 1996) and show
tissue and region-specific differences in their relative expression (Kwak et ah, 1993;
Vazquez et ah, 1998). Furthermore, the a and p variants of the rat mineralocorticoid
receptor are specifically upregulated in the hippocampus by adrenalectomy (Vazquez
et ah, 1998). If the hypothesis that none of the glucocorticoid receptor exons 1 is
individually regulated by glucocorticoids is correct, then there is an interesting
difference in the regulation of these members of an otherwise similar gene family.
A significant increase in GR mRNA levels was seen in all hippocampal subfields
with ST adrenalectomy, while the effects of LT adrenalectomy were of lesser
magnitude and were confined to CA2 and CA4. In previously published studies,
adrenalectomy of up to 8d duration caused significant increases in hippocampal GR
mRNA (Herman et ah, 1989a; Herman and Spencer, 1998; Holmes et ah, 1995b;
Reul et ah, 1989; Sheppard et ah, 1990) and GR binding sites (Lowy, 1989; Spencer
et ah, 1991), while after adrenalectomy of greater than 14d duration hippocampal GR
mRNA levels returned to normal (Holmes et ah, 1995b; Reul et ah, 1989). Although
increased hippocampal total GR mRNA (Kalinyak et ah, 1987) and GR binding sites
(Reul et ah, 1987a) have been reported 2 weeks after adrenalectomy, the balance of
evidence suggests an initial rise in hippocampal GR after adrenalectomy with a
gradual fall back towards resting levels over a period of approximately 2 weeks, in
agreement with the data presented here.
In the experiments described here physiological corticosterone replacement in
adrenalectomised animals restored hippocampal total GR mRNA levels to those of
control animals, in agreement with previous studies showing that corticosterone
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replacement orally over 5d (Sheppard et al., 1990) or by subcutaneous pellets over 4
(O'Donnell et al., 1995), 6 (Spencer et al., 1991), or 7d (Reul et al., 1987a) either
abolishes (O'Donnell et al., 1995; Sheppard et al., 1990; Spencer et al., 1991) or
significantly reduces (Reul et al., 1987a) the adrenalectomy-induced rise in
hippocampal GR and reduces the number of GR binding sites in adrenally intact
animals (Sapolsky et al., 1984b; Sapolsky and McEwen, 1985; Spencer et al., 1991).
The data presented here are also in agreement with the results of studies using
dexamethasone administration, which abolishes the adrenalectomy-induced rise in
GR mRNA (Herman et al., 1989a; Holmes et al., 1995b; Peiffer et al., 1991a; Reul et
al., 1989) and variably reduces hippocampal GR mRNA in adrenally intact animals
(Sheppard et al., 1990).
In contrast, ST supraphysiological corticosterone replacement increased total GR
mRNA levels in CA3/4 and DG, suggesting the effects are region specific and dose-
dependent. A dose-dependent effect of both dexamethasone (Reul et al., 1987a) and
corticosterone (O'Donnell et al., 1995; Spencer et al., 1991) on hippocampal GR has
been previously reported. However, studies using corticosterone replacement at
"supraphysiological" doses, either orally (Tornello et al., 1982), by injection
(Patacchioli et al., 1998; Peiffer et al., 1991a; Sapolsky et al., 1984b; Sapolsky and
McEwen, 1985) or by subcutaneous pellet (O'Donnell et al., 1995; Sheppard et al.,
1990; Spencer et al., 1991; Tornello et al., 1982) report unaffected (Sheppard et al.,
1990) or reduced hippocampal GR mRNA (Peiffer et al., 1991a) and reduced
hippocampal GR binding sites (Patacchioli et al., 1998; Sapolsky et al., 1984b;
Sapolsky and McEwen, 1985; Tornello et al., 1982). None of these studies reported
increased hippocampal total GR mRNA with supraphysiological corticosterone
replacement.
In fact, in this experiment radioimmunoassay showed that the ST animals receiving
supraphysiological corticosterone replacement do not have significantly higher
plasma corticosterone levels than those receiving physiological replacement. This is
surprising given the tenfold difference in the doses given and the different effects on
hippocampal GR in the two groups. However, the plasma for the assay was obtained
approximately 17h after the last injection of corticosterone so the levels obtained are
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likely to be close to the lowest levels present in the animals over a 24h period, which
might account for their similarity. An indication of the likely maximum levels of
corticosterone achieved in the plasma of these animals and their physiological effect
could be obtained by assessing the effect of the replacement regimens on the
bodyweight of the animals, since glucocorticoid excess is known to cause catabolism
and negative nitrogen balance in animals with Cushing's disease (Bush, 1991) and 4
weeks of chronic stress has been shown to cause weight loss in rats (Mizoguchi et al.,
2001). Animals in the supraphysiological replacement group tended to lose more
weight than the physiologically-replaced group, although the difference did not reach
statistical significance. However, as the experimental period was only 3d it is
possible that insufficient time had elapsed for the two groups to lose significantly
different amounts ofweight and thus it is hard to draw firm conclusions from these
results.
Increased hippocampal total GR mRNA with supraphysiological corticosterone
replacement is an interesting and novel finding. This may not have been detected in
previous studies due to differences in methodology. The replacement regimen used
here mimics the natural diurnal rhythm of corticosterone release in the rat (Spencer et
al., 1993), which is abolished in studies using corticosterone pellets. Also, none of
the previous studies used a similar dose of corticosterone to that used here and many
used different routes of corticosterone administration. The oral bioavailability of
corticosterone is unknown and the bioavailability of corticosterone given by different
parenteral routes e.g. intraperitoneal (Peiffer et al., 1991a) or subcutaneous (Sapolsky
et al., 1984b) may vary. Furthermore, different strains of rat may show different HPA
responses to glucocorticoids (Oitzl et al., 1995) and none of the previous studies used
the Wistar strain, so the response of this strain may be unique. Further research is
required to establish if other rat strains respond in a similar way to the same
corticosterone replacement regimen and to elucidate any physiological effects of the
increased hippocampal GR e.g. on cognitive function or behaviour (section 1.9.2.6).
It is tempting to speculate that at very high levels of circulating corticosterone the
GR in hippocampus become saturated, requiring an increased number of receptors to
transduce a greater glucocorticoid signal and increase negative feedback from the
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HPA axis. Under these circumstances, an increased number of activated receptors
would be present in the nucleus and thus would be more likely to decrease
production of factors involved in HPA axis control such as CRH and POMC by
associating with negative GREs (section 1.11.2). Also, if a subset of hippocampal
neurones were to upregulate GR in response to elevated glucocorticoid levels while
the majority downregulate them, the neurones with elevated GR levels might
undergo apoptosis while those with low levels survive. Indeed, glucocorticoid
upregulation ofGR has been associated with T cell apoptosis (Tonko et al., 2001)
and it is possible that the reduction in GR levels seen during thymocyte maturation
(Ranelletti et al., 1987) could be due to the deletion of a subset of thymocytes that
highly express GR. This hypothesis is supported by the observation that different
thymocyte subpopulations have different levels ofGR (Wiegers et al., 2001). Neither
the rate of apoptosis nor changes in GR levels in specific subpopulations of cells
were addressed in the studies of hippocampal GR regulation described here. Further
experiments to quantify these variables would be extremely interesting.
Interestingly, a transient increase in hippocampal GR has been reported in rats
undergoing 7 hours of restraint stress (Fujikawa et al., 2000), suggesting that
increases in circulating corticosterone might upregulate hippocampal GR in these
animals. However, chronic stress causes downregulation of hippocampal GR over 7d
(Paskitti et al., 2000), 14d (Kitraki et al., 1999), 18d (Kim et al., 1999), 3 week
(Sapolsky et al., 1984b) and 4 week (Mizoguchi et al., 2001) experimental periods.
Furthermore, stress clearly affects other brain regions than the hippocampus, e.g. the
medial prefrontal cortex (Diorio et al., 1993) and in the hippocampus stress
modulates the expression of a wide range of receptor proteins, e.g. growth hormone
receptor (Fujikawa et al., 2000), the gamma-amino butyric acid A receptor (Cullinan
and Wolfe, 2000), MR (Fujikawa et al., 2000) and the serotonin 2C (Holmes et al.,
1995a) and 7 (Yau et al., 2001c) receptors. Since serotonin regulates GR in
hippocampal neurons in vivo (Seckl et al., 1990; Yau et al., 1997b) and in vitro
(Erdeljan et al., 2001; Hery et al., 2000; Mitchell et al., 1990b; Mitchell et al., 1992)
and other neurotransmitters regulate hippocampal GR (Tritos et al., 1999), any
effects of stress on hippocampal GR levels are a combination of glucocorticoid-
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mediated effects and those acting via other signalling cascades. Consequently, results
of experiments investigating stress-induced changes in hippocampal GR are not
directly comparable with those described here.
The results described in this chapter suggest that although there is specific "static"
regulation ofGR mRNAs containing at least one variant exon 1 (exon 17,
(McCormick et al., 2000)) by neonatal programming, there is no specific dynamic
regulation of individual hippocampal GR mRNA variants by glucocorticoids in the
adult animal. This finding led to the question of whether the same was true in the
liver, where neonatal programming ofGR levels has been shown to affect the
relative abundance of variant GR mRNAs (McCormick et al., 2000). The results of
experiments investigating this are described in Chapter 5.
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5 The effect of glucocorticoid manipulations on the
expression of the GR gene and alternate exons 1 in the
liver
5.1 Introduction
The repression of GR expression by glucocorticoids in the hippocampus has been
discussed (Chapter 4). Also, evidence suggests that glucocorticoids regulate GR
expression in the liver: GR levels are increased by adrenalectomy and reduced by
glucocorticoid replacement in mice (Svec, 1988; Svec et al., 1989) and hepatic GR is
downregulated by stress (Alexandrova and Farkas, 1992). Furthermore, previous
work in our laboratory has shown that hepatic GR levels may be permanently
"programmed" by prenatal exposure to dexamethasone in a region-specific manner
(Nyirenda et ah, 1998). Some evidence suggests that "programming" of hepatic GR
levels may be mediated by changes in variant exon 1 usage (McCormick et ah,
2000).
The experiments in this chapter were designed to investigate whether glucocorticoid
regulation of hepatic GR involves differential regulation of variant exon 1 expression
in adult rats. The exons 1 studied were U, 1 io and In since GR mRNA transcripts
containing these exons form the majority of the GR mRNA in the liver (McCormick
et ah, 2000). In addition, exon I5 was also included in the study since
semiquantitative RT-PCR had suggested it may be present at levels comparable to
exon In in rat liver (section 3.3.1).
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5.2 Experimental Design
Tissues used in the experiments described in this chapter were obtained from the
same animals described in Chapter 4.
Two complementary techniques were used to study variant exon 1 expression:
(a) Solution hybridisation (section 2.2.11). This technique is highly quantitative
and allows determination of both the total amount ofGR mRNA present in
the tissue and the proportion of the total which contains any individual exon
1.
(b) In situ mRNA hybridisation (section 2.2.10). This technique gives anatomical
resolution and permits separate but semiquantitative analysis of expression of
individual exons 1 in periportal and perivenous regions of the hepatic acinus.
5.2.1 Design of RNase protection analysis
The RNase protection assay has been previously described and has been used to
investigate tissue-specificity of alternate exon 1 usage (McCormick et al., 2000).
Briefly, the principle of the technique is that a GR mRNA transcript containing a
particular exon 1 and the total population of GR mRNAs may be simultaneously
quantified using a riboprobe complementary to both the exon 1 of interest and part of
exon 2 of the GR gene (Figure 5.1). To determine whether GR mRNA levels were
regulated by glucocorticoids, an actin cRNA probe was included as an internal
control (section 2.2.11.2).
In all cases, quantitation ofRNase protection analyses was performed by
phosphoimager (section 2.2.11.3).
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Figure 5.1: principle of the RNase protection assay.
A radiolabeled cRNA probe is incubated with total RNA from the tissue of interest. A common
portion of 186 nucleotides is complementary to the 5' end of exon 2 of GR and can hybridise
with all GR mRNAs. The 3' region of the probe can hybridise to the exon 1 of interest if GR
mRNA transcripts containing it are present in the sample, producing a longer protected
fragment. Hybridised regions of the probe are protected from RNase digestion and can be
resolved on a denaturing polyacrylamide gel. The sum of the intensities of the bands produced
by these two fragments gives the total amount of GR mRNA in the sample. The amount of the
exon 1 of interest present can be expressed as a percentage of total GR mRNAs. Adapted from
McCormick J. (2000), PhD thesis, University of Edinburgh.
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5.3 Results
5.3.1 Optimisation of RNase protection analysis.
Quantitation ofRNA using RNase protection analysis requires
(i) the cRNA to be in excess of the target mRNA
(ii) total digestion of the unbound probe.
To establish the linear range of the assay and titrate the amount of RNase necessary
to completely digest excess cRNA, a pilot experiment was performed using different
amounts of total RNA and a range of concentrations of the RNase provided in the
HybSpeed RPA Kit II (AMS Biotechnology). In addition, to establish whether
dissolution in formamide affected the assay, a comparison was made between RNA
dissolved in water and formamide. Varying quantities of liver RNA were hybridised
to probes complementary to exon 1 io-exon 2 ofGR mRNA (exon 1 io probe) and
actin mRNA (as an internal control).
Figure 5.2 shows a representative autoradiograph: autoradiographs of RNase
protection analysis gels are used for illustrative purposes throughout this chapter and
Chapter 6 since they provide good resolution and clear definition of bands. However,
analysis of the assays was performed using a phosphoimager (section 2.2.11.3) as
this allows rapid and accurate quantification. An example phosphoimager image,
corresponding to the autoradiograph shown in Figure 5.2, is shown in Figure 5.3.
Phosphoimager analysis of the band intensities for the exon 1 io protected fragment in
both the formamide and water suspended RNA (lanes 10 to 17, Figure 5.2)
confirmed that the assay was approximately linear with respect to RNA added
between 12.5 and 50pg in both cases (Figure 5.4).
In addition to the expected fragments, several fragments were obtained with sizes
between that of the exon 2 and exons 1+2 protected fragments (186 nucleotides and
306 nucleotides respectively for exon 1 io). In particular, one band appeared of a
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similar size to the full-length actin probe (Figure 5.2). Similar fragments had been
detected previously in other experiments in this laboratory (McCormick J, PhD
thesis, University of Edinburgh). As the same bands appeared in RNase protection
analyses using a "sense" exon 110 transcript (McCormick J, PhD thesis, University of
Edinburgh), they were attributed to artefacts due to the high GC content in the probes
causing them to form secondary structures.
Using the RNase provided in the kit, complete digestion of the unhybridised full-
length exon 1 and actin probes was achieved by using a 1/5 dilution of RNase (lanes
1 and 8, Figure 5.2). RNase-free control probes remained undigested (lanes 2 and 9,
Figure 5.2). When hybridised to liver RNA suspended in formamide, the full-length
exon 1 io and actin probes were completely digested by RNase at 1/5 dilution (lane 7,
Figure 5.2). However, use of lower dilutions of RNase resulted in incomplete
digestion of the full-length actin probe (lanes 4-6 and 10-17, Figure 5.2) although the
full-length exon 1 io probe was completely digested with RNase at 1/125 dilution
(lanes 3, 5 and 10-17, Figure 5.2).
To see ifRNase T1 from different manufacturers was comparable, another RNase
protection analysis was performed using RNase T1 provided by Roche Diagnostics
along with the AMS RNase. In this analysis, use of a 1/5 dilution of Roche RNase
degraded the protected fragments in addition to excess cRNA while a 1/25 dilution
did not (lanes 1-3, Figure 5.5).
In view of these results, subsequent RNase protection analyses were performed using
50pg of liver RNA (suspended in formamide) per reaction and a 1/25 dilution of
Roche Diagnostics RNase.
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Figure 5.2 (facing page): autoradiograph showing pilot RNase protection analysis of GR mRNA
transcripts containing exon 1I0 of the GR gene in rat liver total RNA.
The cRNA probe, amount of liver RNA and RNase concentration in each reaction are indicated
at the top of the figure. The cRNA probes were complementary to exon l10/exon 2 of the GR
gene (1I0 cRNA) or actin (actin cRNA). The reactions in lanes 3-7 and 10-13 used RNA
suspended in deionised formamide, the remainder of the lanes used RNA suspended in RNase-
free water. Arrows indicate the 380 nucleotide full-length 110 cRNA, the 218 nucleotide full-
length actin cRNA, the 306 nucleotide protected fragment produced by GR mRNA containing
both exon 1I0 and exon 2, the 186 nucleotide protected fragment produced by GR mRNA
containing exon 2 but not exon li0 and the 125 nucleotide protected fragment produced by actin
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Figure 5.3: example phosphoimager image used for quantitation of RNase protection analysis.
Image corresponds to the autoradiograph shown in Figure 5.2 and is an 8h exposure. For
contents of lanes 1-17 see Figure 5.2.
Arrows indicate the 380 nucleotide full-length li0 cRNA, the 218 nucleotide full-length actin
cRNA, the 306 nucleotide protected fragment produced by GR mRNA containing both exon 110
and exon 2, the 186 nucleotide protected fragment produced by GR mRNA containing exon 2
but not exon 1]0 and the 125 nucleotide protected fragment produced by actin mRNA.
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Figure 5.4: quantitation of RNase protection assay shown in Figure 5.2.
Density of bands representing the exon 1I0 protected fragment was measured using a
phosphoimager (section 2.2.11.3) and plotted against the amount of liver RNA added to the
reaction. The results of the assay were approximately linear for both RNA suspended in water
and RNA suspended in formamide between 5 and 50pg RNA.
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Figure 5.5: autoradiograph showing second pilot RNase protection analysis of GR mRNA
transcripts containing exon 110 of the GR gene in rat liver total RNA.
The cRNA probe, amount of liver RNA and RNase concentration in each reaction are indicated
at the top of the figure. The reactions in lanes 1-3, 7, 8 and 10 contained RNase T1 provided by
Roche Diagnostics, while lanes 4-6 contained RNase T1 provided by AMS Biotechnology. The
cRNA probes were complementary to exon l10/exon 2 of the GR gene (110 cRNA) or actin (actin
cRNA). All RNA was dissolved in deionised formamide. Arrows indicate the 218 nucleotide full-
length actin cRNA, the 306 nucleotide protected fragment produced by GR mRNA containing
both exon 110 and exon 2, the 186 nucleotide protected fragment produced by GR mRNA
containing exon 2 but not exon 110 and the 125 nucleotide protected fragment produced by actin
mRNA. Exposure is 7d.
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5.3.2 Effects of glucocorticoid manipulation on expression of GR mRNA
containing exons Is, 16,110 and 1n in the livers of ST animals
RNase protection analysis showed that there was a significant (approximately 50%)
decrease in the absolute amount ofGR mRNA containing exon 110 in the Adx/phys
group compared to the Adx animals, although the proportion ofGR mRNA
containing exon 1 jo (approximately 60-70%) was unaffected by changes in
glucocorticoid levels (Figure 5.6, Figure 5.7).
RNase protection analysis showed that approximately 14% ofGR mRNA in the liver
contained exon % (Figure 5.8, Figure 5.9). Glucocorticoid manipulation had no effect
on either the proportion of the total GR mRNA population containing exon % or the
absolute amount of GR mRNA containing exon 16 in the liver (Figure 5.9). However,
there were strong trends for a significant effect of treatment on both these values
(p=0.07 and p=0.09 respectively) with glucocorticoid replacement tending to lower
exon 1 g expression (Figure 5.9).
Expression of GR mRNA containing exons 15 and 111 was below the level of
detection in total liver RNA from any experimental group (Figure 5.10, Figure 5.11),
indicating that they must make up less than 1-2% of the total GR mRNA population
(McCormick et al., 2000).
Comparison of the Adx and Adx/phys groups had shown an approximately 2x
decrease in exon 110 expression and a strong trend for the same effect on exon %
expression. Together, these exons 1 are present in approximately 75% of the total GR
mRNA. To determine the magnitude of the change in total GR mRNA with
glucocorticoid manipulation in the livers of ST animals, data from the individual
RNase protection analyses was combined. This analysis showed no difference in
levels of total GR mRNA between adrenalectomised and sham-operated control
animals (Figure 5.12). The difference between the adrenalectomy with replacement
groups and the adrenalectomised group did not reach statistical significance,
although both replacement groups showed significantly (approximately 50% and
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40% respectively) lower levels ofGR mRNA than the sham-operated controls
(Figure 5.12).
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Figure 5.6: representative autoradiograph showing RNase protection analysis of expression of
exon 110 of the GR gene in liver of ST animals.
Each lane shows the product of an RPA reaction carried out on 50pg of liver RNA from a single
animal. Arrows indicate the 306 nucleotide protected fragment produced by GR mRNA
containing both exon 110 and exon 2, the 186 nucleotide protected fragment produced by GR
mRNA containing exon 2 but not exon 110 and the 125 nucleotide protected fragment produced
by actin mRNA. Upper panel shows a 7d autoradiograph exposure, lower panel is an overnight
exposure.
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Figure 5.7 (facing page): RNase protection analysis of GR mRNA containing exon 1|0 in livers of
ST animals.
Data are presented as mean ± SEM.
A: total amount of GR mRNA containing exon 1,0, expressed as a ratio to actin mRNA.D ata
were analysed with ANOVA and Tukey's HSD test. There was a significant effect of
glucocorticoid manipulation, with a reduction in exon 110 expression in the Adx/phys group
compared to the Adx group (p<0.05, indicated by *).
B: proportion ofGR mRNA containing exon 110. ANOVA showed no significant effect of
treatment.
Adx/phys n=5, Adx/supra n=4, Adx n=5, Sham n=6.
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Figure 5.8: representative autoradiograph showing RNase protection analysis of expression of
exon 16 of the GR gene in liver of ST animals.
Each lane shows the product of an RPA reaction carried out on 50pg of liver RNA from a single
animal. Arrows indicate the 221 nucleotide protected fragment produced by GR mRNA
containing both exon 16 and exon 2, the 186 nucleotide protected fragment produced by GR
mRNA containing exon 2 but not exon 16 and the 125bp protected fragment produced by actin
mRNA.
Autoradiograph shown is a 5d exposure.
Sham = sham-operated control, Adx = adrenalectomised, Adx/phys = adrenalectomised with




















Figure 5.9: RNase protection analysis of GR mRNA containing exon 16 in livers of ST animals.
Data are presented as mean ± SEM.
A: Total amount of GR mRNA containing exon 16 expressed as a ratio to actin mRNA. ANOVA
showed no significant effect of treatment group on exon 16 expression. n=5 except Adx/phys n=6
and Sham n=8.
B: Proportion of total GR mRNA containing exon 16. ANOVA showed no significant effect of










Figure 5.10: representative autoradiograph showing RNase protection analysis of GR mRNA
containing exon 15 in livers of ST animals.
Each lane shows the product of an RPA reaction carried out on 50pg of liver RNA from a single
animal. Arrows indicate the expected location of the 242 nucleotide protected fragment
produced by GR mRNA containing both exon ls and exon 2, the 186 nucleotide protected
fragment produced by GR mRNA containing exon 2 but not exon 15 and the 125 nucleotide
protected fragment produced by actin mRNA.
Autoradiograph shown is a lOd exposure.
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Figure 5.11: representative autoradiograph showing RNase protection analysis ofGR mRNA
containing exon ln in livers of ST animals.
Arrows indicate the full-length exon In probe, the expected location of the 247 nucleotide
protected fragment produced by GR mRNA containing exon ln and exon 2, the 186 nucleotide
protected fragment produced by GR mRNA containing exon 2 but not exon ln and the 125bp
protected fragment produced by actin mRNA.
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Figure 5.12: RNase protection analysis of total GR mRNA in liver of ST animals.
Data (presented as mean ± SEM) is compiled from 4 separate RNase protection analysis
experiments (shown in Figure 5.7 and Figure 5.9 and represented in Figure 5.10 and Figure
5.11) using probes specific for exon 2 and one of exons 15,16,1 to and ln of the GR gene.
Ratios are calculated as described in section 2.2.11.3. Data from each experiment was
normalised to the mean value for the Adx animals, then the values for each animal were
averaged across all 4 experiments. Data were analysed by ANOVA and Tukey's HSD test. There
was a significant effect of treatment on GR mRNA expression, which was significantly lower in
the Adx/phys and Adx/supra animals than in the Sham animals (p<0.05, indicated by *).
n=6 per group except Sham where n=7.
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5.3.3 In situ mRNA hybridization reveals that expression of total GR mRNA
varies with glucocorticoid manipulations in ST but not LT animals.
An approximately 2x reduction in the total amount ofGR mRNA containing exon 110
was seen with glucocorticoid replacement in adrenalectomised animals, along with a
near-significant approximately 2x reduction in the total amount ofGR mRNA
containing exon 16. Although highly quantitative, RNase protection analysis cannot
provide anatomical resolution in a complex organ like the liver, so region-specific
changes might be masked. In view of this, in situ mRNA hybridization was
performed to determine whether there was a region-specific effect of treatment on
GR mRNA expression. Since there was little change in GR mRNA levels in the
brains of LT animals after glucocorticoid manipulation, the livers from these animals
were not included in the RNase protection analysis. However, as there might be
small but significant difference in the region-specific regulation ofGR mRNA and
variant exons 1 in these animals, their livers were included in the in situ mRNA
hybridisation experiments.
There was clear zonal expression of total GR mRNA in the livers of both ST and LT
animals (Figure 5.13), with expression appearing higher periportally in all animals
(Figure 5.14). Densitometric analysis of autoradiographs of whole sections of liver
tissue showed a significant effect of adrenalectomy with glucocorticoid replacement
compared to adrenalectomy alone in the ST animals, in broad agreement with RNase
protection analysis (Figure 5.15). However, there was no effect of glucocorticoid
manipulations in the LT animals (Figure 5.15). To determine whether regulation of
GR mRNA in the periportal and perivenous regions of ST animals was similar, GR
mRNA expression in the periportal and perivenous regions was analysed by
densitometry. This revealed significant changes in GR mRNA levels in both regions
(Figure 5.16).
Densitometry gives a good assessment of the overall changes in mRNA expression in
different regions of the tissue, but it does not provide cellular detail. To provide this
level of resolution grain counting analysis ofGR mRNA was performed on sections
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of liver from both ST and LT animals. This showed a significant overall effect of
treatment on GR mRNA in both periportal and perivenous regions in the ST animals,
confirming the data from analysis of autoradiographs (Figure 5.17). In the periportal
region, physiological glucocorticoid replacement caused a significant reduction in
GR mRNA compared to sham-operated controls, while expression in both groups of
animals receiving glucocorticoid replacement was significantly lower than in Adx
animals which received no glucocorticoid treatment (Figure 5.17 A). The differences
between groups in the perivenous region failed to reach statistical significance when
analysed using Tukey's HSD Test (Figure 5.17 A). However, analysis using Fisher's
LSD Test showed that physiological glucocorticoid replacement caused a significant
reduction in GR mRNA compared to sham-operated controls, while expression in
both groups of animals receiving glucocorticoid replacement was significantly lower
than in Adx animals which received no glucocorticoid treatment (Figure 5.17 A).
Interestingly, although glucocorticoid manipulation had no effect on total GR mRNA
levels in livers of LT animals, the ratio of expression ofGR in the periportal
compared to the perivenous region of the hepatic acinus is altered by changes in
glucocorticoid levels in LT animals (Figure 5.18). Adrenalectomy caused a
significant increase in the periportal:perivenous ratio, an effect that was abolished by
physiological corticosterone replacement (Figure 5.18). In contrast, ST animals
showed no difference in the periportal [perivenous ratio ofGR expression between
the treatment groups.
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Figure 5.13 (facing page): representative autoradiographs showing in situ mRNA hybridisation
of a probe complementary to exons 5-9 of the GR cDNA to rat liver.
A: ST animals.
B: LT animals.
ST = short-term adrenalectomy, LT = long-term adrenalectomy, Sham = sham-operated
control, Adx = adrenalectomised, Adx/phys = adrenalectomised with physiological
corticosterone replacement by injection, Adx/supra = adrenalectomised with supraphysiological
corticosterone replacement by injection, Adx/cort = adrenalectomised with physiological
corticosterone replacement by subcutaneous pellet, Sense = sense control representative of both


























Figure 5.14: representative photomicrographs showing GR mRNA in periportal (PP) and
perivenous (PV) regions of livers of ST animals.
Magnification x 400. Sham = sham-operated control, Adx = adrenalectomised, Adx/phys =
adrenalectomised with physiological corticosterone replacement, Adx/supra = adrenalectomised
with supraphysiological corticosterone replacement, Ve = portal vein, Ar = hepatic arteriole.
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Figure 5.15 (facing page): densitometric analysis of in situ mRNA hybridisation of a probe
complementary to exons 5-9 of the GR cDNA to rat liver.
A: ST animals.D ata (presented as mean ± SEM) were analysed by ANOVA and Tukey's HSD
test. There was a significant effect of treatment on GR mRNA expression. Although no group
differed significantly from Sham animals, expression of GR in both Adx/phys and Adx/supra
animals was significantly lower than that in Adx animals (p<0.05, denoted by *). n=6 per group
except sham where n=7.
B: LT animals. ANOVA revealed no significant effect of treatment on GR expression. n=8
except Adx n=7.
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Figure 5.16: densitometry analysis of in situ mRNA hybridisation of a probe complementary to
exons 5-9 of the GR cDNA to livers of ST animals.
Data (presented as mean ± SEM) were analysed by ANOVA and Tukey's HSD test.
There was a significant effect of treatment on GR mRNA expression in both periportal and
perivenous regions. No group differed significantly from the Sham animals in either region.
However, in the periportal region GR mRNA in both the Adx/phys and Adx/supra animals was
significantly lower than in the Adx animals while in the perivenous region GR expression in the
Adx/phys animals was significantly lower than in the Adx animals. Marked results (*) are
significantly different to Adx animals (p<0.05). n=6 except Adx n=5 and Sham n=7.
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Figure 5.17 (facing page): grain counting analysis of in situ mRNA hybridisation of a probe
complementary to exons 5-9 of the rat GR cDNA to rat liver.
A: ST animals.D ata (presented as mean ± SEM) were analysed by ANOVA and Tukey's HSD
test. There was a significant effect of treatment on GR mRNA levels in periportal and
perivenous regions. In the periportal region, expression in Adx/phys animals was significantly
lower than in Sham animals (p<0.05: indicated by *) while expression in both Adx/phys and
Adx/supra animals was significantly lower than in Adx animals (p<0.05: indicated by x).In the
perivenous region,post-hoc analysis using Fisher's LSD Test showed that expression in
Adx/phys animals was significantly lower than in Sham animals (p<0.05: indicated by *) while
expression in both Adx/phys and Adx/supra animals was significantly lower than in Adx
animals (p<0.05: indicated by x). n=6 except Adx n=5 and Sham n=7.
B: LT animals. ANOVA revealed no significant effect of treatment on GR expression in
periportal or perivenous regions. n=8 except Adx n=5.
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Figure 5.18 (facing page): grain counting analysis of periportakperivenous ratio of GR mRNA
expression in rat liver.
A: ST animals. Data are presented as mean ± SEM.A NOVA showed no significant effect of
treatment on periportakperivenous ratio. n=6 except Adx n=5 and Sham n=8.
B: LT animals. Data (presented as mean ± SEM) were analysed by ANOVA and Tukey's HSD
test. There was a significant effect of treatment on periportakperivenous ratio, which was
significantly higher in Adx animals than in Sham animals (p=0.05, indicated by *). n=8 except
Adx n=5.
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5.3.4 In situ mRNA hybridization analysis of the distribution and regulation of
GR mRNA transcripts containing variant exons 1 in the liver.
In situ mRNA hybridisation had revealed zonal distribution and glucocorticoid-
induced changes in total GR mRNA levels in livers of ST animals, as well as a
change in the periportahperivenous ratio of GR mRNA in LT animals. Therefore the
same technique was used to investigate the distribution ofGR mRNA containing
variant exons 1 in the livers of ST and LT animals and the effects of glucocorticoid
manipulation on their expression.
There was zonal expression of exon 1 io in the livers of ST and LT animals (Figure
5.19). Densitometric (Figure 5.20) and grain counting (Figure 5.21, Figure 5.22)
analysis showed no effect of glucocorticoid manipulation on expression ofGR
mRNA containing exon 1 io in ST or LT animals. In addition, the
periportahperivenous ratio ofGR mRNA containing exon 1 io was unaffected by
glucocorticoid manipulations in ST and LT animals, although there was a strong
trend for treatment to affect the periportahperivenous ratio in the LT animals
(p=0.055, Figure 5.23), similar to that seen for total GR mRNA.
In agreement with the RPA results, in situ mRNA hybridisation using a probe
specific for exon 111 showed no specific hybridisation (data not shown).
269
Figure 5.19 (facing page): representative autoradiographs showing in situ mRNA hybridisation
of a probe complementary to exon 110 of the GR gene to rat liver.
A: ST animals
B: LT animals
ST = short-term adrenalectomy, LT = long-term adrenalectomy, Sham = sham-operated
control, Adx = adrenalectomised, Adx/phys = adrenalectomised with physiological
corticosterone replacement by injection, Adx/supra = adrenalectomised with supraphysiological
corticosterone replacement by injection, Adx/cort = adrenalectomised with physiological
corticosterone replacement by subcutaneous pellet, Sense = sense control representative of both
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Figure 5.20: densitometric analysis of in situ mRNA hybridisation of a probe complementary to
exon 110 of the GR gene to rat liver.
Data are presented as mean ± SEM
A: ST animals. ANOVA showed no significant effect of treatment on exon 110 expression.
B: LT animals. ANOVA showed no significant effect of treatment on exon li0 expression.
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Figure 5.21: representative photomicrograph showing silver grains after in situ mRNA
hybridisation of a probe specific for exon li0 of the GR gene to ST rat liver.
Magnification x 400. Ve = portal venule.
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Figure 5.22: grain counting analysis of in situ mRNA hybridisation of a probe complementary to
exon 110 of the GR gene to rat liver.
A: ST animals. Adx/phys n=6, Adx/supra n=4, Adx n=5 and Sham n=7.
B: LT animals. n=8 except Adx n=6.
ANOVA showed no significant effect of treatment on exon 1]0 expression in periportal or
perivenous regions for either ST or LT animals.
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Figure 5.23 (facing page): analysis of periportal:perivenous ratio of GR mRNA containing exon
lio, determined by grain counting.
A: ST animals. Adx/phys n=6, Adx/supra n=4, Adx n=5 and Sham n=7.
B: LT animals. n=8 except Adx n=6.
Data are presented as mean ± SEM.
ANOVA showed no significant effect of treatment on periportal:perivenous ratio of GR mRNA
containing exon 1,„ in either experiment.
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5.3.5 Preliminary data reveals a specific area of DNase I sensitivity in the GR
gene promoter region.
To determine if tissue-specific differential expression of exons 1 was associated with
changes in the chromatin structure of the GR gene promoter region, preliminary
experiments were performed to localise DNase I hypersensitive sites in liver
chromatin at the 5' end of the GR gene. The material used was obtained from control
Wistar rats.
The location of restriction enzyme sites and probe used are shown in Figure 5.24. A
Ncol fragment spanning nucleotides -4534 to -2350 of the GR gene, which includes
exons U to I9 and part of exon 110 (Figure 5.24), was sensitive to DNase I digestion
(Figure 5.25). However, no smaller "daughter" band was observed, suggesting that
this may not be a true DNase I hypersensitive site but rather a region of general
DNase I sensitivity. In contrast, the PstI fragment extending from ~ -5000 to -3326
and the PvuII fragment extending from ~ -5300 to -3911 (Figure 5.25) showed little
or no DNase I sensitivity.
To localise the region of DNase sensitivity the Ncol fragment was cleaved in double
digests carried out on the same DNA samples. None of the fragments were affected
by DNase I (Figure 5.26). This suggests that the observed region of DNase I


































Figure 5.25: representative autoradiograph showing DNase I hypersensitive site mapping of rat
liver genomic DNA.
Nuclei were treated with 0, 20 or 40 units of DNase I, DNA was extracted, digested with PstI,
PvuII or Ncol then blotted as described in section 2.2.8 and hybridised to radiolabeled probe
corresponding to -4438 to -4300 (see Figure 5.24). Autoradiograph was exposed for 12hr.
Arrows indicate hybridising fragments: the 1.7kb PstI fragment (= -5000 to -3326), the 1.4kb
PvuII fragment (= -5300 to -3911) and the 2.2kb Ncol fragment (-4534 to -2350). The PstI and














Figure 5.26: representative autoradiograph showing localisation of a region of DNase sensitivity
in rat liver genomic DNA.
Nuclei were treated with 0 or 40 units of DNase I, DNA was extracted, digested with Ncol
together with either SphI, PstI, Kpnl or SstI then blotted as described in section 2.2.8 and
hybridised to a probe generated from the template shown in Figure 5.24. Autoradiograph was
exposed for 12hr.
Arrows indicate hybridising fragments: the =0.9kb NcoI/SphI fragment (-4534 to -3552), the
l.lkb Ncol/Pstl fragment (-4534 to -3362), the 1.6kb Ncol/Kpnl fragment (-4534 to -2802) and




Consistent with previous data (McCormick et al, 2000), exon 110 is present in the
majority (~ 63%) ofGR mRNA in liver, with a substantial minority (~ 14%)
containing exon U. These exons together are therefore present in only approximately
77% of the GR mRNA in liver. A small amount ofGR mRNA containing exons I5
and In was previously detected in liver (McCormick et al., 2000), although they
were undetectable in these experiments. Thus, -23% of GR mRNA remains
unaccounted for, suggesting that other (perhaps novel) exons 1 may be expressed in
liver. This is consistent with previous data (McCormick et al., 2000).
RNase protection analysis demonstrated glucocorticoid regulation ofGR mRNA
containing exon 110 and a strong trend for glucocorticoid manipulation to regulate the
expression of GR mRNA containing exon \(,. In both cases the magnitude and
direction of these changes is very similar to the changes seen in total GR mRNA
analysed by both RNase protection assay and in situ mRNA hybridisation. However,
in situ mRNA hybridisation failed to demonstrate any effect of treatment on exon 110
expression, possibly because it is less quantitative than RNase protection. Exons U
and 110 together are present in the majority of GR mRNA in the liver (this work and
(McCormick et al., 2000)), suggesting that the observed changes in the total levels of
these transcripts reflect the changes in total GR mRNA levels caused by
glucocorticoid manipulation. Conversely, exons I5 and In were undetectable by
RNase protection analysis in these experiments, thus even if GR mRNA containing
these exons was subject to glucocorticoid regulation they would make only a very
small contribution to any change in total GR mRNA levels. It remains possible,
however, that expression ofGR mRNA containing novel exon 1 variants is being
regulated by glucocorticoid manipulation.
There was a strong trend for changes in glucocorticoid levels to affect the proportion
of the total GR mRNA containing exon 16 (determined by RNase protection
analysis). Since exon U forms only ~ 14% of total GR mRNA in liver, the statistical
effect of experimental variation will be greater than for exon 110, which is present in
- 63% ofGR mRNA. This may explain why these data failed to reach statistical
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significance. Alternatively, expression of exon If might be changing in one part of
the hepatic acinus but not the other, with the change being partially masked since the
RNase protection analysis used RNA derived from homogenised liver. It was not
possible to carry out in situ mRNA hybridisation for exon 16 as the region containing
1 § is short and extremely GC-rich, so an appropriate probe template could not be
designed (discussed in Chapter 3). Repeating the RNase protection analysis using
RNA obtained from separated periportal and perivenous hepatocytes would address
this question. However, it is possible that expression of exon If is unaffected by
changes in glucocorticoid levels.
RNase protection analysis cannot detect region-specific changes in mRNA levels in a
complex organ such as the liver. In situ mRNA hybridisation was used to investigate
the anatomical distribution of total GR mRNA as well as GR mRNA containing exon
1 io and to determine whether levels of these transcripts changed in a particular region
of the hepatic acinus. There was clear differential expression ofGR mRNA in the
periportal and perivenous regions of the hepatic acinus, as previously described
(Nyirenda et al., 1998) and noted in Chapter 3. Also, there was clear zonal
expression ofGR mRNA containing exon 1 io, with a periportalperivenous ratio
similar to that of total GR mRNA. Interestingly, the distribution ofGR protein has
been previously described as homogeneous in the liver (Antakly and Eisen, 1984),
although this report did not quantitatively assess GR levels in the periportal and
perivenous hepatocytes. Also, there may be a difference between GR mRNA and
protein levels in a tissue since there is some post-transcriptional regulation ofGR
levels (Dong et al., 1988; Paskitti et al., 2000). The differentiation of hepatic
metabolism in the periportal and perivenous hepatocytes (the "metabolic zonation"
theory) and the distribution of enzymes regulated by glucocorticoids is discussed in
detail in section 1.9.4. It is possible that GR is co-localised periportally with the
enzymes of gluconeogenesis, where a higher level ofGR will confer greater
glucocorticoid sensitivity.
In contrast to the observed effect in the hippocampus (Chapter 4) adrenalectomy did
not significantly increase hepatic total GR mRNA levels compared to controls in
either the periportal or perivenous regions. This is in agreement with previous data,
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where 2 week adrenalectomised rats showed only a 15% increase in hepatic GR
compared to a 40% increase in brain (Kalinyak et al., 1987). Interestingly, there may
be species-specific differences in the effect of adrenalectomy since 24h
adrenalectomy in mice caused a 2-2.5 x increase in hepatic glucocorticoid binding
capacity (Svec et al., 1989). However, it is possible that there is an acute change in
hepatic GR with adrenalectomy that has returned to normal by the time the tissues
from the ST and LT animals were harvested: this possibility is discussed further
below. Alternatively, it may be that the increase in hepatic GR seen by Svec et al
was not due to increased GR mRNA synthesis, but to a change in stability or
translation efficiency of the GR mRNA or decreased rate of receptor degradation
(none ofwhich were assessed in the current study). This is possible, since there may
be some post- transcriptional control of GR level by glucocorticoids (Dong et al.,
1988; Paskitti et al., 2000).
In situ mRNA hybridisation showed that adrenalectomy and corticosterone
replacement in ST animals significantly downregulated hepatic GR mRNA relative
to adrenalectomy alone. This data is in agreement with previous studies where
corticosterone treatment of adrenalectomised rats significantly reduced hepatic
glucocorticoid binding capacity (Alexandrova et al., 1989), dexamethasone treatment
of adrenal-intact rats caused a 40% decrease in hepatic GR mRNA levels (Kalinyak
et al., 1987) and intraperitoneal injection of adrenalectomised mice with lmg of
corticosterone downregulated hepatic GR number by 25% compared to
adrenalectomised animals (Svec, 1988). Also, rats subjected to repeated stressors
showed significantly reduced hepatic GR number, attributed by the authors to
sustained corticosterone secretion (Alexandrova and Farkas, 1992). However, the
role of stress in regulation of hepatic GR is not clear; in adrenally-intact mice, 3d of
repeated stressors did not affect glucocorticoid binding capacity in liver cytosol
(Svec et al., 1989). This may be a species difference between rat and mouse:
alternatively, it may be due to the tissues being obtained from the rats immediately
post-stress (Alexandrova and Farkas, 1992) while those from the mice were obtained
24h after the last stressor (Svec et al., 1989).
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In contrast to the in situ mRNA hybridisation results, RNase protection analysis
showed that adrenalectomy and both doses of corticosterone replacement in ST
animals significantly downregulated hepatic GR mRNA relative to sham-operated
controls rather than to adrenalectomised animals. This difference is probably a
statistical effect due to the RNase protection data being averaged from 4 separate
experiments. Alternatively, it may be due to the difference in quantitative precision
of the two techniques.
There was no difference in effect between the physiological and supraphysiological
replacement doses of corticosterone, unlike in the hippocampus (Chapter 4). Also,
neither adrenalectomy nor glucocorticoid replacement in LT animals produced a
significant difference in hepatic GR mRNA compared to sham-operated controls.
These data suggest that there are tissue-specific differences in GR regulation by
glucocorticoids between hippocampus and liver.
An obvious question is why adrenalectomy or adrenalectomy with
supraphysiological glucocorticoid replacement had no effect on hepatic GR levels
compared to sham-operated controls. Since the LT animals showed no differences in
total GR mRNA levels, perhaps there is an acute change in hepatic GR number with
glucocorticoid manipulation that returns to the programmed "set-point" over time, as
is seen in the hippocampus (Holmes et al., 1995b; Reul et al., 1989). It is possible
that this was occurring by the time the tissues were harvested from the ST animals,
resulting in a significant difference between the animals with the highest GR mRNA
levels (the adrenalectomised group) and those with the lowest (the physiologically-
replaced group) but no differences between the treatment groups and the sham-
operated controls.
Alternatively, it is tempting to speculate that glucocorticoids have an important role
in determining the "set point" of hepatic GR expression during development (where
hepatic GR mRNA levels may be permanently "programmed" by prenatal exposure
to dexamethasone (Nyirenda et al., 1998)) but do not dramatically regulate hepatic
GR levels in the adrenally-intact adult animal. This would be logical in terms of the
central role ofGR in the control of hepatic metabolism (section 1.9.4). For example,
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in an animal under chronic stress increased glucocorticoid levels would cause an
increased glucocorticoid signal to the hepatocytes. However, if this signal caused the
downregulation of hepatic GR the maximum level of glucocorticoid signal that could
be transduced might eventually be reduced, impairing the liver's capacity to produce
glucose during the fight or flight response by reducing the level of expression of
gluconeogenic enzymes. This might plausibly put the animal at a disadvantage.
The increase in the periportal :perivenous ratio of total GR mRNA seen with
adrenalectomy in the LT animals was unexpected. Adrenalectomy had no effect on
total GR mRNA in either region individually and no similar change in ratio was seen
in the ST animals despite the significant regional changes in GR mRNA. Possibly in
the LT animals adrenalectomy increased GR mRNA slightly in the periportal region
while decreasing it slightly in the perivenous, with neither change being significant
alone but reaching significance when taken together. Indeed, GR mRNA in
adrenalectomised animals tends to be higher in the periportal region and lower in the
perivenous region than that of sham controls, but the individual differences were not
significant. A change in the periportal:perivenous ratio of GR expression might be of
relevance to the metabolic zonation theory discussed above and in Chapter 1. Further
investigation of this effect with a larger number of animals to give greater statistical
power is perhaps warranted.
Preliminary data is presented here regarding the chromatin structure of the GR gene.
Technical difficulties and time limitations precluded a more detailed analysis.
Although very preliminary, the results of these experiments in control animals
suggest that a region ofDNase I sensitivity lies close to or within exon 110. This
would be consistent with the chromatin being open in this transcriptionally active
area. The absence of the expected "daughter" bands from the blot may be due to the
fact that these bands are often indistinct due to there being up to 200bp variability in
the location of the site where DNase I cleaves the DNA . It could be argued that poor
transfer ofDNA onto the nylon membrane caused the disappearance of the Ncol
fragment. This is unlikely, however, as the parent fragment as well as smaller
fragments were efficiently transferred. Work is currently underway in our laboratory
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to further characterise the chromatin structure of the GR promoter region in liver and
a variety of cell lines.
The data presented here and in Chapter 4 have suggested that in hippocampus and
liver variant exons 1 of the GR gene are regulated similarly to total GR mRNA. The
results of experiments investigating the effects of glucocorticoids on the expression
ofGR and its alternate exons 1 in the thymus are described in the following chapter.
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6 The effect of glucocorticoids on expression of the GR
gene and alternate exons 1 in the thymus
6.1 Introduction
Glucocorticoids have an important role in the physiology of the immune system
(section 1.9.5). The thymus has perhaps the highest level ofGR in the body (Lowy,
1989; Reul et al., 1989). GR is down-regulated as T cells mature (Miller et ah, 1998)
and the amount ofGR in tissues of the immune system parallels their sensitivity to
glucocorticoids (Miller et ah, 1998). Glucocorticoid downregulation ofGR in the
thymus and T lymphocytes is well-recognised (Miller et ah, 1990; Peiffer et ah,
1994; Spencer et ah, 1991).
However, in some lymphoid cell lines glucocorticoids upregulate GR (Antakly et ah,
1989; Antakly et ah, 1990; Ashraf et ah, 1991; Denton et ah, 1993; Eisen et ah,
1988). Also, there is evidence that, in human CEM-C7 cells, glucocorticoids increase
expression of GR mRNA containing exon 1A (equivalent to rat exon 11) (Breslin et
ah, 2001). Current data suggests that expression of exon 11 is restricted to tissues of
the immune system ((McCormick et ah, 2000; Strahle et ah, 1992), Chapter 3):
indeed, exon 1A is the predominant exon 1 in GR mRNA from S49 lymphoma cells
(Strahle et ah, 1992). Furthermore, exon H is located at least 15kb 5' of exon 2 and
most of the other known exons 1, which lie in a 3kb CpG island ~1.5kb 5' of exon 2
(McCormick et ah, 2000). These observations led to the hypothesis that expression of
transcripts containing exon 11 might be regulated differently by glucocorticoids to
that of the other exons 1. The experiments described in this chapter were designed to
test this hypothesis.
6.2 Experimental design
Expression of the three exons 1 present in the majority ofGR mRNA in the thymus
(11, le and 1 io) was studied in the experiments described in this chapter. The thymi
used were harvested from the same animals described in Chapters 4 and 5. For
details of the adrenalectomy and glucocorticoid replacement see section 2.2.1.
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The experimental design was the same as that described for the experiments in
Chapter 5, using an RNase protection analysis to provide accurate quantification of
GR mRNA levels and in situ mRNA hybridisation to provide anatomical detail.
Although autoradiographs are used for illustrative purposes throughout this chapter,
analysis of all RNase protection assays was performed using a phosphoimager
(section 2.2.11.3).
6.3 Results
6.3.1 Effects of glucocorticoid manipulation on expression of GR mRNA
transcripts containing exons 1i, 16 and 1io in the thymus of ST animals
RNase protection analysis using total RNA extracted from thymus showed that short
term glucocorticoid replacement significantly lowered the amount of GR mRNA
containing exon 1 io compared to sham animals (Figure 6.1, Figure 6.2). However,
there was no effect of treatment on the proportion of total GR mRNA transcripts
containing exon lio (Figure 6.2).
There was a significant overall effect of treatment on the amount ofGR mRNA
containing exon 11 (Figure 6.3, Figure 6.4), though the individual differences
between groups did not reach statistical significance. Since the lanes containing
samples from the Sham animals suffered from excessive background (Figure 6.3),
the data from these animals was excluded from this analysis. A second analysis was
performed comparing the Sham and Adx animals, which showed that adrenalectomy
had no effect on exon 11 expression (Figure 6.5).
There was no effect of treatment on the proportion ofGR mRNA transcripts
containing exon 11 (Figure 6.4). Similarly, there was no significant effect of
treatment on either the amount or the proportion ofGR mRNA containing exon 1$ in










Figure 6.1: representative autoradiograph showing RNase protection analysis of GR mRNA
containing exon ll0 in thymus of ST animals.
Each lane shows the product of an RPA reaction carried out on 50pg of thymus RNA from a
single animal. Arrows indicate the 306bp protected fragment produced by transcripts
containing exon 1]0 and exon 2, the 186bp protected fragment produced by transcripts
containing exon 2 but not exon 110 and the 125bp protected fragment produced by actin mRNA.
The top panel was taken from a 7d exposure and the centre and bottom panels were taken from
an overnight exposure of the same gel.
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Figure 6.2 (facing page): phosphoimager analysis of RNase protection assay of GR mRNA
transcripts containing exon 1I0 in rat thymus.
Data are presented as mean ± SEM.
A: amount of GR mRNA containing exon li0 in thymus of ST animals expressed as a ratio to
actin mRNA. Data were analysed with ANOVA and Tukey's HSD test. There was a significant
effect of treatment (p<0.05) with lower expression in Adx/phys and Adx/supra animals than in
sham-operated controls (p<0.05, indicated by *). n=6 per group except Adx/supra n=4 and
Sham n=7.
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Figure 6.3: representative autoradiograph showing RNase protection analysis of GR mRNA
containing exon I, in the thymus of ST animals.
Each lane shows the product of an RPA reaction carried out on 50|ig of thymus RNA from a
single animal. Arrows indicate the 228bp protected fragment produced by transcripts
containing exon 1| and exon 2, the 186bp protected fragment produced by transcripts
containing exon 2 but not exon li and the 125bp protected fragment produced by actin mRNA.
The upper panel was taken from a 7d exposure while the lower was taken from a 5d exposure.
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Figure 6.4 (facing page): phosphoimager analysis of RNase protection assay of GR mRNA
containing exon l! in thymus of ST animals.
Data are presented as mean ± SEM.
A: amount ofGR mRNA containing exon 1, expressed as a ratio to actin mRNA. Data were
analysed by ANOVA and Tukey's HSD test. There was a significant effect of treatment (p<0.05).
Post-hoc analysis using Tukey's HSD Test failed to reveal significant differences between
groups, but analysis using Fisher's LSD Test showed that glucocorticoid replacement
significantly reduced the amount of GR mRNA containing exon l! compared to adrenalectomy
alone (p<0.05, indicated by x).
B: proportion of GR mRNA containing exon 1,.A NOVA showed no significant effect of
treatment.
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Figure 6.5: phosphoimager analysis of RNase protection assay of GR mRNA containing exon lt
in thymus ofAdx and Sham ST animals.
A: amount of GR mRNA containing exon lj expressed as a ratio compared to actin mRNA.
ANOVA showed no significant effect of treatment.
B: proportion of total GR mRNA containing exon lj. ANOVA showed no significant effect of
treatment. Adx n=5, Sham n=6.
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Figure 6.6: representative autoradiograph showing RNase protection analysis of GR mRNA
containing exon 16 in the thymus of ST animals.
Each lane shows the product of an RPA reaction carried out on 50pg of thymus RNA from a
single animal. Arrows indicate the 221bp protected fragment produced by transcripts
containing exon 16 and exon 2, 186bp protected fragment produced by transcripts containing
exon 2 but not exon 16 and the 125bp protected fragment produced by actin mRNA transcripts.
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Figure 6.7: phosphoimager analysis of RNase protection assay of GR mRNA containing exon 16
in thymus of ST animals.
A: amount ofGR mRNA containing exon 16 expressed as a ratio to actin mRNA. ANOVA
showed no significant effect of treatment.
B: proportion of total GR mRNA containing exon 16. ANOVA showed no significant effect of
treatment. Adx/phys n=6, Adx/supra and Adx n=5, Sham n=7.
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6.3.2 Total GR mRNA levels are significantly affected by glucocorticoid
manipulation in the thymus of ST animals
To confirm that short term glucocorticoid manipulations had produced an effect on
thymic GR, total GR mRNA levels were assessed in the thymus of the ST animals.
Data from the RNase protection analyses for exons 11, 16 and 1 io was combined to
determine the abundance ofGR mRNA in each experimental group. This showed a
significant decrease in total GR mRNA levels in ST animals adrenalectomised and
given glucocorticoid replacement compared to sham (Figure 6.8). There was also a
strong trend for GR mRNA levels to be significantly lower in the same animals
compared to adrenalectomised animals (p=0.06).
In situ mRNA hybridization confirmed the distribution of total GR mRNA described
in Chapter 3 (Figure 6.9). Unfortunately, initial in situ mRNA hybridization
experiments revealed a lack of distinct cellular architecture on the emulsion-dipped
slides (Figure 6.), with individual thymocytes being all but indistinguishable in the
thymic cortex and only occasionally visible in the thymic medulla, although the same
protocol had clearly visualized hippocampal and liver tissue architecture (Chapters 4
and 5). However, sufficient detail was visible to partially resolve the tissue
architecture and see that silver grains appeared to be evenly distributed over all the
cells in both regions (Figure 6.). Grain counting analysis is usually performed by
selecting areas for analysis over individual cells. Since these were not clearly visible
several relatively large areas of cortex on each section were selected for counting. As
the cell density in the medulla varied, it was decided to count over both several cell-
dense areas (henceforth referred to as "medulla") and several large areas of medulla
similar in size to those selected over the cortex (henceforth referred to as "medulla
overall"). The same counting method was used for all the probes used in the thymus.
Analysis of autoradiographs (Figure 6.11) and dipped slides (Figure 6.12) showed a
significant decrease in GR mRNA in the cortex and medulla of thymi from ST-
adrenalectomised animals given glucocorticoid replacement compared to sham-
operated controls. In the ST animals there was no significant effect of adrenalectomy
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alone compared to sham-operated controls. In LT animals there was no significant
effect of glucocorticoid manipulation on GR mRNA levels or distribution (Figure
6.1 If igure6.12).
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Figure 6.8: phosphoimager analysis of RNase protection assay of total GR mRNA in the thymus
of ST animals.
Data (presented as mean ± SEM) is compiled from 3 separate RNase protection analysis
experiments using probes specific for exon 2 and one of exons 1,, 16 and 110 of the GR gene.
Ratios are calculated as described in section 2.2.11.3. Data from each experiment was
normalised to the mean value for the Adx animals, then the values for each animal were
averaged across all 4 experiments. Data were analysed by ANOVA and Tukey's HSD test. There
was a significant effect of treatment on GR levels (p<0.05), which was significantly lower in the
Adx/supra animals compared to Sham (p<0.05, indicated by *).









Figure 6.9: representative autoradiographs showing in situ mRNA hybridisation of a probe
complementary to exons 5-9 of rat GR cDNA to rat thymus.
ST= short-term adrenalectomised, LT = long-term adrenalectomised, Sham = sham-operated
control, Adx = adrenalectomised, Adx/phys =adrenalectomised with physiological glucocorticoid
replacement by injection, Adx/supra = adrenalectomised with supraphysiological glucocorticoid
replacement by injection, Adx/cort = adrenalectomised with physiological glucocorticoid
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Figure 6.10: representative photomicrographs showing in situ mRNA hybridisation of a probe
complementary to exons 5-9 of rat GR cDNA to rat thymus.
Magnification x 400. Legend as for Figure 6.9.
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Figure 6.11 (facing page): densitometric analysis of in situ mRNA hybridisation of a probe
complementary to exons 5-9 of rat GR cDNA to rat thymus.
Data are presented as mean + SEM.
A: ST animals. Data were analysed using ANOVA and Tukey's HSD test. There was a
significant effect of treatment on GR expression in cortex and medulla (p<0.01), with lower GR
mRNA levels in the thymic cortex and medulla of Adx/phys and Adx/supra animals relative to
sham-operated controls (p<0.01, indicated by *). Also, expression in the Adx/supra animals was
lower than that in Adx animals (p<0.05, indicated by x). n=6 except Sham where n=8.
B: LT animals. ANOVA showed no significant effect of treatment on GR mRNA levels. n=7,
except Adx/cort where n=8.
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Figure 6.12 (facing page): grain counting analysis of in situ mRNA hybridisation of a probe
complementary to exons 5-9 of rat GR cDNA to rat thymus.
Data are presented as mean ± SEM.
A: ST animals. Data were analysed by ANOVA and Tukey's HSD test. There was a significant
effect of treatment on GR expression in cortex, medulla and medulla overall (p<0.01). GR
mRNA levels in Adx/phys (p<0.05, indicated by *) and Adx/supra (p<0.01, indicated by *)
animals were significantly lower than in sham operated controls. GR mRNA levels in Adx/supra
animals were significantly lower than in Adx animals (p<0.05, indicated by x). Adx/phys and
Adx n=6, Adx/supra n=5, Sham n=8.
B: LT animals. ANOVA showed no significant effect of treatment on GR mRNA levels. Adx
n=6, Adx/cort n=8, Sham n=7.
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6.3.3 In situ mRNA hybridization analysis of the distribution and regulation of
GR mRNA transcripts containing variant exons 1 in the thymus
RNase protection analysis and in situ mRNA hybridization clearly showed that total
GR mRNA levels in the thymus were altered by glucocorticoid manipulations.
Furthermore, RNase protection analysis showed that glucocorticoid manipulations
altered expression ofGR mRNA containing exons 1 io and 11 in the same way. Since
the experiments described in Chapter 3 had shown a regional distribution of GR
mRNA containing alternate exons 1 in thymus, it was necessary to determine
whether region-specific changes in the expression of GR mRNA transcripts were
being diluted in the RNase protection analysis and missed. Thus, in situ mRNA
hybridization was used to determine whether regulation of expression of these
transcripts by glucocorticoids was region-specific.
Analysis of autoradiographs (Figure 6.13, Figure 6.14) showed no significant effect
of changes in glucocorticoid levels on expression ofGR mRNA transcripts
containing exon 11 in ST or LT animals. Grain counting analysis gave similar results
(data not shown).
Also, analysis of autoradiographs (Figure 6.15f igure 6.16) showed no significant
effect of glucocorticoid manipulation on expression ofGR mRNA containing exon
1 io in the thymic cortex or medulla of ST or LT animals. Grain counting analysis











Figure 6.13: representative autoradiographs showing in situ mRNA hybridisation of a probe
complementary to exon l! of the GR gene in rat thymus. Legend as for Figure 6.9.
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Figure 6.14 (facing page): densitometric analysis of in situ mRNA hybridisation of a probe
complementary to exon li of the GR gene in rat thymus.
Data are presented as mean ± SEM.
A: ST animals. ANOVA showed no significant effect of treatment on expression. n=6, except
Sham where n=8.
B: LT animals. ANOVA showed no significant effect of treatment on expression. Adx n=6,
Adx/cort n=8, sham n=7.
309


































Figure 6.15: representative autoradiographs showing in situ mRNA hybridisation of a probe
complementary to exon 1]0 of the GR gene to the thymus of ST and LT animals. Legend as for
Figure 6.9.
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Figure 6.16 (facing page): densitometric analysis of in situ mRNA hybridisation of a probe
complementary to exon 1)0 of the GR gene to rat thymus.
Data are expressed as mean ± SEM.
A: ST animals. ANOVA showed no significant effect of treatment on expression. n=6, except
Sham where n=7.
B: LT animals. ANOVA showed no significant effect of treatment on expression. n=8, except
Adx where n=7.
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6.3.4 LT adrenalectomised animals receiving glucocorticoid replacement show
reduced thymus weight.
There was a significant reduction in thymus weight in LT Adx animals given
corticosterone replacement compared to those adrenalectomised alone (Figure 6.17).
However, there was no effect of adrenalectomy on thymus weight compared to
sham-operated controls (Figure 6.17).
There was no effect of glucocorticoid manipulation on thymus weight in ST animals
(Figure 6.17). However, in ST sham animals thymus weight formed an
approximately 4-fold greater percentage of the animal's bodyweight than in LT sham
animals (Figure 6.17). The most likely explanation for this is that when the ST
tissues were harvested, variable amounts of fat were dissected out along with the
thymus due to unfamiliarity with the exact anatomy of the area, rendering the data
unreliable.
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Figure 6.17 (facing page): thymus weights of LT and ST animals expressed as a percentage of
bodyweight at the time of tissue harvesting.
Data (presented as mean ± SEM) were analysed by ANOVA and Tukey's HSD test.
A: LT animals. There was a significant effect of treatment on thymus weight (p<0.05). Thymus
weights were significantly lower in Adx/cort animals compared to Adx animals (p<0.01,
indicated by *). Adx n=6, Adx/cort n=8, sham n=7.
B: ST animals. ANOVA showed no significant effect of treatment on thymus weight. n=6 except
sham n=7.
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Supraphysiological or physiological glucocorticoid replacement in ST
adrenalectomised animals decreased the level ofGR mRNA in thymus containing
exons 11 or 110 compared to sham-operated controls. Also, there was a strong trend
for the level ofGR mRNA containing exon 16 to be reduced by the same
glucocorticoid manipulations. In each case, the magnitude of the effect is similar to
the magnitude of the effect on total GR mRNA. The effects of glucocorticoid
manipulations on total GR mRNA expression are in agreement with the results of
previous studies (Peiffer et al., 1994; Spencer et al., 1991). Thus one can rule out a
dramatic and differential downregulation ofGR mRNA containing exon 11, H or lio
by glucocorticoids.
GR mRNAs containing the 3 variant exons 1 studied here made up a total of 78-90%
of the total population ofGR mRNAs, indicating that transcripts containing other
exons 1 are likely to be expressed in thymus. If so, these exons 1 must be novel,
since none of the other known exons 1 were detected in thymus by RNase protection
analysis (McCormick et al., 2000). However, there was no effect of treatment on the
percentage of the total population of GR mRNAs containing each of the exons 1
studied, suggesting that an increase or decrease in the expression of a novel exon 1
cannot account for the change in total GR mRNA seen with adrenalectomy and
glucocorticoid replacement, unless it is regulated in exactly the same way as the
known exons 1.
Interestingly, these experiments do not show a glucocorticoid-mediated increase in
expression of total GR or GR mRNA containing exon 11, which might have been
expected since glucocorticoids have been shown to increase expression of total GR
mRNA (Antakly et al., 1989; Antakly et al., 1990; Ashraf et al., 1991; Denton et al.,
1993; Eisen et al., 1988) and GR mRNAs containing exon 1A (Breslin et al., 2001)
in human CEM-C7 T cells. This raises the question of why glucocorticoids seem to
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have opposite effects on total GR and exon 1A expression in this cell line and the
intact thymus.
One possible explanation may be that glucocorticoid upregulation ofGR mRNA
containing exon 1A and total GR mRNA is confined to a subset ofT cells. Indeed,
there may be a different role for exon 11 (1A) and its associated promoter in different
cell types (Breslin et ah, 2001). Regulation of GR levels by changes in the activity of
promoter 1A has been implicated in glucocorticoid-induced T cell apoptosis and T
cell maturation (Chen et ah, 1999b; Chen et ah, 1999a). Also, exon 1A has been
suggested to encode membrane-associated GR (mGR) or direct GR to the plasma
membrane (Chen et ah, 1999b), although it is unclear how this might occur since the
in-frame stop codon at the start of exon 2 means that transcripts containing different
exons 1 will produce identical GR proteins. However, preliminary work from our
laboratory has suggested that GR mRNA containing exons H and lio are expressed
at similar levels (-20-25% and 50-70% of total GR mRNA respectively) in whole
thymus, thymocytes, thymic epithelium and mature splenic T cells (Dammermann,
A., unpublished observations). Additionally, both mRNA variants showed the same
distribution as total GR mRNA in the in situ mRNA hybridisation experiments
described here, even when subject to glucocorticoid manipulations. At a gross level,
both variants showed even expression throughout the thymic cortex and medulla.
However, the in situ mRNA hybridisation experiments performed here do not allow
the use of double staining with markers for thymic cell types. Further work using
digoxygenin-labelled probes coupled with immunohistochemistry could allow this
and resolve the question of whether the variant exons 1, particularly 11, respond
differently to glucocorticoid manipulations in different cell types. Also, sorting of
thymocytes into different cell populations (CD4+CD8+, CD4 CD8", CD4+CD8", CD4"
CD8+) and separation from cells of the thymic epithelium (CD45") could allow
investigation of whether expression ofGR mRNAs containing variant exons 1 varies
developmentally and whether glucocorticoid manipulations affect their expression
differently at different stages of T cell maturation.
Alternatively, there may have been loss of a subset of thymocytes that upregulate GR
in response to glucocorticoid administration. Glucocorticoids induce apoptosis in
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thymocytes and T cell lines (reviewed in section 1.9.5)). Also, glucocorticoid-
induced upregulation of GR may occur during thymocyte apoptosis, since induction
ofGR expression in glucocorticoid-resistant T cells confers glucocorticoid sensitivity
(Ramdas et al., 1999) and microarray analysis of gene expression during T cell
apoptosis found that increased GR expression is a primary phenomenon in apoptosis
induced by both short and long-term glucocorticoid administration (Tonko et al.,
2001). Thus it is possible that glucocorticoid administration induced apoptosis in
glucocorticoid-sensitive cells that might upregulate GR in response to
glucocorticoids, leaving cells which may be resistant to apoptosis because they
downregulate GR levels. This hypothesis is supported by the reduction in thymus
weight in the LT adrenalectomised animals receiving glucocorticoid replacement
compared to those adrenalectomised alone, which may indicate thymic involution in
response to glucocorticoid administration.
Another possible explanation for why the cultured cells may respond differently to
glucocorticoids is that they are away from the complex hormonal microenvironment
of the thymus (reviewed in section 1.9.5.2)). Also, since the cell lines are
transformed (i.e. tumour) cells they may respond differently to glucocorticoids,
although down-regulation ofGR (Denton et al., 1993) and exon 1A (Breslin et al.,
2001) by glucocorticoids has been shown in a B cell line, which makes this a less
likely explanation.
While expression ofGR mRNA transcripts containing exons 11 and U in the thymus
of Sham animals was comparable to that described previously for control rats,
transcripts containing exon 1 io made up a lower proportion of total GR mRNA than
reported previously (McCormick et al., 2000). As considerable variation exists in the
proportion of transcripts containing exon 1 io, with work from our laboratory
suggesting that they form between 53% (McConnick et al., 2000)and 80%
(Dammermann, A., unpublished observations) of the total GR mRNA population,
this difference may be due to experimental variability.
There were differences between the results of RNase protection analysis and in situ
mRNA hybridisation analysis of the effect of glucocorticoid manipulation on
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regulation of exons 11 or 110, with the former showing a significant effect and the
latter not. There are several possible reasons for this discrepancy. RNase protection
analysis is highly quantitative, whereas in situ mRNA hybridisation is
semiquantitative at best. As discussed in section 6.2 there were technical problems
with the integrity of the tissue for the in situ mRNA hybridisation experiments,
which may have affected the results. Nevertheless, the in situ mRNA hybridisation
does rule out a dramatic regional difference in the effects of glucocorticoids on
expression of total GR mRNA or GR mRNA containing these variant exons 1.
In contrast to the effects after 72h, 3 weeks of physiological glucocorticoid
replacement had no effect on thymic GR levels. The most likely explanation for this
is that the LT animals had adapted to the glucocorticoid manipulation, leading to the
level of GR in the thymocytes returning to normal. 2 previous studies have reported
that the effects of adrenalectomy on hippocampal GR are abolished 2 weeks post-
adrenalectomy (Holmes et al., 1995b; Reul et al., 1989). Also, rats which failed to
suppress their plasma corticosterone levels in response to dexamethasone after acute
stress showed normal suppression after 4 weeks of daily exposure to the same
stressor (Mizoguchi et al., 2001). These data suggest that adaptation to changes in
circulating glucocorticoid levels is possible. Further work using intermediate time
points would help to resolve this issue.
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7. Discussion
The glucocorticoid receptor is highly expressed in the hippocampus, liver and
thymus, where it has an important physiological role. Glucocorticoid regulation of
GR levels is well-recognised in all these tissues, both associated with perinatal
programming (section 1.7.3) and dynamic regulation ofGR levels in the adult animal
(section 1.7.2.1). The aims of this thesis were to further characterise the expression
of variant exons 1 of the GR gene in these glucocorticoid target tissues and
investigate whether changes in alternate promoter usage are associated with
glucocorticoid autoregulation of GR levels.
Variant mRNAs can arise from a single gene by 4 basic mechanisms: initiation of
several primary transcripts at alternative promoters, differential termination or 3'
post-translational processing, alternative splicing of the same primary transcript or
recombination of genomic sequences ((Ayoubi and VanDeVen, 1996) and section
1.10.2). Of these, the use of alternative promoters is the most likely to lead to the
formation of mRNAs with variant 5' regions of the type seen with the GR gene.
Tissue-specific alternate promoter usage leading to the production ofmRNAs with
multiple untranslated 5' regions is seen for many genes including the human
oestrogen receptor gene (Flouriot et al., 1998) and the mineralocorticoid receptor
gene (Zennaro et al., 1995). Also, alternate exons 1 of the GR gene are associated
with promoter activity in transfected cells (Breslin et al., 2001; McCormick et al.,
2000), again suggesting that GR exon 1 variants arise due to alternative promoter
usage.
The experiments described in chapter 3 demonstrated tissue and region-specific
differences in relative expression of variant exons 1 of the mouse and rat GR genes,
consistent with the results of previous studies (McCormick et al., 2000; Strahle et al.,
1992). Tissue-specific expression ofGR variant mRNAs may be due to changes in
promoter usage in different tissues, with some (e.g. the promoter associated with the
rat exon I7) proposed to be tissue-specific while others (e.g. the promoters associated
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with exons 110 and U) proposed to be constitutively active (McCormick et al, 2000).
Similar alternate promoter usage is found in other nuclear hormone receptor genes
such as the rat MR gene (Kwak et al., 1993) and human and mouse ER genes (Kos et
al., 2000; Osterlund et al., 2000).
However, it is debatable whether the expression of the majority of exons 1 is truly
tissue-specific, since GR mRNA containing all of the exons 1 except exons li and I4
was detected in all the rat and mouse tissues studied. Most of the other exons 1 in the
rat are within the 3kb CpG island that lies between approximately -1620 and -4520
relative to the translation start at +1 in exon 2 (McCormick et al., 2000). It is possible
that transcription starts at multiple sites throughout the CpG island, with the specific
mRNA produced depending on the first available splice donor site encountered by
the transcriptional machinery. This hypothesis is supported by the observation that
several of the exons 1 in the CpG island exhibit multiple transcription start sites
(McCormick et al., 2000). Such a mechanism might lead to expression of all the
variant mRNAs associated within the CpG island, with relative levels ofpromoter
usage determined by the tissue-specific mix of transcription factors present. Since a
substantial proportion of the GR mRNA in immune tissues (-25%) contains exon 11
and this exon lies a considerable distance 5' of the other exons 1 in rat (McCormick
et al., 2000), mouse (Strahle et al., 1992) and human cells (Breslin et al., 2001) it is
plausible that the promoter associated with it might be regulated differently those
associated with the other exons 1, perhaps by a tissue-specific transcription factor.
However, exon 14 is much less abundant and is located much closer to the other
exons 1 on the genomic DNA at the 5' end of the CpG island (McCormick et al.,
2000). This raises the question of how the promoter associated with exon 14 might be
regulated differently to the other CpG island promoters. Interestingly, when the
sequence of the GR gene 5' flanking region is examined using GRAIL (Uberbacher
and Mural, 1991), the area around exon 14 is less strongly predicted to be a CpG
island than that around the more 3' exons 1. This raises the possibility that there is a
difference in methylation status of the DNA in these two areas. The 5' area around
exon 14might be less protected from methylation during development by binding of
transcription factors (perhaps including GR) than the more 3' area, which could
322
account for the lack of exon I4 expression in some tissues. Apart from exon 14, it
appears that there is transcription of all the other exons 1 in the CpG island.
The observed tissue-specific differences in the relative expression of variant GR
mRNAs raises the question of what their physiological relevance might be. The
existence of alternate promoters can confer greater flexibility in the regulation of
genes (section 1.10.2). Indeed, changes in the activity of specific GR promoters in
liver and hippocampus has been suggested as a mechanism for perinatal
programming of GR expression by glucocorticoids (McCormick et al., 2000). This
led to the hypothesis that similar changes would be seen during glucocorticoid
autoregulation ofGR levels in adult animals. However, in the studies described here
GR mRNAs containing variant exons 1 were either regulated by glucocorticoids in
the same manner as total GR mRNA or were unresponsive to glucocorticoid
manipulations. Thus although expression of all variant GR exons 1 appears to be
regulated by glucocorticoids, the changes in total GR mRNA expression seen with
glucocorticoid manipulations cannot be accounted for by changes in expression of a
specific exon 1. This, in turn, suggests that the mechanism by which glucocorticoids
regulate GR expression may be by uniformly altering activity of all the promoters of
the GR gene, rather than by effecting changes in the activity of specific alternate
promoters in different tissues. This is perhaps surprising since alternate promoters of
the MR gene are reported to be specifically regulated by adrenocorticosteroids, with
the expression of rat aMR mRNA specifically upregulated in hippocampus by
adrenalectomy (Kwak et al., 1993) and the P2 promoter of the human MR gene being
stimulated by aldosterone in a dose-dependent manner in transfection experiments
(Zennaro et al., 1996). There is little information available regarding the location of
glucocorticoid-responsive sequences in the GR gene promoter region, which might
indicate whether GR is likely to regulate transcription at all or a subset of the
promoters and provide insights into the mechanisms ofGR regulation. Leclerc et al
identified a 500bp glucocorticoid responsive region upstream of exon 1C of the
human GR gene, which they report is responsible for dexamethasone-mediated
downregulation ofGR levels in cultured cells (Leclerc et al., 1991). However, no
footprint analysis was performed and sequence analysis of the region failed to locate
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potential GR binding sites (Leclerc et al., 1991). If footprinting analysis were to
demonstrate the presence of GR binding sites throughout the promoter region, this
might support the hypothesis that glucocorticoid autoregulation affects the activity of
all promoters equally. The data from the experiments described in this thesis suggest
that changes in activity of specific promoters may be involved in determining the
tissue-specific "set-point" of GR expression and in perinatal programming, while
glucocorticoid autoregulation ofGR levels involves changes in the activity of all the
alternate promoters. Further experiments are required to test this hypothesis.
The mechanism by which perinatal programming might induce changes in alternate
promoter usage is unclear. Experiments to further investigate the effects of perinatal
glucocorticoid manipulations could address this issue, perhaps by investigating the
methylation status or chromatin structure of the DNA associated with the various
promoters, either of which might be modified in programmed animals. Interestingly,
it has recently been proposed that increased levels ofNGFI-A and AP-2 in
hippocampal neurones after neonatal handling might lead to reduced methylation of
the GR gene promoter region and permanently increased GR gene expression
(Weaver et al., 2001), although this is highly speculative. The methylation status of
the promoter regions could be assessed in a variety ofways e.g. by methylation-
specific PCR (Herman et al., 1996). Preliminary data on the chromatin structure of
the GR gene in rat liver suggests that a region of DNase I sensitivity lies close to or
within exon 1 io. This would be consistent with the chromatin being open in this
transcriptionally active area and might suggest that modifications of chromatin
structure influence variant exon 1 expression. Work is currently underway in our
laboratory to further characterise the chromatin structure of the GR promoter region
in liver cells and a variety of cell lines.
Some of the variant GR mRNAs that were identified by RT-PCR could not be
detected by RNase protection analysis in the same tissue, suggesting that these exons
are probably either expressed in a small proportion (1-2%) of the GR mRNAs in all
cells in the tissue or are present at higher levels in a subpopulation of cells. This
question could be addressed by investigating the expression of variant GR mRNAs in
different cells, for example by sorting subpopulations of thymocytes or hepatocytes
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or by performing single-cell RT-PCR. If the transcripts are present in all cells, it is
likely that glucocorticoid-induced variations in usage of the promoters associated
with the more common transcripts would be more physiologically relevant than
would variations in those associated with the rarer transcripts. However, levels ofGR
mRNA may not be directly proportional to levels ofGR protein in a given tissue
since some post-translational control of GR levels may occur (Dong et al., 1988;
Rosewicz et al., 1988). This raises the intriguing possibility that the pattern of
alternate variant exon 1 expression in a tissue could control the level of GR protein in
the cell by generating a tissue-specific mix ofGR mRNAs which might have
different stabilities or translation efficiencies. The mRNA stability of several genes is
regulated during development (e.g. the c-myc proto-oncogene), in response to
hormonal cues (e.g. various serum protein mRNAs) and various environmental
factors like hypoxia, hypocalcaemia and tissue injury (reviewed in (Guhaniyogi and
Brewer, 2001)). Acute stress has been reported to cause a reduction in hippocampal
GR mRNA levels without affecting levels of GR heteronuclear RNA (Paskitti et al.,
2000) and treatment of rat hepatoma cells with the cAMP analogue 8-bromo-cAMP
causes a 2.5-fold increase in GR mRNA stability, suggesting that changes in GR
mRNA levels may be mediated by changes in mRNA stability (Dong et al., 1989).
Also, glucocorticoids have been shown to decrease the stability ofmRNAs encoding
the type I procollagen (Raghow et al., 1986) and cyclin D3 (Reisman and Thompson,
1995) genes. mRNA stability may be affected by several determinants in the 3'
untranslated, coding and 5' untranslated regions of the mRNA (reviewed in
(Guhaniyogi and Brewer, 2001)). Since the 5' UTR ofmRNAs can alter stability by
either containing translation-inhibiting stem loops or by containing binding sites for
RNA-stabilising proteins (reviewed in (Guhaniyogi and Brewer, 2001)) and alternate
exon 1 expression alters the 5' end of the GR mRNA (McCormick et al., 2000),
glucocorticoid-induced changes in GR mRNA stability could be a plausible
mechanism for autoregulation ofGR levels. A fruitful line of enquiry could be to
assess the stability of variant GR mRNAs e.g. by actinomycin or in vitro decay
assays.
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The existence of alternate exons 1 might also be relevant to the control of the
translation, stability or activity ofGR. Dexamethasone reduced the half-life ofGR
protein in rat hepatoma cells (Dong et al., 1988); one possible explanation for this
could be that dexamethasone administration is inducing the expression of a GR
protein variant with lower stability. Alternatively, dissociation from HSP90 might
leave GR more susceptible to proteosome-mediated degradation (Wallace and
Cidlowski, 2001). The recent discovery of human GR isoforms with different c-
terminal ends (Yudt and Cidlowski, 2001) and the existence of the GRp isoform in
human cells (Encio and Detera-Wadleigh, 1991; Hollenberg et al., 1985; Oakley et
al., 1996) raises the possibility of the existence of GR protein isoforms with different
stability, although the physiological relevance of the GRa/p and A/B isoforms
remains to be established.
In summary, the experiments described in this thesis have shown that the structure of
the GR gene is highly conserved between rats and mice. Furthermore, most variant
exons 1 of the mouse and rat GR genes appeared ubiquitously expressed, although
they showed tissue and region-specific differences in their relative expression. The
distribution and regulation by glucocorticoid manipulations of total GR mRNA in
hippocampus, liver and thymus was consistent with that shown in previous studies,
apart from in hippocampus where a novel observation of upregulation of GR mRNA
levels by adrenalectomy with supraphysiological glucocorticoid replacement was
made. However, the observed changes in total GR mRNA in hippocampus, liver and
thymus could not be accounted for by dramatic regulation by glucocorticoids of any
single one of the exons 1 studied here, suggesting that glucocorticoid autoregulation
of GR levels may regulate the activity of all the promoters equally. Finally,
preliminary data suggests that a region ofDNase I sensitivity and hence open
chromatin structure may be associated with the widely-expressed exon 1 io of the GR
gene. Further work is required to elucidate the molecular mechanisms of
transcriptional control of the GR gene.
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Appendix A: sequences of the rat and mouse GR gene
promoter regions
Sequence alignment of rat and mouse GR gene promoter regions using the published
rat GR cDNA sequence (MIESFELD et al., 1986) and mouse GR promoter sequence
accession number X66367, shown as the upper and lower sequences respectively.
Exon 1 sequences isolated from rat hippocampal GR mRNA by 5'-RACE
(McCormick et al., 2000) are represented by shaded areas (except for exon 16 where
the shaded nucleotides are those identified from the rat cDNA sequence (MIESFELD
et al., 1986)). Corresponding exons 1 found in the mouse GR promoter sequence are
boxed. Splice donor sites and the splice acceptor site 13 nucleotides into exon 2 are
shown in bold type.
Position of primers for reverse transcriptase PCR (section 2.1.8.1) are indicated by
coloured areas. Red areas indicate primer position. Yellow areas indicate regions
where two primers overlap.
-4599 ....TAGTATAGGTTTTCCTTCTTGAGGTATCAAGCTTCTATTCCTTTGC -4554
I I II I I I I I II II II I I I I I II II I I I I I I I I I I II I II
-4721 GCACTGGGATGGGTTTTCCTTCTTGAGGTGTCAAGCTTCGGCTCCTTTGC -4672
-4553 CAAGATGGCTGCCCTGGATCCCATGGAGGTAGCGACCGTGCGGCATCTCT -4504
I I I I I I I I I II I I I I I I I I I I I I II I I I I I I II I I I I III I I I I
-4671 CAAGATGGCGGCCCTGGCTCCCATGGAGGTAGCGATTGTGCAGCACCTCT -4622
-4503 GCCCAAGGAGCCCGCTTACAGTCACGTTCTCCCCGTGCAAAGCGGACGAT -4454
I II III III I I I I I I I I I I I II I I I I I II I I I I I I I II
-4621 GGCCCAGGGGCCGTCTTACAGCCACGGCCTACCCGCGCAAAGCGGAAGAC -4572
-4453 ACATTGGGCAGCCTTTAAGCTTTTCATCCAAGAAAGAACGACTCGGGTTT -4404
I I I I I I I I I I I I II I I I III I I II I I I I I I I I II I I I I I III
-4571 ACATTGGGCAGCCTTTACATTTTCCATCCAAGAAAGGGCGCCTCGGTTTT -4522
-4403 GACGCCAAAGAGCACCTTTGCCAAGATGGTGACCGTGCGGCGTCACTGCT -4354




I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I I I I I
-4471 CTTTACCAAGATGGCGGCGAGAGACTTCCGGCACGCGCTTCCCCAATCAG -4422
-4303 GGATCTCCAAGAGGTCAGGCAGAGGAGACCGCCCTTGGAGTCGAAGTGCG -4254
I I I I I I I I I I I I I I I I I I I I II I I I I I I I I I I I I II I II I I II I I I
-4421 AGATCTCCAAGAGGTCAGGCAGAGGAGACCGCCCTCGGAGTCCAAGTGCT -4372
-4253 GCGCGAGCCGCTTCTGCCGCCCGCCGCGGGAGGGCATGAGGTGGAGTCAT -4204
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
-4371 GCGCGATCGGCT [GGGGGAGAGAATGGGGTGGAGCCAC] -4335
-4203 GGCCACCTCCGCTCTAATCAGAAGTGCCAAGCGCTGGCACCTGTGGGGGA -4154







III I I I I II I I I I I I I I I III I I I I I I I I I I I I I
-4234 |CCAACCCCCAGGCCCCTAAACCGTAGCGTGCGGCGCGAGGTAG■GGGGCA| -4186
-4061 CGGTCCCGGCGTCGCCCCAGCCTGCCTAACACAGAGGACACCCGAGGGGC -4012




I I I I I II I I I I I I I I I II III I II I I I I I I I I I I I I I I I
-4136 |AG|GTCCGCGCGGCGGCTGCACTGTCACCCCCACGCCCCTCTCCTGTCCTA -4087
-3964 GGGGGACCGGCCATGTGTTTCTCTTGGAGACCCGGGGACTCGTATTGGGC -3915
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I
-4086 GGGGGACCGGCCACGTGTTTCTCTTGGAGACCCGGGG.CTCGCCCTGGGA -4038
-3914 ACAGCTGGACGGAGCTAAAAGCTGACGTTTTAAAGATGCATGTTTTTGTT -3865
I I I I I I I I I I I I I I I II I I I I I I I I I I I I I I I I I I I II I I I I I I I
-4037 ACAGCTGGAGGGAGCTAAACGCTGACGTTGTAAAGATGCGTG.TTTTGTT -3989
-3864 TTATTTGGAGGGACAGAGGGGTCCCTGGAACCCAGAAA GCTGAGCA -3819
I I I I I II I II I I I I I I I I I I I I I I I I I I II I I I I I I II I II I
-3988 TTATTTGGAGGGGCAGAGGGGTCCCTGGAACTCAGAAAGAAGGCAGAGCG -3939
-3818 AGGCACCGAGCCTGGAGCAGCAAATGTCAAGATTCGGGGGAGGGGCCTCC -3769
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
-3938 AGGCACTGAGCCTGGAGCAGCAAATGTCAAGATTTGGGGGAGGGGCCTCC -3889
-3768 GCGGGGAGCTTGGATGCTGGCCCCGAAGGGGGTGGAAGGAGAGGTCAGGA -3719




I I 1 I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I
-3838 GTTTGGGGTAAGAGGAGGGCGGACTTCGCCAGCAACTTACTATTCCGTCT -3789
-3669 GCAACTTGCTTCTAGGCCTGCACACACCCCCTCCC.GCCCCGCAAGGCTT -3621
I I II I I I I I I I I I I II I I I II II II II I I I I I I I I I I I I I I I I I I I I I I
-3788 GCAACTTGCTTCTAGGCCTGCACACACCCCCTCCCGGCCCCGCAAGGCTT -3739
-3620 CCTTAATCACAA TTTTTTTTTTA -3598
I I I I I I II I I I I I I I I I I I I I I I
-3738 CCTTAATCACAATTTTTTTCTTTTTTCTTTTTTTTTCTTTTTTTTTTTTA -3689
-3597 AGTGCAAAGAAACCCAGCTCTCTGAGAGGGTTTTGCATTCGGCATGCAAC -3548




I I I I I I I I I I I I II I I I I I I I I I I I II I I I I I I I I I I I I I I I I I I I
-3638 |TTCCTCCGAAT|GTGAGCGCGCTGGCAGGCAGGGAGGGAGCGGTGGGGGGG -3589
-3499 TTGAACTTGGCAGGCGGCGCCTCCTGCTGCCGCCGCC. -3463
II I I I I II I I I I I I I I I II I I II I I I I I I I I I I I I I I
-3588 GGGGGGGGAGGTTTGAACTTGGCAGGCGGCGCCTCCTGCTGCCGCCGCCG -3539
-3462 GCCGCCGCCTCTCAGACTCGGGGAAGAGGGTGGGGGACGATC -3421
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I I
-3538 CCGCTGCTGCCGCCTCCTCTCAGACTCGGGGAAGAGGGTGGGGGACGATC -3489
-3420 GGGGCGCGGGGGAGGGTGGGTTCTGCTTTGCAACTTCTCCCGGTTGCGAG -3371
I I I I I I I I I I I I I I I I I I I I II I I I I I I I II I I I I II I I I I I I I I I I I I
-3488 GGGGCGCGGGGGAGGGTGGGTTCTGCTTTGCAACTTCTCCCGGTGGCGAG -3439
-3370 CGAGCGCGCGC GCGGCGGCGGCGGCGGCGGCTGCAGACGGG -3330




II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
-3388 GCCGCCCA[GACGATGCGGGGGTGGGGGACCTGGCAGCACGCGAGTCCCCCl -3339
-3279 CCCGGGCTCACAGTATGTATGCGCTGACCCTCTCCTCTGCGCTCCCCTCC -3230
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I III
-3338 |CCCGGGCTCACA|GTATGTATGCGCTGACCCTCTGCTCTGCCCTCCCGTCC -3289
-3229 CC AGGCCTCCCCAGAGGGCGTGTCTGCAGTCCTGCCCCG -3191
II II I I I I I I I I I I I I I I I I I I I II I I I I II
-3288 CCTCCCCAAGCCTCCCCCCACCCCGAGGGCGTGTCTGCCGTCCTGTCCCG -3239
-3190 AGAGCAAGCGGCCAGGGCTCTGCGGCACCGTTTCCGTGCCATCCTGTAGC -3141
II I II I I I I I I I I I II I I I I I I I I I I I I I I I I I I II I I I I I I I I I
-3238 AG AGCGGCCAGGGCTCTGCGGCACCGTTTCCGTGCCATCCCGTAGC -3193
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-3140 CCCTCTGCTAGTGTGACACACTTCGCGCAACTCCGCAGTTGGCGGGCGCG -3091
I II I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I I I I I I I I I I I
-3192 CCCTCTGCTAGAGTGACACACTTCGCGCAACTCGGCAGTTGGCGGACGCG -3143
-3090 GACCACCCCTGCGGCTCTGCCGGCTGGCTGTCA..CCCTCGGGGGCTCTG -3043
I I II I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II
-3142 GACCACCCCTGCGGCTCTGCCGGCTGGCTGTCACCCCCTCGGGGGCTCTG -3093
-3042 GCTGCCGACCCACGGGGCGGGCTCCCGAGCGGTTCCAAGCCTCGGAGCTG -2993




I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II
-3042 GGCGGGGGCGGG[AAGGAGCCAGGGAGAAGAGAAACTAAAGAAACTCGCTT| -2993
-2942 TCCCTCCCAGGCCAGGTCGGCACCCGCTGCCGCAC TTTTTCTCG -2899
I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I I I I I I I II I
-2992 |TCCCTCCCAGGCCAG|GTCGGCAGCCGCTGCCGCACTTTTTTTTTTTCTCG -2943
-2898 TTCCTTGGGTGGGGA AAGGCGAAGCCGCGCGCCCCAGCGAG -2858
I I II I I I II I I I I III I II I I I I I II
-2942 TCCCTCGGGTGGGGAAAAAAGGCCAAGAAGCCGCGCGGCCCCCGGCGGTG -2893
-2857 GCGATGCCCTGAGC..CGCGGGCTTGCAGGCGCCGTCGGGGCCGGGCTGG -2810
I I I I I I I II I I I I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I
-2892 GCGATGCCCGGAGCCGCGCGGG|CTTGCAGGCGCCGTCGGGGCCGGGCTGG| -2843
-2809 CGGGTACCGCGCGCTGGGAGAAAAGAGGGCGAGGGCCACGGGCGCCCTTG -2760
I I I I I I I I I I I I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I
-2842 |CGGGGCCCGCGCGCTGGGCGAGAAGAGGGCGAGGGCCGAGGGCGCCCTTG| -2793
-2759 CAGTTGCCGACAGTCGCCAACAGGTTGCACCGTTCCCCGCG...GCCGCG -2713
I I I I I I I I I II I I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I
-27 92 |CAGTTGCCGACAGTCGCCAACAG|GTTGCACCGTTCCCCGCGGCCGCCGCG -2743
-2712 CGGCCCCTCGGGCGGGGAGCGGCC.GGGGGTGGAGTGGGAGCGCGTGTGT -2664
I I I I I I I I I I I I I I I II I I I I I I I I II I I II I I I I I I I I I I I I I I I I I I
-2742 CGGCCCCTCGGGCGGGGAGCGGCCGGGGGGTGGAGTGGGAGCGCGTGTGT -2693
-2663 GCGAGTGTGTGCGCGCCGTGGCGCCGCCTCCGCCCGCCCCTCGCTCGGTC -2614
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
-2692 GCGAGTGTGTGCGCGCCGTGGCGCCGCCTCCGCCCGCCCCTCGCTCGGTC -2643
-2613 CCGCTCGCCTGCCGCGGCCGGGCGGCCCTTTCGCGTGTCCGCGCTCCCCC -2564
I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
-2642 CCGCTCGCCTGCCGCGGCCGGGCGGCCCTTTCGCGTGTCCGCGCTCCCCC -2593
-2563 CCC.TCCCCTCCGCCTCCTCCATTTTGCGAGCTC.GAGTCAGTGCCTGGA -2516




I II 1 1 I I I I I I I I I I II I I I I I I I I I I I I I I I I I I II II II I I I I I I! I I
-2542 |GCCCGAGTCGCCGCCCGCCCGTCGGGGACGGATTCTAA|GTGGGTGGAACA -2493
-2465 AGACGCCGCAGCCGGGCGGCGCGGCGCCGGGACGGG.GGACGCGCGC.GG -2418
II I I I I I I I I I I I II II I II I I I I I I I I I I I I I I II I I II I II II II
-2492 AGACGCCGCAGCCGGGCGGCGCGGCGCCGGGACGGGAGAACGCGCGCGGG -2443
-2417 GAGACGGGAGCGGCGCGGGGGCCCGGCTTGTCAGCCGGGAACGGGTGACT -2368
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
-2442 G|AGACGGGAGCGGCGCGGGGGCCCGGCTTGTCAGCCGGGAAGGGGTGACT| -2393
-2367 TTCAGCGCTAGGGGCTCTCCCCTCCCCCATGGAGAAGAGGGGGCGACTH -2318




I I I I I I I I I I I I I I I I I I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I
-2342 |TGACTTCCTTCTCCGTGACACGCGCGCCTCCCGCGTCCGCACGCCGACTT[ -2293
-2267 GTTTATCTGGCTGCGGTGGGAGC...CGCGAGCGGGCGAGCGCGCGGGTG -2221
I I I I I I I I I I I I I I I I I I I I I I I III I I I I I I I I I I I I I I I I I I I
-2292 IGTTTATCTGGCTGCGGTGGGAGCGCAGGCGGGCGGGCGAGCGCGCGGGTG] -2243
-2220 CTGAGGTGAGCGGGGGCTGGGCGAGCGGGCGAGCGGGGCCGGCCCGCGCT -2171
I I I I I I I I I I I I II II I II II I I I I II I I I I I I I I I I I I
-2242 |CTGAG|GTGAGCGGGGGCTGGGCGAGCGGGC GCCCGCGCT -2204
-2170 GAGGTGAGCCGGACTGGGCGCGCTCCCCTAGGGGCTCGGCACCGGGGGCG -2121
I I I I I I I I I I I I I I I I I I I I I I I I II II I I I I I II I I I I I I I I I I I I
-2203 GAGGTGAGCCGGACTGGGCGCGCTCCCCGAGGGGCTCGGCAGCCGGGGCG -2154
-2120 GCCGGACTTGGCAAACTTTTGCCAGCCCGGGGTT GG -2085
II I I I I I I I I I I I I I I I I I I I I II I I I I I I II II
-2153 GCGGGACTTGGCAAACTTTTGCCAGCCCGGGCTTGGGGGCGGGGGAGGGG -2104
-2084 GGGTGGAGGCTGGCGAGGGCAGGGTGACGGTGACGAAAGGGCCTTGGCGG -2035
I I I II I I I I I I I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
-2103 GGGTGGAGGCTGGCGAGGGCAGGGTGACGGTGACGAAAGGGCCTCGGCGG -2054
-2034 TGACAGCGCTGGCGCTTCCTCTCCCCGCACCGCCATCCCTGGCCCAGCGC -1985
I I I I I I I I I I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II
-2053 TGACAGCGCTGGCGCTTCCTCTCCCCGCACCGCCATCCCTGGCCCAGCGC -2004
-1984 GCTGCCCCGCCGTGGAGCCTCGGGCGCCCGGGCGGGAGTCTGGCGTCCTT -1935
I I I I I I I I I I I I I I I I I I I I I III II I II II I I I I I I I I I II I I I I
-2003 GCTGCCCCGCCGCGGAGCCTCGAGCG.CCTGGCGGGAGTCTGGCGTCCTT -1955
-1934 TTTGGTTTTGCTT TTGCCGCAAGCCCTCGGGTCT -1901
II I I I I I I I I I I III I I I I I I I I I I I I I I I I
-1954 TTCGGTTTTGCTTTTTTTTTTTTTTTTCCTTGTCGCAAGCCCTCCGGTCT -1905
-1900 TCGCTGTCCTCGGAGCCGCCGAGACACC...CGCTTTTCCCGGGGGGCAA -1854




II I I I I I II III I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 111
-1854 GGCAGAGGGGCGGCTGCGACCCGCGGTCTCAGGGCGCGCGGClTGCGGGCTl -1805
-1803 GCGGGCTTGTAGGGTGGATT.GGGGCTCACAGCCTGCAGCCCAGACTTCG -1755




I I I I I I I I I I I I I I I I I I II I III I I I I I I I I I I II I I II I I I I I II I I I
-1754 |CCCGCCCGGCCTTATCTGCTAGAAGTGGGCGTGCCGCAGAGAACTCAACA| -1705
-1704 GGTCTGGACACATTTCTCCCTTCACCTCCCACCTTTCTCCCTCCTTCTCC -1655
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I I I I
-1704 gGTCTGGACACA.TTCTCCCTTCACCTCGCACCTTTCTCCCTCCTTCTCC -1666
-1654 CCCAACCCCACCCCC.GACAACTTGGGCGCTAGCTTTGGGGCATGATTTC -1606
I I I I I I I I I I I I I I I II I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I
-1655 CCCAACCCCACCCCCGGACAACTTGGGCACTAGCTTTGGGGCATGATTTC -1606
-1605 GCGCCTGACTTTTCTGAGTGGTCCCCTTTTAGAAAGAGACCCTCCCTAGC -1556
I I I I I II I I I I I I I I I II II I I I I I I I I I I I I I I I I I II I I I I II I I I
-1605 GAACCTGACTTTTCTGAGTGGTCCCCTTTTAGAAAGAGACCCTCCCTAGC -1556
-1555 CGCAG.TTTTTGATGCAGCGA TTTTTTTTTTTTTTTTTGACAAGT -1463
I III I I I I I I I I I I I I I I I I I II I I I I I I I I I II I I I I I I I I
-1555 CACAGTTTTTTGATGCAGCGATTTTTTTTTTTTTTTTTTTTTTAACAAGT -1467
-1511 GCTACTTTGACATTTGAGGTTGCAGCCTCGGTAATTGCAGCCTTACCACT -1462
II II I I I I I I I I I I I I I I I I I I I I III I I I I I I I I I I I I II I I II
-1505 GCTACTTTGACGTTTGAGGTTGCAGGCTCAGGAATTGCGGCCTTACCACT -1466
-1461 TAAGACCCTGGGCAAGG.TTCGTGTGACTAATGTCACAGGGTTATTTACA -1413
I I I I I I I I I I I I I I II III I II I I I I I I I I II I I I I I I I I I I I I I I I
-1455 TAAGACCCTGGGCATGGTTTCCTGTGACTAATGTCACAGGGTTATTTACA -1406
-1412 GTTTTAACTGGGGGATAAATGTCGCTTAAGGGAGCATCTTGTTTTATGAA -1363
I I I I I I I I I I I I I I I I I I I II I II I I II I I I I II I I I II I I I I I I I I I I
-1405 GTTTTAAATGGGGGATAAATGTCGCTTAAGGGAGCATCTTGTTTTATGAA -1356
-1362 G...TGTTACGGTTTCGGGCTGGAAGGGGCAGTTGTCAAAAAAGCAGGTC -1316
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I III
-1355 GTGTTGTTATGGTTTCAGGCTGGAAGGGGCAGCTGTCAAAAAAGCGGGTG -1306
-1315 TGAAAATTCTTTAAGGTCTATTAGATATCTTACATTTAGAGATCCTTATC -1266
I I I I I I I I I I I I I I I I I III I I I I II I I I I I I I I I I II II
-1305 TGAAAATTCATTAAGGTC.ATTTGATAACTAATGTTTAGAGACCGTTCTC -1257
-1265 AAAGGCATAGGACCGACCGGGGTTCTGAGAGAGAAGCCCTTTACAGGGAA -1216
I I I I I I II I I I I I II II I I I I II I I III III I I I I I I I II
























































i i i i i i i i i i ii ii ii i iii i i i ii ii i i i i ii i i i i i i i i i ii
-516 taccttgaaaggtttagatgtgtggggattggcacaggtgaaattgtgaa -467
-477 tcataaaatgtgtaaacatttatattgtagcatttatcaaacggtttatg -428
i i i i i i i ii i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i ii
-466 tcatgaggtgtgtaaacaattatagtatagcatttatcaaacggtttatg -417
-427 tattggtttccagaaaggcaatcactcaatcgaaaggggctggaaatgta -378
ii i i i i i i ii i i i iii i i i i i i i i i i i i i i i i i i i i i i i ii ii
-416 tagtggtttccagagagg.aatctctcaattgaaaggggttggaaattta -368
-377 aggatcatgccttt aaaaaaaaaaagttaaatactttgacatca -334
i i i i i ii i i ii i i i i i i i i i i i i i i i i i i i ii i ii i i i i i i
-367 aggatcacgcctttaaaaaaaaaaaaaaaaagttaaatactttgacgtaa -318
-333 acttgaacctttacaataattgcgtatgacaaattacaatccccatggtt -284
i i i i i ii i i i i i i i i ii i i ii i i i i i i i i i i i i i i ii i ii
-317 atttgaacctttgcaataatcacaaataacaaattacaacctccatgctt -268
-283 accaaatgtgtatgtttagcgagtgacaggataaacagtcaaattcagtt -234
i i i i i ii ii ii i i i i i i i i i ii i i i ii i i i i i i i i iii ii i i
-267 accaaatgtgtacatttagcgagtggcaggataaacagccaagtttaaat -218
-233 ggttcaatgtaactttgttgtctctgtgcaaatgagctgccttgcagatg -184
i i i i i i i i i i i i i i i i ii i i i i i i i
-217 cggtcga ccgggcagatgagctgctttgtggatg -184
-183 ggaaacgggggtgggggtatagctttattttaaaagataggaactatttt -134
iii i i i ii i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i
-183 gga....gcagggaggatatagctttattttagaagataggaactattct -138
-133 tctgataatggagactttgatttgggagttacctaaagggtttatttaat -84
i i i i i i i i i i i i i i i i i i i i i i ii i i i i i i i i i i i i i i i i i i i i i i i i
-137 tctgataatgaagactttggtttgggagttacctaaagggtttatttaat -88
-83 gggcag..tcttactaatcggatcagaaataatgt..ttttatagcttat -38
iii i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i
-87 aggctgtctcttactaatcggatcagagataatgtggttttatagcttat -38
-37 tatgtcttttttttttcttttgtagttaatatttgccaatggactccaaa +12
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